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ABSTRACT 
 
Interleukin 4 (IL-4) signaling has been implicated in tumorigenesis in many 
types of malignancies including breast, lung, brain, renal and pancreatic 
cancer through different cell-intrinsic mechanisms. In order to understand how 
IL-4 signaling might affect inflammation-dependent colorectal tumor 
development and progression, this study aimed to investigate the most 
prominent components of this pathway: (i) interleukin 4 receptor alpha (IL-
4Rα) and (ii) signal transducer and activator of transcription 6 (STAT6). 
Taking advantage of genetically modified mice and a well-established colitis-
associated cancer model functional relevance of IL-4Rα and STAT6 in 
intestinal epithelial cells was evaluated. Employing the AOM/DSS tumor 
model mice with global deletion of IL-4Rα developed fewer and smaller 
colonic tumors than WT mice. Additionally, IL-4Rα loss during colitis-
associated tumorigenesis reduced STAT3 activity in transformed colonocytes 
causing cell cycle arrest at G2-phase due to decreased CYCLIN B1 and 
CYCLIN E expression. Knowing that STAT6 is crucial to provide gene 
activation signals in the IL-4 pathway it was expected that Stat6 ablation 
during colitis-associated tumorigenesis would generate similar results as the 
ones obtained with IL-4Rα mice. Surprisingly, Stat6 deficient animals showed 
enhanced susceptibility to chemically induced intestinal epithelial damage and 
subsequent colonic inflammation. A significant increase in tumor load and 
tumor size was observed in these animals followed by an increased STAT3 
activation in tumors. STAT3 is known to influence colon cancer development 
and its compensatory upregulation could explain the phenotype observed in 
Stat6 knockout mice. The findings here add further insights on STAT6 and IL-
4Rα signaling during intestinal tumorigenesis and stress that the loss of a 
single pathway component can exert dramatic influences for the phenotype of 
genetically modified mice and for the therapeutical use of inhibitors of 
signaling pathways. Moreover, considering that STAT6 is the most important 
known transcription factor downstream of IL-4 these data highlight 
unexpected IL-4-independent functions of STAT6. 
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ZUSAMMENFASSUNG 
 
Der Interleukin-4 (IL-4) Signalweg wird über unterschiedliche Zell-intrinsische 
Mechanismen mit der Entstehung von Tumoren in verschiedenen Organen, 
wie Brust, Lunge, Gehirn, Niere und Pankreas, in Verbindung gebracht. Um 
zu verstehen, wie dieser Signalweg die Entwicklung von Tumoren des Dick-
und Enddarms beeinflusst, wurden in dieser Studie die wichtigsten 
Komponenten des IL-4 Signalwegs untersucht: (i) Interleukin-Rezeptor 4 
alpha (IL-4Rα) und (ii) Signal-Transduktor und Transkriptions-Aktivator 6 
(STAT6). Die funktionelle Bedeutung von IL-4Rα und STAT6 in 
Darmepithelzellen wurde unter Verwendung von genetisch veränderten 
Mauslinien und einem etablierten Modell für Kolitis-assoziierte 
Darmkarzinome untersucht. Im AOM/DSS-Modell entwickelten Mäuse mit 
globaler Deletion von IL-4Rα  weniger und kleinere Dickdarmtumoren als 
Mäuse vom Wildtyp. Ergänzend dazu führte der Verlust von IL-4Rα in diesem 
Modell zu einer reduzierten Aktivierung von STAT3 in transformierten 
Epithelzellen des Kolons und verursachte einen Stillstand im Zellzyklus in der 
G2-Phase durch verminderte Expression von Cyclin B1 und Cyclin E. Unter 
der Annahme, dass wichtige Aktivierungssignale für Gene im IL-4-Signalweg 
STAT6-abhängig vermittelt werden, erwarteten wir, dass die genetische 
Inaktivierung von STAT6 ähnliche Effekte in der Entwicklung von im Kolitis-
assoziierten Darmkarzinomen zeigen würde wie Inaktivierung von IL-4Rα. 
Überraschenderweise zeigen STAT6-defiziente Tiere erhöhte Anfälligkeit für 
chemisch-induzierte Schädigung der Darmschleimhaut und darauffolgende 
Entzündung. Eine signifikant erhöhte Tumorlast und –größe konnte im 
Zusammenhang mit verstärkter STAT3-Aktivierung in Tumoren beobachtet 
werden. STAT3 ist ein bekannter Einflussfaktor in der Entwicklung von 
Darmkarzinomen und seine kompensatorische Aktivierung könnte den 
Phänotyp der STAT6-defizienten Tiere erklären. Die hier erzielten Ergebnisse 
zeigen die Bedeutung des IL-4-Signalwegs für die Entwicklung von 
Darmtumoren aus entzündlichen Reaktionen der Schleimhaut. Unsere 
Beobachtung, dass die Manipulation einzelner Komponenten dieses 
Signalwegs unterschiedliche Auswirkungen auf das Endergebnis zeigen, hat 
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große Bedeutung für die eventuelle Entwicklung von Inhibitoren dieses 
Signalwegs für die klinische Anwendung. Darüberhinaus zeigen unsere Daten 
unerwartete, IL-4 unabhängige, Funktionen von STAT6 auf, gilt doch STAT6 
als wichtigster IL-4 abhängiger Transkriptionsfaktor. 
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1. INTRODUCTION 
 
1.1 The Large Intestine 
 
1.1.1 Anatomy, structures and cell composition 
 
 The gastrointestinal tract (GI-tract) is the responsible organ for 
digestion and absorption of nutrients. Therefore, it is the largest mucosal 
surface of the body with 8,50 meters length in humans and 30 centimeters 
length in mice. Remarkable, up to 80% of its structure is comprised by the 
small intestine, which has an average length of six meters in an adult human. 
Both humans and mice digestive tracts share very close anatomical, 
histological, physiological and pathological similarities. Duodenum, jejunum, 
and ileum constitute the proximal to distal parts of the small intestine, whilst 
the large intestine being composed by caecum, colon, and rectum (Figure 1 
and 2) [1, 2].  
 
 
Figure 1. Characteristics of the normal human gastrointestinal tract. (Extracted and adapted by permission from 
Macmillan Publishers Ltd: Nature Reviews Gastroenterology and Hepatology 9, 590-598 [3]). 
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Figure 2. Gross anatomy of the human and murine gastrointestinal tract. (Extracted from Thi Loan Anh Nguyen 
et al. Dis. Model. Mech. 2015;8:1-16 [4]). The gastrointestinal segments can be directly compared between mice and 
humans. The main gross anatomic difference observed is the murine enlarged cecum and appendix. 
 
The large intestine can be divided in 4 anatomic segments: the most 
proximal is the cecum with its vermiform appendix followed by the colon, the 
rectum and the anal canal, which is the most distal segment. In addition, the 
colon is subdivided into ascending colon, transverse colon, descending colon 
and sigmoid. The mucosa contains straight tubular glands, called crypts of 
Lieberkühn. They are the functional unit of the intestine and are present 
through its full thickness. These glands consist of simple columnar epithelium, 
which invaginate deep through the intestinal wall. At the microscopic level, 
examination of the luminal surface of the large intestine reveals the opening of 
the glands, which are arranged in an exceptionally organized pattern (Figure 
3), [1].  
 
Figure 3. Histology of the large intestine mucosa. (Extracted and adapted with permission from Disease Models & 
Mechanisms 2012 5: 107-114; doi: 10.1242/dmm.007591v [5]). Hematoxylin and Eosin (A) of the mucosa and part of 
the submucosa. The surface of the epithelium is continuous and unbranched depicting the crypts of Lieberkühn 
arranged side-by-side. The arrows identify the openings of the crypts. The epithelial cells consist mainly in absorptive 
and goblet cells, which can be easily visualized by Alcian-Blue staining (B). The lamina propria contains numerous 
lymphocytes and other cells of the immune system. 
INTRODUCTION 
	 3	
 Contrary to the small intestine, the large intestine lacks villi (finger-like 
protrusions that point towards the lumen and increase the absorptive area of 
the small intestine dramatically). Histologically, the colon is organized into 
three spatially distinct layers. The most exterior consists of several sheets of 
smooth muscle that in collaboration with the intramural enteric nervous 
system perform the rhythmic peristaltic movements of the intestine. The space 
between the outer muscle and the inner luminal epithelial layer is called 
submucosa. It is filled with connective tissue that contains numerous blood 
and lymphatic vessels, nerve fibers, and various cells of the immune system 
[6]. A simple single line of columnar epithelial cells that fold themselves into 
“finger-like invaginations” form the luminal surface of the intestine. These 
invaginations are further supported by the lamina propria, generating the so-
called crypts of Lieberkühn (also often referred as colonic crypts) [7].  
The mucosal epithelium of the large intestine holds the same cell types 
as the small intestine, with the exception of Paneth cells, that produce 
antimicrobial peptides which regulate the gut microbiota, as well as growth 
factors involved in the maintenance of the neighboring stem cells, and are 
usually absent in the colon of healthy humans and mice [8]. Four terminally 
differentiated epithelial cell lineages can be recognized in the colon luminal 
surface. Absorptive cells, goblet cells, endocrine cells, and tuft cells are found 
in the top middle-third of the crypt and are derived from stem cells located at 
the bottom of the crypt. These bottom-based stem cells undergo self-renewal 
by asymmetric division generating a population of transit amplifying cells (TA) 
that migrate towards the top of the crypt, proliferating and differentiating into 
one of the many epithelial cell types that compose the intestinal epithelium 
(Figure 4 and 5). Moreover, these proliferating intestinal crypts rely on 
paracrine signals (cell-to-cell signals) exchanged between the epithelium and 
the surrounding mesenchymal cells, such as fibroblasts. The maintenance 
and protection against the ectopic formation of crypts are controlled by a 
delicate balance between the expression of morphogenetic proteins and its 
antagonists (e.g. noggin and gremlin). Additionally, intestinal epithelial cell 
(IEC) differentiation towards secretory versus non-secretory lineages is highly 
influenced by the activation of Notch and WNT pathways, which can 
respectively promote stemness (maintain the self-renewal of stem cell 
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population at the bottom of the crypt) and induce proper differentiation of IEC 
at the top of the crypt [9-11].  
 
Figure 4. Diagrammatic representation of the colonic crypt. (Extracted and adapted by permission from 
Macmillan Publishers Ltd: Nature Reviews Cancer 8, 415-424 [12]). Intestinal stem cells (in red) are located in the 
base of the colonic crypt in close proximity with other crypt-niche cells, such as fibroblast (in green). Those form an 
outer layer and direct communicate by cellular signals with the stem cell niche. Transient amplifying and committed 
progenitor cells (in dark gray) can be can be found directly above, and will give rise to all different cell lineages.  
 
In 2007, the Wnt target gene Leucine-rich repeat containing G protein–
coupled receptor 5  (Lgr5) was identified as a marker of crypt base columnar 
cells. The study performed cellular lineage-tracing experiments identifying 
Lgr5+ cells as multipotent and self-renewing intestinal epithelial cells 
population [13]. Additionally, in the small intestine, cells located above the 
stem cell compartment (transient amplifying and committed progenitor cells 
zone) and expressing the Bmi1 polycomb ring finger oncogene (Bmi1) have 
been reported to have stem cell features, which partially overlap with Lgr5 
cells expression. [14].  
 
 
Figure 5. Electron micrography and diagram colonic crypts. (Extracted and adapted by permission from 
Macmillan Publishers Ltd: Nat Rev Mol Cell Biol. 2014 Jan;15(1):19-33 [15]). The micrography depicts the colonic 
crypt at its totality and the luminal linear surface of the intestinal colonic epithelium. The diagram exemplifies the 
localization of the different cell types inside the crypt highlighting the newly identified Lgr5 stem cells (in green). 
Additionally, all different cell lineages originated by Lgr5 stem cells are shown. 
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Although a lot of progress has been made regarding stem cell niche, 
most of the published studies have only addressed the niche components of 
the small intestine. Therefore, the colonic stem cell niche still needs better 
characterization not only about its cell composition but also about the 
signaling pathways involved in its maintenance. Addressing this issue, 
Rothenberg and colleagues [16] suggested that colonic cKIT-expressing 
goblet cells might support Lgr5+ cells secreting factors such as Notch ligands, 
TGF-α and WNT ligands, similar to what Paneth cells do at the small intestine. 
However, intestinal stem cell function and fate are still a major issue of 
investigation and debate.  
 
Absorptive Cells – Enterocytes 
 
The primary roles of the large intestine and its columnar absorptive 
cells are reabsorption of water, electrolytes, and compaction of the stool. The 
morphology of the absorptive cell - also called enterocyte - is similar 
throughout all of small and large intestine. Basically, they are tall columnar 
cells with a basally positioned nucleus. These cells have a striated border on 
its apical surface and junctional complexes that seal the lumen of the intestine 
from the lateral intracellular space (Figure 6), [17]. Reabsorption of water and 
electrolytes is accomplished by active transport systems like sodium pumps, 
which reduce the intracellular concentration of sodium by moving it through 
the cell into the extracellular space bellow the tight junction. The accumulation 
of sodium in the intercellular space makes with the intracellular water also 
moves there in order to reduce sodium levels. Once the sodium is pumped 
into the intercellular space water will always be absorbed at the surface of the 
colonic epithelium and redirected into the intercellular space by osmosis. 
Subsequently, the water and other electrolytes accumulated at the 
intercellular space will cross the basal membrane and will be diffused into the 
surrounding connective tissue, entering in capillaries and reaching the body 
blood circulation [17, 18]. 
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Figure 6. Electron micrography and diagram of an intestinal absorptive cell. (Micrograph extracted from J Cell 
Biol 34: 123–155, 1967 [19]). Micrography of a rat intestine shows several absorptive cells close to a goblet cell (top 
right). The nuclei of the absorptive cells are elongated and located basally, surrounded by cluster of mitochondria. 
Both the Golgi (G) and the rough endoplasmic reticulum (RER) can be visualized. The intestinal lumen is at the top. 
The diagram depicts two absorptive cells and their sodium pumps located at the lateral plasma membrane. The 
sodium flow through the cell to the extracellular space below the basal membrane is shown.  
 
Goblet Cells 
Goblet cells produce and secrete large amounts of mucus into the 
intestinal lumen facilitating the elimination of solid and semi-solid dietary 
residues. One of the main components of the secreted mucus are mucins, 
which not only lubricates the lumen of the intestine facilitating the excretion of 
the stool but also forms a mechanical barrier that protects the epithelium from 
potential harmful substances and microorganisms. Goblet cells are distributed 
among the other intestinal epithelial cells and are easily recognized by their 
morphology. As their own name says, they exhibit a chalice shape due to their 
distended theca, which is heavily packed with mucin granules (Figure 7), [20]. 
Anatomically, they are more numerous in the large intestine than in the small 
intestine, and the ratio of absorptive intestinal cells versus goblet cells 
decreases from the colon to the rectum, where the number of goblet cells is 
heavily increased [21]. From their generation at the bottom of the crypt until 
the point where they reach the intestinal epithelium surface, goblet cells 
produce and secrete not only mucins but also other bioactive factors, which 
are going to compose the mucus, such as cytokines that can act during 
intestinal inflammatory insults contributing to the restoration of epithelial 
homeostasis [22]. 
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Figure 7. Electron micrography and diagram of mouse goblet cell between two intestinal absorptive cells. 
(Micrograph extracted by permission from the Electron Microscopy Research Laboratory, Kansas University, KUMC. 
Diagram adapted by permission from Macmillan Publishers Ltd: Nature Reviews Genetics 7, 349-359 [9]). Both in the 
micrography and in the diagram the presence of mucin at the apical surface of the cell can be easily observed over 
its basal cytoplasm. 
 
From the secreted bioactive molecules, mucin 2 (MUC2) is by far the 
major goblet cell-derived mucin. Genetical experiments performed with Muc2-
deficient mice showed that its ablation affects goblet cell morphology due to 
the collapse of the theca, although the continuous production of other goblet 
cell-factors is observed [20, 23]. Even more important than cellular 
morphological changes, inactivation of Muc2 in different mouse models 
triggered colorectal tumorigenesis and spontaneous tumor formation without 
overt inflammatory insults. [23-26]. Therefore, the available literature 
demonstrates the importance of the goblet cells for the intestinal homeostasis 
and that a reduction in goblet cells and/or a reduction of the mucus layer 
produced by them has a significant impact on the promotion of colorectal 
tumorigenesis.  
Along with the intestinal absorptive cells and goblet cells, other two 
important cell types can be identified in the colonic intestinal mucosa: (i) 
enteroendocrine cells; (ii) and tuft cells. 
Enteroendocrine Cells 
It has been already shown that the human digestive system is able to 
synthesize a vast diversity of hormones, being considered an important part of 
the endocrine system along with the thyroid, the adrenal glands, the 
reproductive system (ovary and testis) and the hypothalamus, to cite some. 
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This concept is firmly based on the function of the highly specialized 
enteroendocrine cells (EECs), which are diffusely distributed in the intestinal 
mucosa  (Figure 8), [27, 28] [29]. Interestingly, the reason for this diffused 
distribution in the intestinal epithelium is due to the action of Notch signaling 
on these cells, which directly inhibits the nearby intestinal epithelial cell to 
differentiate into the enteroendocrine lineage [30]. EECs can be classified in 
more than 10 subtypes that may overlap in function, however three of these 
subtypes deserve special consideration: (i) enterochromaffin cells (also known 
as Kulchitsky cells), which are found mainly in the colon and rectum, secrete 
5-hydroxytryptamine (5-HT) and are extremely important for the intestinal 
motility due to their direct interaction with the enteric nervous system [31]; (ii) 
L cells, which produce hormones including Glucagon-like peptide-1 (GLP-1) 
that are involved in insulin secretion and are found principally in the ileum and 
colon [32], and (iii) D cells, that are mainly known for their production of 
somatostatin, which regulates glucagon and insulin production. D cells are 
found in the small intestine and scarcely in the rest of the gut [33]. 
 
 
 
Figure 8. Enteroendocrine cell micrography and diagram. (Micrograph extracted from Electron Microscopy 
Research Laboratory, Kansas University, KUMC. Diagram adapted by permission from Macmillan Publishers Ltd: 
Nature Reviews Genetics 7, 349-359 [9]). The existence of cytoplasmic secretory vesicles is one of the main features 
for enteroendocrine cells identification and characterization. Chromogranin A, synaptophysin, enolase and protein 
gene product 9.5 are often detected components [27, 34]. The secretory granules are marked with a black arrow at 
the micrography.  
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Tuft Cells 
 
While migrating towards the top of the crypt, progenitor cells 
differentiate into perhaps the most distinct and less characterized cell type of 
the intestinal epithelium: the tuft cells. 
Since their first identification in the rat trachea and mouse 
gastrointestinal tract in 1956 by Rhodin and Dalhamn [35] and Jarvi and 
Keyrilainen [36], tuft cells, also known as brush cells, have been confirmed in 
the respiratory tract [37-41] and the GI tract [42-49], of many other mammals 
including humans, rats, cats, pigs, cows, mice, rabbits, guinea pigs, and 
ferrets [50]. When compared to other intestinal epithelial cells, tuft cells exhibit 
a very distinct morphology due to their round and elongated microvilli, 
followed by a highly complex and specialized vesicular system composed of 
tubules and sacs, located over the cell nucleus (Figure 9). Tuft cells exact 
functions need to be better defined and are still under debate. Nevertheless, it 
was recently proposed that they might participate in the chemical sensation of 
antigens found in the gut’s lumen [51, 52]. Taking this into consideration, it is 
possible that the recognition of parasitic infections is based on the ability 
described above, as intestinal worms alter the concentration of the intestinal 
luminal contents. Additionally, scientific data have demonstrated that tuft cells 
are also an important source of interleukin 25 (IL-25), a cytokine directly 
involved in the resolution of parasitic infections [53, 54].  
Several markers have been proposed for tuft cells, such as Dcamkl1 
[55] and Atoh1 [51]. However, other intestinal epithelial cells also express 
these markers, so they cannot be fully recognized as tuft-cell specific. 
Therefore, tuft-cells precise identification must be made taking into account 
their unique, distinctive morphology and the expression of different molecular 
markers.  
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Figure 9. Tuft cell: histology and diagram. (Diagram extracted from The American Physiological Society: 
Physiology.1 February 1999 Vol. 14 no. 1, 18-23 [56]. Histological figure extracted and adapted by permission from 
Macmillan Publishers Ltd: Nature Cell Biology 14, 1099–1104 (2012) [55]). The diagram shows the unique cellular 
morphology of the tuft cells and depicts their delicate tubule-vesicular system located in the supranuclear area. 
Interesting, the taste cells of the tongue exhibit similar cellular features such as abundant microtubules, long actin 
filaments and lateral villi associated with microvilli. Additionally, alpha-gustducin, a G protein found in tate receptors is 
identified in both cell types. On the right, the histological picture highlights the expression of Dcamkl1, a proposed tuft 
cell marker. 
 
 
1.1.2 Intestinal microbiota 
 
 Due to its fascinating capacity to host millions of microorganisms the 
gastrointestinal tract is considered the most significant of all mucosal barriers 
of the human body. It is estimated that the total microbial load existent in the 
GI-tract is between 1013 to 1014 microorganisms. That is proximally 100 times 
more than our genome [11, 57]. The amount and complexity of bacteria, fungi, 
viruses and archaea rises exponentially from the beginning to the end of our 
GI tract (Figure 10). Moreover, whilst in the proximal parts of the GI tract we 
observe mainly aerobic germs, at the distal parts they are outnumbered by 
anaerobic ones. Interestingly, although at an early age of life the human GI 
tract exhibits a significantly heterogeneous microbiome, during adulthood this 
diversity decreases and the microbiome becomes a more homogenous 
phylum, presumably due to environmental influences [58-60]. 
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Figure 10. The gut microbiota and its localization. (Extracted and adapted from GASTROENTEROLOGY 
2008;134:577–594 [58], with permission from Elsevier). Composition and luminal concentrations of main microbial 
species in various regions of the gastrointestinal tract.  
 
The backbone of this extraordinary symbiotic relationship is the ability 
to maintain the distinction between host and microbial organisms, which is 
achieved mainly by two mechanisms: first by the gut motility (peristaltic 
movements) which prevents the long-term interaction between microbes and 
mucosal areas; second, by the luminal secretion of mucins and antimicrobial 
proteins, establishing a physical and biochemical barrier that restrains most 
bacteria, viruses, fungi and noxious substances from directly contacting the 
epithelial cell layer [20, 61, 62] . The potential damage caused by the 
translocation of germs into the mucosa and dissemination across the 
intestinal barrier is rewarded by their significant contribution to the host 
homeostasis. The microbiota existent in the intestinal tract is not only involved 
in the further digestion of the chyme, but also in many other complex 
processes such as the synthetisation of vitamins (mainly B and K), host 
metabolism, development of gut-associated lymphoid tissues and direct 
influence on host protection against opportunistic infections [63-74].  
Notably, when the microbiota’s composition or function gets disrupted a 
dysbiotic state is generated. In this scenario, the unbalanced gut microflora 
may disrupt the host-microbe homeostasis, which can have severe 
implications to the health of the host [75]. Recently, dysbiosis has been the 
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focus of innumerous scientific studies, and its correlation with the 
development of inflammatory bowel diseases (IBDs), such as Crohn’s 
Disease (CD) and Ulcerative Colitis (UC) seems to be a relevant factor in the 
establishment and progression of these diseases  (Figure 11) [76-81]. 
Additionally, quantitative and qualitative microbiological analysis of the 
intestinal luminal content of IBD patients revealed an increase in the levels of 
harmful pathogenic bacteria over the beneficial ones [82, 83]. 
           
Figure 11. Dysbiosis and inflammatory bow diseases. (Extracted from J Clin Invest. 2014;124(10):4190–4196 
[84], with permission of AMERICAN SOCIETY FOR CLINICAL INVESTIGATION in the format “Republish in a 
thesis/dissertation” via Copyright Clearance Center). IBDs are caused by a confluence of factors that perturb the 
balance between the environment, gut microbes, and host. IBDs are believed to arise from a “perfect storm” that 
involves the confluence of environmental and genetic factors tipping the balance between host immune and gut 
microbial factors and thus triggering disease in genetically susceptible individuals. IBDs are maintained by 
pathophysiological host processes and events that feed forward to promote a dysbiotic microbiota that can in turn 
worsen inflammation and create a vicious loop. 
  
 Although the precise risk rates for colorectal cancer development in 
patients with IBDs are still under debate, these patients present an apparent 
increased risk for malignant intestinal neoplasia, when compared with healthy 
individuals [85], therefore, a dysbiotic microflora might have a significant 
impact on intestinal tumorigenesis. The increase of harmful luminal bacteria 
can trigger mucosal inflammation, which in turn generates genotoxic stress on 
intestinal epithelial cells, which finally may give rise to cancer [86-89] (Figure 
12). 
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Figure 12. Inflammation-induced mechanisms of cancer development in the colon. (Extracted and adapted 
from Molecular Cell 54, April 24, 2014, [89]. with permission from Elsevier). (1a) Mutagens from food or excreted by 
the intestinal microbiota enter into the intestinal epithelial cell (IEC), causing DNA damage or inducing the production 
of reactive oxygen species (ROS). (1b) ROS and reactive nitrogen intermediates (RNI) species released by the 
microbiota or by immune cells are able to trigger genotoxicity in the IEC. (2a) The constant release of pro-
inflammatory cytokines can deregulate the expression of genes involved in cell survival, proliferation, and 
angiogenesis, establishing a pro-tumorigenic intestinal environment. (2b) Pro-inflammatory cytokines, such as IL-6 
and IL-1β, might drive the expression of DNA methyltransferases (DNMT), resulting in the silence of tumor 
suppressor genes. (2c) The activation of other inflammatory signaling pathways can induce microRNA (miRNA) 
expression that can further silence the expression of tumor suppressor genes.  
 
 
1.1.3 Immune cells 
 
 The symbiotic relationship between mammal hosts and microbes 
formed over millions of years of evolution is based on its benefits for both the 
host and the microbiome. Unfortunately, the microbiome has the ability to 
cause harm to the host by spreading from their gut luminal location to the 
intestinal submucosa and disseminating to other distant organs. In order to 
prevent and protect the host from such destructive threats, the intestinal tract 
is equipped with a highly complex and intrinsic immune system (Figure 13).  
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Figure 13. Anatomy of the intestinal mucosa and its immune apparatus. (Extracted and adapted by permission 
from Macmillan Publishers Ltd: Nature Reviews Immunology 14, 667–685 (2014)) [90]. Most of the intestinal immune 
cells are found in the lamina propria, with exception of the intraepithelial lymphocytes (IELs), which are located 
between intestinal epithelial cells. Reversely goblet and Paneth cells, IELs become less frequent progressing to the 
distal part of the small intestine, and are rare in the colon. Villi and Paneth cells are absent in the normal colon and 
the colonic crypts are smaller when compared with the crypts from the small intestine. DC, dendritic cell; SIgA, 
secretory immunoglobulin A. 
 
 Aside from all the already mentioned functions, the gastrointestinal 
tract is also considered a lymphoid organ, and the lymphoid tissue within it is 
referred to as the gut-associated lymphoid tissue. Directly under the intestinal 
epithelium – in the lamina propria – we find most of the intestinal immune cells 
and lymphoid structures that compose the gut-associated lymphoid tissue, 
such as lymphoid aggregates in the large intestine or Peyer’s patches in the 
small intestine. [91, 92]. These both small and nodular lymphoid structures 
present on their surface a singular layer of follicle-associated epithelium (FAE), 
which hide underneath many different immune cell types [93, 94].  
 Strikingly, the FAE is not solely responsible for sheltering underneath 
innumerous immune cells, but also for harboring specialized antigen-sampling 
cells: Microfold or simply, M-cells. Microfold cells exhibit the extraordinary 
capability to sample intact intestinal luminal contents (transcytosis), such as 
soluble proteins, antigens, bacteria and viruses and directly present them to 
lymphocytes, dendritic cells and macrophages located in the lamina propria 
(Figure 14). Furthermore, germs opsonized by immunoglobulin A (IgA) can be 
abducted by microfold cells thanks to their IgA receptor expression, 
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redirecting them to immune cells [95-100].  
      
     
Figure 14. Diagram of an intestinal M cell. (Extracted and adapted by permission from Macmillan Publishers Ltd: 
Nature Reviews Immunology 5, 905-916 (December 2005) [101]). Particulate antigens are recognized by receptors at 
the surface of M cells and are presented to lymphocytes and macrophages. Soluble antigens, as well as small 
pathogens, can permeate the epithelium and be recognized by dendritic cells. 
 
 The extremely refined action of M cells in sampling the intestine is 
followed by a close interaction with immune cells residing in the lamina 
propria, such as macrophages and dendritic cells (DC). These both cell types 
make part of the innate immune system and can be considered the frontline 
defense against microbial infection. After activation, dendritic cells migrate to 
the mesenteric draining lymph nodes and further activate lymphocytes by 
presenting them with antigens captured directly, or given to them by M cells. 
This extremely coordinated process gives rise to the activation of our adaptive 
immunity and consecutively extra immune protection against pathogens [102-
106].  
 Along with dendritic cells, macrophages are the most prevalent 
phagocytic cells in the intestine, and it is believed that the organ is the “largest 
reservoir” of these cells in the body [107, 108]. Different from dendritic cells, 
which are best known for being efficient antigen presenting cells (APCs), the 
macrophages exhibit extraordinary phagocytic capabilities to clear cellular 
debris, germs and foreign bodies (like pigments). Thus, their proper function is 
crucial for the gastrointestinal homeostasis [109, 110].  
 
INTRODUCTION 
	 16	
 Unlike the cells of the innate immune system, which do not need 
previous activation (priming) to exert their immune functions, cells from the 
adaptive immune system require additional co-stimulation to generate proper 
effector responses. Notably, B and T lymphocytes are the main components 
of this system, and although they may need longer periods to undergo 
activation their responses against pathogens are extremely specific and 
continuous [111]. In the GI tract, most of the B and T lymphocytes are 
localized in lymphoid nodules, generally in a resting, naive state. Upon 
priming (generally by DCs), they undergo activation, proliferation and migrate 
to the sites of damage and infection to exert their effector functions, which in 
the case of the gut is usually the lamina propria [112]. Activated B cells will 
become plasma or memory B cells. The first will produce large amounts of 
immunoglobulins A and M and affinity antibodies against a specific antigen. 
The second, as its name describes will become a memory cell, providing fast 
antibody production in case of contact with an already known antigen [113].  
 Working in parallel with B lymphocytes to provide adaptive immunity 
another important cell population can be found: T lymphocytes. These cells, 
alike the B cells need co-stimulatory signals to acquire effector functions. 
They can be subdivided in CD8+ and CD4+ T cells.  CD8+ T cells display 
robust cytotoxic capabilities towards infected, dysfunctional and transformed 
cells, being also known as a result of that as “T cytotoxic” cells. They exert 
their cytotoxicity through the release of cytolytic proteins, such as granzins 
and perforins or by the expression on their surfaces of FAS ligand. In both 
situations, the outcome will cause the apoptosis of the target cell [114]. 
Dissimilar, CD4+ T cells (also known as T helper or Th cells) are not 
recognized by their cytotoxic features, but by their ability to secrete regulatory 
and suppressive cytokines and chemokines. They can be characterized into 
at least four different subsets. In a simplistic overview, Th1 cells mainly 
produce interferon gamma (IFNγ), interleukin 2 (IL-2) and are directly involved 
in the defense against intracellular pathogens and eventually transformed 
cells; Th2 cells are mostly known for their production of IL-4 and IL-13, being 
involved in immune suppression, allergic reactions and in the resolution of 
parasitic infections. Th17 cells produce Il-17, IL-21, IL-22 and provide 
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protection against extracellular pathogens [115, 116]. Lastly, T regulatory cells 
(or Treg cells), express the transcription factor Foxp3 and produce large 
amounts of IL-10, which has a key role in the regulation of inflammatory 
signals being the major regulatory cell population in the GT tract of both 
humans and mice (Figure 15), [117, 118].  
 
 
Figure 15. Adaptive immune system. The figure depicts cells from the adaptive immune system (T and B cells) 
becoming activated and exerting effector activities. Antigen presenting cells, like dendritic cells (DC), generally 
migrate to the secondary lymphoid structures activating resting, naïve B and T cells. Upon activation T and B cell 
differentiate into different subsets and migrate to the site of damage/ infection, mostly within the lamina propria.  
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1.2  The IL-4 Signaling Pathway 	 	
1.2.1 IL-4, IL-13, IL-4Rα and Stat6  
 
 Maureen Howard and William E. Paul first described interleukin 4 (IL-4) 
in 1982, in “The Journal of Experimental Medicine. They identified a factor 
present in the supernatant of mouse thymoma cells that when applied on B 
cell cultures would lead to the sustained maintenance of the cultured B cells. 
They later called it “B cell growth factor” [119]. 
 Since its discovery, the accurate functions that IL-4 can exert on cells 
are still not entirely known. The main reason for that is the abundant 
expression of IL-4 receptors in different tissues, and the evidence that 
different cell types exhibit distinct responses to IL-4 stimulation [120-122]. IL-4 
and its receptor are believed to be the central components of the IL-4 pathway. 
However, other important molecules such as IL-13 (which has approximately 
30% homology with IL-4 protein), and the signal transducer and activator of 
transcription 6 (STAT6) have already proven to be as much relevant and 
dynamic as IL-4 itself [123-126]. 
 To date, IL-4 is still best known for being a Type 2 cytokine, produced 
by activated Th2 lymphocytes, but it is pertinent to mention that other immune 
cells like macrophages, γ/δ T cells, mast cells, natural killer T-cells, basophils, 
and eosinophils are also reported to produce IL-4 [127, 128]. Additionally to its 
effects on B cell differentiation, immunoglobulin production and survival, IL-4 
(and in some instance IL-13) takes action on many other physiological 
processes. The most relevant and well-defined are: (i), inhibition of pro-
inflammatory cytokine production in other immune cells [129]; (ii), upregulation 
of major histocompatibility complex class II on monocytes [130], (iii), wound 
healing, and (iv) resolution of parasitic infections [131, 132]. Nevertheless, 
perhaps the function that has attracted considerably more attention over the 
past years is the ability of IL-4 (and IL-13) to polarize macrophages in an 
alternative pathway, which clearly differ these cells from the IFNγ-mediated 
classical activation. Alternatively activated macrophages (AAM) assume a 
wound-healing/tissue repair phenotype, expressing large amounts of arginase, 
and anti-inflammatory molecules such as IL-4, IL-10, IL-13, Tumor Growth 
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Factor Beta (TGF-β) and Found in Inflammatory Zone 1 (FIZZ-1), between 
many others. AAM, contrarily to classically activated macrophages, lack major 
roles in type 1 response (Th1), such as killing intracellular pathogens 
(including fungi) and tumor resistance  (Figure 16) [133, 134]. 
 
 
Figure 16. Classical versus alternative macrophage activation. (Diagram extracted from F1000Prime Reports 
2014, 6:13 [134]). All copyrights reserved to Faculty of 1000 Limited. Mantovani and colleagues [135] proposed a 
M1-M2 macrophage model, in which M1 cells are polarized by IFNγ, lipopolysaccharide (LPS) or tumor necrosis 
factor alpha (TNFα); M2 cells was subdivided in three main groups accordingly its similarities and differences 
between IL-4 polarization (M2a), immune complexes and Toll-like receptor (TLR) ligands (M2b), and IL-10 and 
glucocorticoids (M2c).  
  
 As previously mentioned, the IL-4 signaling pathway mainly comprises 
the cytokine IL-4 and its receptors. IL-4 can signal through two different types 
of heterodimeric receptors: (i) type I receptor, formed by the IL-2Rγ (also 
known by common gamma chain – “γc”) and IL-4Rα, being this receptor 
conformation normally found in immune cells due to the expression pattern of 
γc in cells of hematopoietic origin; (ii) type II receptor, formed by IL-4Rα and 
IL-13Rα1, being not only found in immune cells but also in other cell types, 
such as epithelial cells and fibroblasts. Curiously, IL-4 is able to signal through 
both types of receptors (I and II), but IL-13 is restricted to receptor type II, or 
to its own receptor, IL13Rα2, whose role is still under debate due to its 
restricted signaling activity in limited conditions. Important to mention, IL-4 
receptors do not present intrinsic kinase capabilities (Figure 17), [135-141].  
 The binding of IL-4 or IL-13 to their receptors initiates JAK-dependent 
tyrosine phosphorylation of IL-4Rα and consequently of the downstream 
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transcription factor, Stat6. This action will lead to dimerization and 
translocation of Stat6 into the nucleus where it regulates the transcription of a 
number of IL-4-responsive genes [124, 142, 143]. IL-4 is considered to be the 
predominant cytokine to trigger STAT6 phosphorylation. Likewise, STAT6 is 
believed to be the IL-4 main transcriptional mediator. 
 
                     
Figure 17. Receptor systems for IL-4 and IL-13. (Extracted and adapted by permission from Macmillan Publishers 
Ltd: Nature Reviews Drug Discovery 15, 35–50 (2016) [140]. The picture depicts the different IL-4 receptor 
conformations. The type I receptor, composed by IL-4Rα and the common cytokine receptor γ-chain (γc), only binds 
IL-4. The type II receptor complex, formed between IL-4Rα and IL-13Rα1, is the primary receptor for IL-13 but also 
binds IL-4. In addition, IL-13 will bind to a second receptor, IL-13Rα2.  
 
 Unlike most of the other members of the STAT family that recognize 
analogous DNA-binding sequences (STAT1, STAT3, STAT4, and STAT5) 
after nuclear translocation, STAT6 exhibits a distinct DNA-binding 
predisposition for palindromic sequences separated by four base pairs (bp) 
spacer (5’-TTCN4GAA-3’, (N4 site)). Most relevant, binding to those 
sequences will activate a genetical program that can regulate in the target-cell 
differentiation, DNA replication and survival [144-148]. 
 Significant progress has been achieved to understand the functions of 
IL-4 signaling mechanistically, but still little is known about STAT6 inducing 
gene expression in non-hematopoietic cells. To date, most of the performed 
studies have evaluated STAT6 functions exclusively in IL-4-driving conditions, 
without focusing on its direct relevance in epithelial cell homeostasis and 
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transformation. Regarding the intestinal tract, very limited data is available on 
its biological functions in the colonic epithelium, and the existing results on 
inflammation are conflicting depending on the model studied.  
 
1.2.2 IL-4 signaling involvement in tumorigenesis 
 
 In addition to its well-established physiologic processes, IL-4 signaling 
has been demonstrated to be involved in a variety of pathological conditions, 
including cancer. IL-4 and IL-13 receptors were found overexpressed in 
different malignancies, such as brain, thyroid, breast, pancreas, lung, colon 
and bladder tumors [122, 149-158]. Moreover, the direct effects on tumor 
promotion of IL-4 and of IL-13 cytokines in the tumor microenvironment cells, 
such as tumor-associated macrophages (TAMs) and myeloid-derived 
suppressor cells (MDSC) have been already shown [159, 160]. 
 Regarding colonic tumorigenesis, the contribution of IL-4 receptors in 
this process has been already investigated [151, 157]. Additionally, xenograft 
experiments have shown that colon cancer cells with constitutive STAT6 
expression had significant growth advantages over STAT6-deficient cancer 
cells. Furthermore, mice bearing constitutive STAT6 expression had higher 
seric levels of IL-4, IL-5, and overexpression of CDK4 and CD44v6 in their 
tumor cells [161]. Then, these findings evidence that the expression of 
different components of the IL-4 signaling axis in colon cancer can create a 
scenario favoring tumor growth, survival and dissemination (Figure 18). 
 The direct involvement of IL-4Rα in colonic tumorigenesis in a mouse 
model was accessed by Felicitas L. Koller and colleagues in 2010 [157]. 
Taking advantage of a colitis-associated tumor model, the investigators 
subjected WT mice or mice with global deletion of IL-4Rα (IL-4Rαdel/del) to the 
pro-carcinogen azoxymethane (AOM) and two cycles of dextran sodium 
sulphate (DSS). Interestingly, IL-4Rαdel/del mice exhibited significantly fewer 
and smaller tumors when compared with WT mice. Reduced tumorigenesis in 
these mice was associated with diminished proliferation and enhanced 
apoptosis of the tumor cells. The authors further showed that administration of 
a soluble chimeric receptor protein, which impairs IL-4 cytokine binding to IL-
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4Rα provided similar results on xenograft cecal implants of tumor cells, 
suggesting that IL-4Rα could be a potential therapeutic target in colon cancer.   
 
 
 Figure 18. IL-4 signaling in epithelial cancer cells and hematopoietic cells of the tumor microenvironment 
(TME). (Extracted and adapted from Clin Exp Metastasis (2015) 32 (8): 847–856) [162], with permission of Springer. 
IL-4 binding to type I receptor results in receptor tyrosine residue phosphorylation and activation of Janus Kinases 
proteins (JAKs), which further causes STAT6 phosphorylation or activation of the IRS/PI3K/AKT pathway. Activation 
of both pathways in immune cells generally results in the expression of IL-4 responsive genes related with cell 
differentiation, proliferation and survival (top, “TME”). Additionally, in transformed non-hematopoietic cells (bottom, 
“Tumor”), such as epithelial cells, the IL-4 receptor type II can be found. In this scenario, IL-4 binding will not only 
induce cell growth and survival, but also might promote uncontrolled cell proliferation, resistance to apoptosis, cell 
invasion and metastatization.  
 
 Additionally, IL-4 signaling seems necessary for colon cancer stem cell 
(CSC) survival and chemotherapy resistance to apoptosis. Using human 
colorectal tumor spheroids, Matilde Todaro and colleagues showed that 
CD133 positive colon CSCs have an autocrine production of IL-4, which 
provides these cells with increased resistance to apoptosis, and protect them 
from chemotherapy-induced death. Furthermore, the authors demonstrated 
that systemic treatment with IL-4Rα antagonist or anti-IL-4 neutralizing 
antibody potentiates chemotherapy efficiency in subcutaneous xenograft 
tumors in nude mice, leading to a significant reduction in tumor size [163]. 
Thus, although the participation of IL-4 signaling in colorectal tumorigenesis 
has been demonstrated, the exact underlying mechanisms that determine 
how IL-4Rα and STAT6 dictate their biological responses and how these 
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molecules are regulated in colonic malignant transformation still require 
further detailed investigation.  
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1.3 Colonic Carcinogenesis 
 
1.3.1 Colonic carcinogenesis 
 
 Colorectal cancer (CRC) is an important cause of mortality 
worldwide. It is the third most common incident malignancy in the western 
societies. When epidemiologically studied, Europe and Oceania share the 
highest rates while South America, Africa and the Caribbean the lowest [164]. 
Approximately 95% of malignant tumors are represented by adenocarcinomas 
and carcinomas, followed by a small fraction of lymphomas, leiomyosarcomas, 
carcinoids, histiocytomas, fibrous histiocytomas, hemangiosarcomas and 
melanomas [165]. Smoking, unbalanced or high-fat diet and sedentary 
lifestyle are all well-acknowledged risk factors for the development of the 
disease [166-168]. Colonic carcinogenesis is commonly classified as (i) 
sporadic (or non-hereditary), generally caused by somatic mutations in the 
WNT signaling, and being the vast majority of the cases (Figure 19a). 
Sporadic cases can be further linked to the presence or not of chronic colonic 
inflammation (so-called colitis-associated cancer - CAC); (ii) hereditary or 
familial cases, which are caused by inherited mutations, such as the ones 
found in hereditary non-polyposis colorectal cancer (HNPCC) syndrome, 
familial adenomatous polyposis (FAP) and Peutz-Jeghers syndrome [169, 
170].  
 As previously mentioned, inflammatory bowel diseases (IBD) are 
another predisposing factor for colorectal cancer development as long-lasting 
inflammation increases the overall risk of developing colorectal carcinoma to 
approximately 18 % after 30 years of the setup of the condition [171]. The two 
most common entities are ulcerative colitis and Crohn’s disease. Both have 
unknown etiology and are defined by persistent and recurrent inflammation of 
the gastrointestinal tract. Ulcerative colitis generally starts from the rectum 
and spreads across the whole mucosa till the proximal colon, while in Crohn’s 
disease the transmural inflammation is observed predominantly in the ileum 
and proximal colon, with occasional involvement of other parts of the 
gastrointestinal tract, such as anus and mouth [172, 173]. A conception that a 
genetical susceptibility exists in patients afflicted by IBD is emphasized by the 
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knowledge that IBD-development is significantly increased in people who 
have a first–degree relative affected by these conditions [174, 175], (Figure 
19b). Interestingly, although these patients exhibit an increased risk of CRC 
development, they just represent approximately 1 % of the new cancer cases, 
presumably, due to their frequent medical monitoring [175].  
 
         
Figure 19. Inflammatory basis of sporadic CRC and CAC. (Extracted and adapted by permission from Macmillan 
Publishers Ltd: Nature Immunology 17, 230–240 (2016) [170]). (a) In sporadic CRC, the mutations in the Wnt 
signaling, commonly in the APC gene, along with loss of cellular polarity and loosening of tight junctions, promotes 
the translocation of the microbiota into the epithelium leading to the secretion pro-inflammatory cytokines such as IL-
23 and IL-17 by immune cells, creating a pro-tumorigenic microenvironment. APC mutations are usually followed by 
KRAS and p53 mutations inducing the progression of the initial benign adenoma lesions to carcinoma. (b) In CAC, 
the chronic inflammation might induce mutation in tumor suppressor genes, such as p53. Additionally, constant 
activation of the NF-κB signaling pathway increases inflammation. As in the sporadic CRC situation, barrier defects 
will lead to microbiota translocation into the intestinal epithelium, generating genotoxic stress on the IECs, which can 
finally lead to mutations on APC and progression to carcinomas.  
 
1.3.2 Molecular events of colonic carcinogenesis 
 
Independent of its heredity or not, there are well-described molecular 
pathways leading to the development of colorectal cancer. The basic principle 
triggering colorectal carcinogenesis is generally a product of genomic 
instability, which leads to the inactivation of essential tumor suppressor genes, 
such as Adenomatous Polyposis Coli (APC). Inactivation of APC is found in 
approximately 80% of intestinal adenomas and carcinomas, being considered 
to be an early event in colorectal malignancies [176]. APC is a key tumor 
suppressor gene in CRC due to its exceptional ability to maintain tissue 
INTRODUCTION 
	 26	
homeostasis through the interaction with many important proteins, such as 
AXIN, RAC1, and β-CATENIN. APC activity controls the WNT signaling 
pathway by negatively regulating β-CATENIN, preventing its stabilization and 
constant nuclear translocation, which is known to have crucial effects on cell 
proliferation and induce oncogenic activity. Additionally, APC is able to bind to 
microtubules, promoting their stabilization and consequently a normal cellular 
architecture [177-180]. After APC inactivation, KRAS and TP53 gene 
mutations are common successive events in the transformation of the 
intestinal epithelium (already dysplastic) to neoplasia. Moreover, both are 
products of genetical instability and are highly prevalent in colorectal tumors 
[181, 182], (Figure 20). 
 
 
Figure 20. Genetic model of colorectal cancer (CRC). (Extracted from Annu. Rev. Pathol. Mech. Dis. 2011. 6:479–
507 [176]. Copyright 2011 by Annual Reviews. All rights reserved) (a) Sporadic cases of CRC are believed to 
develop from benign adenomas driven by genetical events over the past of many years. The initial inactivation of 
APC is followed by additional somatic mutations in the KRAS gene, and later by inactivation of the tumor suppressor 
gene P53 (b) In familial cases of CRC, patients already carry inherited somatic mutations, which can lead to the 
formation of adenomas. Additional acquired mutations, for example in mismatch repair genes generate a second hit 
to further malignant transformation. Commonly, in both cases (sporadic and familial) the microsatellite instability-
drove tumors exhibit inactivation of BAX and TGFβRII. 
 
Aberrant function or silencing of DNA mismatch repair (MMR) genes is 
another triggering-pathway to colorectal tumorigenesis. The MMR system is 
INTRODUCTION 
	 27	
composed of many different proteins (e.g. MSH2, MSH3, MHL1, PMS2), 
which detect and repair mismatched nucleotides in the genome [175, 183]. 
Malfunction of the MMR system might induce the formation of mutations 
(usually insertions and deletions) in microsatellite regions, causing 
microsatellite instability (MSI) [184, 185]. Thus, MSI can lead to frame shift 
mutations of tumor suppressor genes. Moreover, MSI is a regular feature of 
CRC found in approximately 15% of the sporadic cases of CRC and more 
than 95% in the cases of familial CRC [186]. Some examples of genes with 
mutations emerging in their microsatellite regions are RAD50, BAX, TGFβRII, 
IGFRII and PTEN [187].  
 An additional triggering-pathway in CRC is the hypermethylation of 
CpG islands. CpG islands are genomic regions with a high frequency of CpG 
sites, which are found throughout the genome, and are commonly methylated 
[188]. When these sites are located in the promoter regions of tumor 
suppressor genes, the methylation of CpG islands can lead to their silencing 
and complete loss of gene expression [189]. CRCs expressing these 
characteristics are classified as “CpG island methylator phenotype” or CIMP 
[190, 191]. Paradoxically, when methylation occurs outside gene promoter 
regions (gene body methylation), it might induce gene transcriptional 
activation [192, 193]. CDKN2A (P16), CXCLC12 and MLH1 are examples of 
genes found to be hypermethylated in CRC [194]. 
 Finally, a common phenomenon through which the mechanisms 
mentioned above might be initiated and further supported is chronic intestinal 
inflammation [195-197]. Chronic inflammation has the ability to promote 
colorectal tumorigenesis without generating direct early mutations. A perfect 
example of this feature is the fact that activation of inflammatory pathways 
may trigger β-catenin nuclear translocation and accumulation independently 
APC mutations [196, 198-200]. This capacity to initiate colorectal 
carcinogenesis is mainly attributed to the expression of two critical pro-
inflammatory proteins (i) signal transducer and activator of transcription 3 
(STAT3) and (ii) nuclear factor-κB (NF-κB) [201-205].  
 STAT3 belongs to a group of transcription factors (STAT family, STAT1, 
STAT2, STAT4, STAT5a/b and STAT6), which intermediate cellular signals 
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usually generated at the cell cytoplasmic membrane to the nucleus. Therefore, 
its activation can be induced by a plethora of cytokines and growth factors, 
such as IL-6, IL-10, IL-11, leukemia inhibitory factor (LIF), platelet-derived 
growth factor (PDGF) and epidermal growth factor (EGF), to cite a few [203, 
206-208]. The binding of STAT3-ligands to their cell-surface receptors can 
trigger STAT3 phosphorylation by Janus kinases and consecutively its 
dimerization. Dimerized, STAT3 translocates into the nucleus of the cell, 
where can initiate the transcription of innumerous STAT3-responsive genes – 
many of them involved in cellular proliferation and survival [175, 209]. 
Importantly, as most transformed cells (and also the tumor microenvironment) 
exhibit persistent activation of autocrine and paracrine signals, STAT3 may 
become constitutively active, further supporting colorectal tumorigenesis [208, 
210-212]. 
 STAT3 and NF-κB do not fit in the typical oncogene definition as their 
activation mostly relies on paracrine stimuli. However, upon activation both 
molecules can govern the expression of relevant genes, becoming important 
mediators to tumorigenesis [202, 210, 213-215]. Regarding NF-κB, the five-
member of this transcription factor family are RelA (P65), RelB, cRel, 
P105/P50 (NFκB1), and P100/P52 (NFκB2). When inactive, NF-κB, family 
members are cytoplasmic found in dimeric conformation (homo/heterodimers) 
linked to a member of the IκB inhibitory family. NF-κB activation happens 
when paracrine or autocrine signals induce the phosphorylation of the IκB 
element by IκB kinase (Iκκ), which leads to IκB degradation and consequently 
release of NF-κB dimers. Free, nuclear translocated NF-κB will bind to 
promoter regions, and as STAT3, start the transcription of genes implicated in 
cell survival, proliferation, and differentiation [216-218]. Similarly to STAT3, 
NF-κB activation is triggered by cytokines and growth factors, such as IL-1b, 
TNFa, and EGF. Moreover, constitutive NF-κB activation is observed in many 
tumor entities, including CRC [219-223], in which NF-κB ablation reduced 
tumor incidence [201].  
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1.3.3 Mouse models of colonic carcinogenesis  
 
The possibility to evaluate colorectal tumorigenesis through the 
continued accumulation of mutations in vivo is only possible due to the 
existence of animal models, in particularly mouse models. Mouse models are 
powerful tools to recapitulate and study the many different aspects involved in 
colitis-associated colon cancer. Nevertheless, due to CRC heterogeneity, the 
available mouse models do not recreate the process of malignant 
transformation in its totality, being necessary to use different models to fully 
understand the mechanisms involved in CRC development and progression 
[224, 225]. 
 As a result of this heterogeneity, several different genetically 
engineered mice (GEM) and scientific animal protocols have been developed 
to evaluate the genetical, morphological and clinical aspects of CRC (Table 1). 
Basically, these different mouse models can be divided into three categories: 
(i) genetically engineered mice, which exhibit contrasting tumorigenic features 
and allow the study of intestinal tumorigenesis from its benign initiation to its 
malignant transformation (e.g. MMR system-deficient mice, APCMin/Δ mice, IL-
10 and MUC2 deficient mice, β-CATENIN-transgenic mice); (ii) xenograft 
mouse models, which are mainly useful to evaluate tumor growth, metastasis 
and the efficiency of new therapeutic compounds, but as generally make use 
of immune-deficient animals leave the contribution of the immune system to 
tumorigenesis or therapy response unaddressed; (iii) chemically induced 
mouse models, which use of pro- and carcinogenic drugs to induce cellular 
transformation [226, 227]  
Regarding chemically induced models, one of the most used 
mutagenic drugs is azoxymethane (AOM). AOM is a pro-carcinogen that 
when injected intraperitoneally in rodents is fast metabolized to 
methylazoxymethanol (MAM) leading to the formation of O6-methylguanine 
and consequently DNA damage. [228, 229]. When combined with the 
administration of dextran sodium sulphate (DSS) in the drinking water a 
synergism between these two drugs is observed inducing the rapid growth of 
intestinal tumors (approximately 12 weeks) in mice [226, 230]. DSS is toxic to 
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the IECs, causing their death and consecutively the destruction of the 
intestinal epithelial layer. The direct contact of the microbiota and dietary 
products with the mucosa and lamina propria result in strong immune cell 
activation and inflammatory response, with the release of cytokines and 
massive generation of genotoxic stress on IEC. These effects can further 
promote intestinal transformation and CRC [88, 89, 231]. AOM/DSS-induced 
tumors display similar histopathological and molecular characteristics as 
observed in human intestinal neoplasms. They usually express β-CATENIN 
nuclear accumulation, Kras mutations and in a lower frequency APC 
mutations [232-234]. Mutations in P53 are rarely observed, and the tendency 
to distant metastatization is very low or absent. [235, 236]. 
 
Table 1. Most Common Mouse Models of CRC 
 
(Extracted from J Carcinog. 2011; 10: 9 [226]. All copyrights reserved to Journal of Carcinogenesis)  
FAP, familial adenomatous polyposis; HNPCC, hereditary nonpolyposis colorectal cancer; MMR, mismatch repair; 
DSS, dextran sulfate sodium; MAM, methylazoxymethanol; DMH, 1,2-dimethylhydrazine; AOM, azoxymethane; PhIP, 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; IQ, 2-amino-33-methylimidazo [4,5-f] quinoline; DMAB, 3,2′-
dimethyl-4-aminobiphenyl; MNU, methylnitrosourea; MNNG, N-methyl-N′-nitro-N-nitrosoguanidine. 
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2 AIM 
 
 Interleukin 4 signaling has been involved in crucial homeostatic and 
pathologic events, including tissue repair, allergy and cancer. It is well known 
for exerting resistance to apoptosis and to promote immune suppression, 
which favors tumor development. Nevertheless, the effects of IL-4 signaling 
cascade on colorectal carcinogenesis are still poorly understood and need 
further characterization. The aim of this study was to evaluate the cell type 
specific contribution of IL-4 signaling axis components IL-4Rα and STAT6 to 
colorectal carcinogenesis using mouse models of colitis-associated 
tumorigenesis to elucidate the molecular mechanisms governing this process.  
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3 MATERIAL AND METHODS 		
3.1  Materials 	
3.1.1  Chemicals, reagents and kits 
 Chemicals, reagents and kits used are listed in table 3.1. 
 
Table 3.1 List of Chemicals, Reagents and Kits 
Chemical/Reagent/Kit Company 
Acrilamide Merck 
Ammonium Persulfate Sigma 
Antigen Unmasking Solution Vector Laboratories 
Avidin/Biotin Blocking Kit Vector Laboratories 
Ciprobay 500mg Bayer 
Dextran Sulfate Sodium Salt (36.000-
50.000 M.Wt) MP Biomedicals 
dNTP mix Carl Roth 
DTT  Invitrogen 
Ethanol 99.8% purity Carl Roth 
LPS Sigma 
Methanol Carl Roth 
Oligo (dT) primer Invitrogen 
Paraformaldehyde 16% Electron Microscopy Sciences 
PBS 10X Invitrogen 
Poly I:C Sigma 
PVDF membrane Millipore 
QIAshredder Kit Qiagen 
Recombinant mouse IL-4 PeproTech 
RNaseOUT Invitrogen 
RNeasy Mini Kit Qiagen 
SDS Ultra Pure Sigma 
SuperSignal West Femto Substrate Thermo Scientific 
SuperSignal West Pico Substrate Thermo Scientific 
TEMED Sigma 
Golgi Plug BD 
Phorbol 12-myristate 13-acetate 
(PMA) Sigma 
Ionomycin Sigma 
RPMI medium Invitrogen 
Trypan Blue Sigma 
FBS Gibco 
ß-mercaptoethanol Sigma 
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3.1.2 Oligonucleotides 	
The following oligonucleotides were used for Quantitative Real Time 
PCR. 
 
Table 3.2 Quantitative Real Time PCR Primer List 
Gene Foward Primer Reverse Primer 
Bax AAACTGGTGCTCAAGGCCCT AGCAGCCGCTCACGGAG 
Cox-2 CAGCCAGGCAGCAAATCCT CTTATACTGGTCAAATCCTGTGCTCA 
Cyclophilin ATGGTCAACCCCACCGTGT	 TTCTGCTGTCTTTGGAACTTTGTC	
Il-1ß AGCAGGATGGAGAATTACAGGAAC	 TGTGGCCTGCTTGGGC	
Il-10 GGTTGCCAAGCCTTATCGGA	 ACCTGCTCCACTGCCTTGCT	
Il-11 CTGCACAGAGAGAGACAAATTCC	 GAAGCTGCAAAGATCCCAATG	
Il-6 ATGGTACTCCAGAAGACCAGAGGA	 GTATGAACAACGATGATGCACTTG	
Kc (Cxcl-1) GCCAATGAGCTGCGCTGT	 CCTTCAAGCTCTGGATGTTCTTG	
Mannose 
receptor TTGGTGGCAATTCACGAGAG	 GGGAAGGGTCAGTCTGTGTTTG	
Mcp-1 CAGCCAGATGCAGTTAACGC	 AGCCTACTCATTGGGATCATCTTG	
Mdm2 AATCCTCCCCTTCCATCACACT	 GATTTCCACTTTATCTTTCCCCTTATC	
Mgmt CGTGCAGTAGGAGGAGCAATG	 GAACCACCCTGTGGCAGG	
Mip-2 ATCCAGAGCTTGAGTGTGACGC	 AAGGCAAACTTTTTGACCGCC	
Noxa CTCCCAGGAAGGAAGTTCCG	 CGAGCGTTTCTCCTATCACATC	
p21 ATTCAGAGCCACAGGCACCAT	 TCTCCGTGACGAAGTCAAAGTT	
Puma ACGACCTCAACGCGCAGT	 GTGAGGGTCGGTGTCGATG	
TNF-α ACTCCAGGCGGTGCCTATG	 GAGCGTGGTGGCCCCT	
 
 The following oligonucleotides were used for mice genotyping. 
 
Table 3.2.1 Oligonucleotides Used for Genotyping  
Gene Forward Primer Reverse Primer 
IL-4Rα Global 
Deletion Mice 
Common 
WT allele 
Mutant 
 
 
CAGGGAACAGCCCAGAAAAG 
TGTGGGCTCAGAGTGACCAT 
CCAGACTGCCTTGGGAAAAG 
 
IL-4R Floxed 
Mice 
WT allele 
knockout allele 
 
 
CCCTTCCTGGCCCTGAATTT 
GGCTGCTGACCTGGAATAACC 
 
 
GTTTCCTCCTACCGCTGATT 
Stat6 mice 
Mutant 
WT allele 
Common 
 
AATCCATCTTGTTCAATGGCCGATC 
AAGTGGGTCCCCTTCACTCT 
ACTCCGGAAAGCCTCATCTT 
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Villin-Cre 
Recombinase 
 
ACCTGAAGATGTTCGCGATTATCT 
 
ACCGTCAGTACGTGAGATATCTT 
3.1.3 Antibodies 
 
The antibodies used are listed in table 3.3. 
 
Table 3.3 Antibody List 
Antibody Company Reference Condition 
BCL-2 BD Biosciences 610539 WB 1:1000 
 
BAD 
Santa Cruz 
Biotec 
 
Sc-8044 
 
WB 1:500 
BCL-XL BD Biosciences 556499 WB 1:800 
BrdU Serotec MCA2060 IHC 1:400 
Cleaved 
CASPASE-3 
 
Cell Signaling 
 
#9661 
 
ICH 1:400 
 
CYCLIN B1 
Santa Cruz 
Biotec. 
 
Sc-752 
 
WB 1:500 
CYCLIN D2 BD Biosciences 554200 WB 1:500 
E-CADHERIN BD Biosciences 610182 WB 1:2000 
phospho-P53 Abnova PAB12640 IHC 1:500 
P53 Novocastra NCL-p53-CM5p IHC 1:500 
phospho-ERK Cell Signaling #9101 WB 1:1000 
phospho-H2AX Cell Signaling #2577 IHC 1:1000 
phospho-
HISTONE H3 
Cell Signalling #9701 IHC 1:200 
phospho-STAT3 
Y705 
Cell Signaling #9131 IHC 1:200 
phospho-STAT3 
Y705 
Cell Signaling #9131 WB 1:1000 
phospho-STAT6 Abcam Ab54461 WB 1:800 
SOCS-3 Abcam Ab16030 WB 1:1000 
t-STAT3 BD Biosciences 610190 WB 1:1000 
 
t-STAT6 
Santa Cruz 
Biotec. 
 
Sc-981 
 
WB 1:500 
t-ERK Cell Signaling #9102 WB 1:1000 
VIMENTIN Abcam Ab92547 WB 1:1000 
ß-ACTIN Sigma A4700 WB 1:5000 
 
 
3.2 Cell Culture-Based Methods 
 
3.2.1 Extraction and stimulation of mouse bone marrow derived 
macrophages (BMDM) 
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Mice were sacrificed and the femur and tibia were isolated. Bone 
marrow cells were flushed out with sterile 1X PBS using a 25 G needle. 
Afterwards, cells were homogenized by pipetting, filtered through a 70 µm 
mash and centrifuged at 500 rcf for 10 minutes (4°C). Finally, cells were 
resuspended in RPMI medium (with glutamine) supplemented with 10% FBS, 
1% penicillin/streptomycin, 10% L929 cells supernatant, plated into 10 cm 
Petri dishes (day one) and kept in humidified cell incubator at 37°C, 5% CO2. 
On day four medium was exchanged and cells were allowed to differentiate till 
day seven. 
To stimulate, approximately 2 x 106 BMDM were plated per well into 6-
well uncoated-plates in 1ml of serum-free RPMI supplemented with 1% 
penicillin/streptomycin.  The following compounds were used at time points of 
6 and 24 hours (table 3.4): 
 
Table 3.4 Compounds Used for Stimulation 
Compound Concentration 
Recombinant mouse IL-4 10 ng/ml 
Recombinant mouse IFNg 5 ng/ml or 100U/ml 
LPS 100 ng/ml 
Poly I:C 100 ng/ml 
H2O2 100 µM/ml 
 
3.2.2 Extraction and stimulation of mouse peritoneal macrophages 
 
To obtain peritoneal macrophages each mouse was intraperitoneally 
injected using a 25 G needle with 3 ml of 3% thioglycolate medium. After 
three days mice were sacrificed, disinfected with 70% ethanol and eight ml of 
ice-cold sterile 1X PBS injected IP with a 27 G needle. To withdraw any 
attached macrophage into the PBS a gently abdominal massage was 
performed for one minute. Using forceps and scissors the skin was cut and 
pulled off, exposing the peritoneal wall. Carefully, a 10 ml syringe attached to 
a 21 G needle was inserted and all intra abdominal fluid was aspirated. The 
cell suspension was passed through a 40 µm mash, centrifuged at 200 rcf for 
10 minutes (4°C), resuspended with RPMI medium (with glutamine) 
supplemented with 10% FBS and 1% penicillin/streptomycin. Approximately 
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2x 106 cells were plated per well into 6-well uncoated-plates and incubated 
over night in humidified cell incubator at 37°C, 5% CO2  for attachment.  
To stimulate, cells were brought to serum-free RPMI supplemented 
with 1% penicillin/streptomycin and the same stimulation conditions of section 
2.2.1 was applied. 
 
3.2.3 Intestinal epithelial cell isolation 
 
To extract intestinal epithelial cells (IEC), first the intestine segment 
was cleaned from feces with ice-cold 1X PBS and cut-open longitudinally. 
Next, the intestine was cut in small pieces and incubated in 10 ml of pre-
warmed HBSS medium supplemented with 5 mM EDTA (Roth) and 2mM DTT 
(Sigma). Samples were gently shaking (80 rpm) for 10 minutes at 37°C. After, 
the 50 ml conic tube containing the tissue was vortexed for 30 seconds and 
put to rest on ice for more 30 seconds to allow the lamina propria to 
precipitate whilst IEC remained in the supernatant. The supernatant was 
carefully transferred to a new 50 ml conic tube passing through a 70 µm mash 
and further centrifuged for 5 minutes at 500G at 4°C. The obtained pellet was 
resuspended with 3 ml of ice-cold 1X PBS and divided in 2 to 3 1.5 ml 
eppendorf tubes. These were further centrifuged for 5 minutes at 2000 rpm at 
4°C. The clean washouts were discarded and the pelleted IEC were 
immediately frozen in liquid nitrogen. Finally, samples were stored at -80°C 
until use.  
 
3.2.4 Intestinal fibroblast isolation 
 
The intestinal fibroblast isolation was performed as described in [237], 
with minor modifications. Basically, the intestinal segment (colon) was 
enzymatically digested and the single cell suspension plated in 10 cm culture 
plates. Cells were used at the 5th passage and stimulation with recombinant 
mouse IL-4 was done in complete medium. 
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3.2.5 Intestinal organoid isolation 	
The colon was harvested and flushed 3X with ice-cold 1X PBS to 
remove the feces. Next, the intestine was cut-open longitudinally, minced in 
small pieces and transferred to a 50 ml conic tube containing 1X PBS 
supplemented with 1% Penicillin/Streptomycin and 50 µg/ml of Gentamicin 
(both Invitrogen). Tissue was pipetted up-and-down 10 times, the supernatant 
discarded and replaced by fresh supplemented PBS. This procedure was 
repeated 15 times until the supernatant become clear. Next, the 15th washout 
was discarded and the tissue was resuspended with 25 ml of 1X PBS 
containing 2mM EDTA (Roth) and left on ice for 30 minutes with constant 
shaking (80rpm). After the incubation with EDTA the tissue was allowed to 
settle down and the supernatant removed. Then, 10 ml of 1X PBS containing 
10% FBS was added and pipetted up-and-down 5 times. Tissue was allowed 
to settle down and the first supernatant discarded due to the high amount of 
debris. This step was repeated more 4 times and the supernatant collected 
passing through a 70 µm mash placed on a 50 ml conic tube. Cells were then 
centrifuged at 1200 rpm for 5 minutes at 4°C. The pellet was further 
resuspended with ERN culture medium (F-12 advanced DMEN/F-12 medium, 
Invitrogen) supplemented with 1% 1M HEPES, 1% Penicillin/ Streptomycin 
(Invitrogen), 1% Glutamine (Invitrogen), 20% Noggin (in-house made), 10% 
R-Spondin (in-house made), 1X N2 (Invitrogen), 80 µΜ n-Acetylcysteine - 
NAC (Sigma), 1X B27 supplement (Invitrogen), 200 ng/ml mEGF, 3.4 µg/ml 
Rock inhibitor - Y (Sigma), 10mM Nicotinamid (Sigma), 5µΜ CHIR (Axon), 
500 nM A83-01 (Tocris) and transferred to a 15 ml conic tube. After 5 minutes 
centrifugation at 800 rpm at 4°C the supernatant was carefully removed and 
matrigel (BD) added to the pellet (generally between 150 to 300 µl). 25 µl 
drops of matrigel-containing cells were plated in 48 well-plates (Sarsted) and 
covered with 250 µl ERN culture medium. Medium was changed every 3 days, 
and organoids passaged at a 1:3 ratio once a week. Stimulation with 
recombinant IL-4 was performed in complete medium. 
 
3.2.6 Determination of cell count and viability 
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Single-cells suspensions were obtained directly or by harvesting with 
0,25% Trypsin/EDTA and counted with a hemocytometer in the presence of 
1% trypan blue. Trypan blue negative cells were considered as viable cells. 
 
 
3.3 Molecular Biology Based Methods 
 
3.3.1 RNA isolation and determination 
 
RNA isolation was performed using RNeasy Mini Kit (Qiagen). Cells, 
whole intestinal mucosa or tumor tissues were lysed with RTL buffer 
containing 1% ß-mercaptoethanol. Complete tissue disruption and 
homogenization was achieved by using the Precellys 24 tissue lyser (Bertin 
Technologies), followed by QIAshredder Column Kit (Qiagen). The remaining 
steps were performed according to the manufacturer’s protocol. RNA 
concentration and purity was determined by NanoDrop 2000 
Spectrophotometer (Thermo Scientific). RNA was either directly subjected to 
cDNA synthesis or stored at -80°C. 
 
3.3.2 Reverse transcription, cDNA synthesis 
 
For cDNA synthesis, generally 1 µg of RNA was used. The reaction 
was performed in a final volume of 20 µl. First, 1 µg RNA, 2.5 µM OligodT 
(Invitrogen) and 0.5 mM dNTP-mix (Invitrogen) were incubated at 65°C for 5 
minutes. The mixture was cooled down on ice for approximately 2 minutes 
and mixed with 1X reaction buffer (Invitrogen), 5 mM DTT, 0.5 U RNaseOUT 
(Invitrogen) and 10 U Superscript II reverse transcriptase (Invitrogen). Next, 
the reaction was performed at 42°C, for 60 minutes followed by reaction 
inactivation, achieved by heating the samples up to 70°C for 15 minutes. 
Finally cDNA was diluted 1:4 with DNA-RNAse free water and stored at -80°C.  
 
3.3.3 Quantitative real time PCR 
 
Quantitative PCR analysis was performed using gene specific primers 
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designed for the gene of interest (table 3.2). For the reaction mix volume of 20 
µl, 1 µl of cDNA, 1X SYBR-Green Master Mix (Roche), 2 mM forward primer 
and 2 mM reverse primer were used. The reaction was carried out in the 
StepOnePlus Real Time PCR system (Applied Biosystems) using the 
conditions in table 3.5. The expression levels were normalized to the 
housekeeping gene Cyclophilin (Relative Expression = POWER 2(CT 
housekeeping gene−CT target gene)).  
 
Table 3.5 Quantitative PCR Program 
Cycles Temperature °C Time (seconds) 
Holding once 50 60 
Holding once 95 600 
Cycling 40X 95 30 
    Cycling ↵ 60 60 
 
3.3.4 DNA isolation and genotyping 
 
 In order to genotype the mice DNA was isolated by tail or ear sampling 
and lysed overnight in 95 µl tail lysis buffer (table 3.6) supplemented with 5 µl 
Proteinase K (Qiagen) at 60°C. The enzymatic digestion was stopped by heat 
inactivation at 95°C for 10 min. DNA samples were diluted with distilled water 
1:10 and centrifuged for 5 min at 10000 rpm to remove insoluble parts. All 
supernatants were directly subjected to polymerase chain reaction (PCR) 
(table 3.7).  
 
Table 3.6 Tail Lysis Buffer 
Compound Concetration 
Tris (pH8.5) 1,5M 
NaCl 200mM 
SDS Ultra Pure 0,2% (w/v) 
EDTA 5mM 
 
Table 3.7 General PCR Reaction 
Reagent Amount 
10X PCR Buffer (Invitrogen) 2 µl 
50 mM MgCl (Invitrogen) 0,8 µl 
100 mM dNTP mix (Carl Roth) 0,4 µl 
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20 pM Forward Primer 0,5 µl 
20 pM Reverse Primer 0,5 µl 
TAQ Polymerase 5 U/ µl (Invitrogen) 0,15 µl 
Destilled Water 14,15 µl 
DNA sample 1.5 µl 
 
3.3.5 Agarose electrophoresis 	
 Agarose gel was prepared by mixing 1X TAE buffer (table 3.8) with 1-
2% (w/v) agarose and by boiling the mixture in a microwave oven at 600W for 
four minutes. The gel was left to cool-down to approximately 60°C for the 
addition of ethidium bromide (0.005%). The gel was poured into the tray to 
cast and appropriate combs were placed for the formation of wells. 
Concomitantly, DNA samples were prepared by mixing 5X loading dye 
(Fermentas). Once the gel had polymerized, combs were removed and the 
gel was put into electrophoresis chamber, submerse in 1X TAE buffer. 1kb 
loading marker (Invitrogen) was used and gel was run at 120V for 30-60 
minutes. The DNA bands were observed under UV-light and they were 
photographed by using Gel Doc XR imaging system (Biorad). 
 
Table 3.8 50X TAE Buffer 
Compound Concentration 
Tris 2M 
Acetic Acid 5,7% 
EDTA 5mM 
 
3.3.6 Protein extraction and determination 
 
 Frozen intestinal epithelial cells, whole intestinal mucosa or tumor 
tissues were lysed with freshly prepared lysis buffer (table 2.9) containing 
protease and phosphatase inhibitors. Tissue disruption and homogenization 
was achieved by using the Precellys 24 tissue lyser (Bertin Technologies). 
Homogenized samples were let stand on ice for complete lysis for 15 minutes.  
For cell cultures, cells grown on culture plates were washed twice with 
ice-cold 1X PBS. Sufficient amount of lysis buffer containing protease and 
phosphatase inhibitors was directly added, cells were scrapped from the 
plates and collected into microcentrifuge tubes and lysed on ice for 15 
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minutes. When kept in suspension, cells were first transferred to a conic 15 ml 
tube, centrifuged 5 minutes, 500G at 4°C to pellet, washed once with ice-cold 
1X PBS and then transferred to microcentrifuge tubes to be lysed. Complete 
homogenization was achieved by hydrodynamic shearing (21 G needle), for a 
minute on ice.  
In all situations cell debris was removed by centrifugation 10 min, 
13.000 rpm at 4°C and supernatants containing total protein lysates collected. 
If not directly used, proteins were stored at -80°C. 
 
Table 3.9. Protein Lysis Buffer 
Compound Concentration 
Tris 50mM (pH 7.8) 
Nacl 250mM 
EDTA 30mM 
EGTA 30mM 
Sodium-pyrophosphate 25mM 
Triton X 100 1% 
NP-40 0,5% 
Glycerol 10% 
DTT 1mM 
ß-glycerophosphate 50mM 
Sodium fluoride 25mM 
Sodium Orthovanadate 5mM 
PMSF 2nM 
Roche Complete protease inhibitor 1 tablet to 50 ml 
 
3.3.7 Western blot 
 
 Protein lysates from tumors, colonic mucosa, intestinal epithelial cells 
or immune cells were subjected to SDS-PAGE in order to evaluate the 
expression of several molecules. The running gel percentage was chosen and 
prepared accordingly to the protein molecular weight of interest (tables 3.10; 
3.11; 3.12; 3.13 and 3.14 provide the composition of running/stacking gels 
and gel buffers). Gel electrophoresis was generally performed at 80 volts, for 
90 minutes in 1X running buffer. 
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Table 3.10 Western Blot Running Gel Composition 
Gel 
Percentage 
Bis-
acrylamide 
40% (ml) 
Running 
Gel 
Buffer 
(ml) 
Destilled 
Water 
(ml) 
10% APS 
(µl) 
TEMED 
(µl) 
08% 2 2,5 5,5 50 7 
10% 2,5 2,5 5 50 7 
12% 3 2,5 4,4 50 7 
15% 3,75 2,5 3,65 50 7 
 
Table 3.11 Western Blot Running Gel Buffer Composition 
Compound Concentration 
Tris-HCL pH 8,8 1,5M 
SDS 0,4% 
 
Table 3.12 Western Blot Stacking Gel Composition 
Gel 
Percentage 
Bisacrylamide 
40% (ml) 
Stacking 
Gel 
Buffer 
(ml) 
Destilled 
Water 
(ml) 
10% 
APS (µl) 
TEMED 
(µl) 
05% 0,713 950 4,6 62,5 15 
 
Table 3.13 Western Blot Stacking Gel Buffer Composition 
Compound Concentration 
Tris-HCL pH 6,8 0,5M 
SDS 0,4% 
 
Table 3.14 Western Blot Electrophoresis Running Buffer Composition 
(10X) 
Compound Concentration 
Tris 250mM 
Glycine 2M 
SDS 1% 
 
After electrophoresis, samples were transferred to PVDF membranes 
by wet blotting, using 1X transfer buffer (table 3.15) applying 300 mA during 
90 minutes, on ice. For proteins larger than 100 KDa the transfer time was 
increased to 120-150 minutes. PVDF membranes were further blocked with 
3% skim milk in PBST for 30 minutes. Antibody incubation was performed 
overnight at 4°C. Phosphorylated antibodies were diluted in 3% BSA/PBST 
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instead of 3% skim milk. Secondary HRP-conjugated antibodies were diluted 
in 3% skim milk in PBST during 30 minutes at room temperature. Detection 
was done by chemiluminescent reaction (SuperSignal West Pico Substrate, 
Thermo Scientific). 
 
Table 3.15 Western Blot Transfer Buffer Composition (10X) 
Compound Concentration 
Tris 12mM 
Glycine 96mM 
* Add 20% methanol to the final volume to obtain 1X transfer Buffer 
 
3.3.8 Formalin-fixed and paraffin embedded tissue processing 
 
 Immediately after sacrifice all necessary organs were harvested and 
fixed overnight in 4% PFA at 4°C. The following day, samples were 
transferred to 70% ethanol and processed by Leica Dehydrator Tissue 
Processor ASP 300S, according to manufacture’s protocol (table 3.16). After 
dehydration tissues were embedded in paraffin blocks and stored at RT.  
 
Table 3.16 Tissue Dehydration Protocol 
Reagent Incubation Time (min) 
Ethanol 70% 45 
Ethanol 86% 45 
Ethanol 96% 45 
Ethanol 96% 60 
Ethanol 100% 60 
Ethanol 100% 60 
Ethanol 100% 60 
Xylene 45 
Xylene 70 
Xylene 75 
Paraffin 60 
Paraffin 60 
Paraffin 60 
 
 For histological staining, 2-4 µm sections were cut with Leica 
Microtome RM 2235, transferred to 46°C water bath and fixed on SuperFrost 
(Thermo) glass slides. Before histological staining, sections were 
deparaffinized and rehydrated using the protocol described below (table 3.17). 
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Table 3.17 Deparaffinization and Rehydration Protocol 
Reagent Incubation Time (min) 
Xylene 5 
Xylene 5 
Ethanol 100% 2 
Ethanol 100% 2 
Ethanol 96% 2 
Ethanol 96% 2 
Ethanol 80% 2 
Ethanol 80% 2 
Ethanol 70% 2 
Ethanol 70% 2 
Ethanol 50% 2 
Ethanol 50% 2 
PBS 5 
 
3.3.9 Immunohistochemistry 
 
 For immunohistochemistry staining, sections were deparaffinized and 
rehydrated (table 3.17). After, antigen retrival was performed. For surface 
markers tissues were incubated in 0.3% Triton 10-20 minutes at 4°C. For 
nuclear or cytoplasmic stainings, sections were microwaved (approximately 
400 watts) in 1X low pH antigen unmasking solution (Vector Laboratories) for 
15 minutes, cooled down to RT and washed with PBS for 5 minutes. In order 
to block endogenous peroxidases the sections were further incubated in 3% 
H2O2 solution for 10 minutes. To avoid unspecific binding of antibody the 
sections were blocked for 30 minutes at RT with 3% BSA/PBS with 
streptavidin (Vector Laboratories). After blocking, the primary antibody was 
applied in the proper concentration (table 3.3) diluted in 3% BSA/PBS with 
biotin (Vector Laboratories), overnight at 4°C. The next day sections were 
washed with 1X PBS for 10 minutes and incubated with the appropriate biotin 
conjugated secondary antibody for 30 minutes at RT.  
After washing twice with 1X PBS for 5 minutes, the slides were 
incubated for 30 minutes at RT with ABC complex (Vector Laboratories). For 
visualization color reaction DAB kit (Vector Laboratories) was freshly prepared 
and used on the sections. The reaction was stopped submerging the slides in 
distilled water after the visualization of the color reaction under Leica Primo 
Star microscope. The sections were then stained with Mayer’s hematoxylin 
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(Merck) for counter-staining. After washing 3 times with distilled water, for 5 
minutes each, the sections were dehydrated according to the protocol in table 
3.18 and covered with mounting medium (Vector Laboratories) and a glass 
cover slide. 
 
Table 3.18 Dehydration Protocol 
Reagent Incubation Time (min) 
Ethanol 50% 3 
Ethanol 70% 3 
Ethanol 80% 3 
Ethanol 96% 3 
Ethanol 100% 5 
Xylene  5 
Xylene 5 
 
 
3.4 Mouse Models  
  
3.4.1 Global deletion of Il-4rα: IL-4Rα -/- mice 
  
 Interleukin 4 receptor alpha deficient (IL-4Rα-/-) mouse was generated 
and described by Dr. Nancy Noben-Trauth and colleagues in Proc Natl Acad 
Sci U S A. 1997 Sep 30; 94(20): 10838–10843 [238].  
   
Figure 21. Targeting of IL-4Rα . (Extracted from Proc Natl Acad Sci U S A. 1997 Sep 30; 94(20): 10838–10843 
[238]. Copyright 1997 © by the National Academy of Sciences). The disruption of the IL-4Rα  locus. (A) After 
homologous recombination exons 7 to 9 were exchanged by a PGKneogene in a anti-parallel orientation to the IL-
4Rα  gene. The targeting vector used had a 6.3 kb homology with IL-4Rα  gene.  
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 Briefly, a targeting vector carrying a neomycin-resistant cassette was 
inserted between exons 7 to 9 into Balb/c mouse embryonic stem cells 
disrupting the Il-4rα locus (Figure 21). Complete Il-4rα deletion was obtained 
by intercrossing heterozygous offspring. Homozygous IL-4Rα knockout mice 
show no apparent phenotypic abnormalities, but exhibit a loss of IL-4 signal 
transduction. This results in a diminished TH2 helper T cell response 
demonstrated both in vitro and in vivo. The strain was donated to The JAX 
Laboratories (Bar Harbor, Maine, USA) in a Balb/c background, and is 
commercially available under the stock number 003514. 
 
3.4.2 Il-4rα  specific deletion in intestinal epithelial cells (IEC): IL-
4RαΔIEC mice 
 
To achieve intestinal epithelial cell-specific deletion of Il-4rα, Il-4rα loxP 
flanked-mice were crossed (IL-4Rαflox/flox) with mice expressing Cre 
recombinase gene downstream the villin gene promoter (Villin-Cre).  
IL-4Rαflox/flox mice were generated and kindly provided by Dr. Frank 
Brombacher (University of Cape Town, Health Sciences Faculty, South Africa) 
and described at Immunity, Vol. 20, 623–635, 2004 [239]. Concisely, a 
neomycin resistance/thymidine kinase cassette flanked by loxP sites was 
inserted into exon 7 and an additional loxP site was inserted into exon 10 of 
the Il-4rα gene. Cre expression in mouse embryonic stem cells bearing the 
construct causes the removal of the selection cassette and joining of the loxP 
sites, flanking exons 7–9 (Figure 22). The intercross between the floxed strain 
with a villin Cre-recombinase-bearing strain [240] generated the intestinal 
epithelial cell-specific IL-4Rα-deficient mice.  
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Figure 22. Il-4rα  gene locus and targeted deletion. (Extracted and adapted with permission from Elsevier: 
Immunity, Vol. 20, 623–635, May, 2004 [239]). Introduction of (neo/tk) selection cassette flanked by two loxP sites 
(arrowhead), and one loxP site 5 of exon 10 resulted in the generation of the conditional “floxed” mouse (exons 7 and 
10) after gene targeting in Balb/c ES cells and transient Cre-mediated recombination. Numbers indicate exons of the 
IL-4Rα gene; B, E, and X, restriction site for BamHI, EcoRI, and XhoI respectively.  
 
Transgenic Villin-Cre mice have the mouse villin (Vil-1) promoter 
controlling the expression of Cre recombinase in villus and crypts of the small 
and large intestines. When these mice are bred with another strain containing 
loxP site sequences, specific deletion of the target gene may be obtained. 
Thus, they are a useful tool for studying intestinal development, functioning 
and its disorders (Figure 23). Villin Cre-recombinase mice were developed 
and first described by Dr. Blair B. Madison and colleagues at J Biol Chem. 
2002 Sep 6;277(36):33275-83 [240]. The strain was later on donated by Dr. 
Deborah L. Gumucio (University of Michigan), to the JAX Laboratories (Bar 
Harbor, Maine, USA). It is commercially available at the stock number 021504. 
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Figure 23. Villin Cre-recombinase mouse. (Extracted and adapted with permission by American Society for 
Biochemistry and Molecular Biology from J Biol Chem. 2002 Sep 6;277(36):33275-83 [240]). (A), Β-galactosidase 
expression due to Cre recombinase activity obtained by crossing hemizygous transgenic Cre mice with homozygous 
Rosa26 report mice. Expression is observed in duodenum (A d), jejunum (A j), ileum (A i) and colon (A c). The 
duodenum-stomach border is depicted by the arrow (A d). (B) The expression of Β-galactosidase was observed in all 
regions of the intestine; note that submucosa tissue do not express Β-galactosidase. (C) Mice exhibiting mosaic 
expression. 
 
3.4.3 Global deletion of Stat6: Stat6-/- mice  
  
 Stat6-deleted mouse was generated in the Department of Cancer 
Biology, Harvard School of Public Health  Boston, Massachusetts USA, under 
the supervision of Dr. Michael J. Grusby, and published by Mark H. Kaplan 
and colleagues at Immunity, Vol. 4, 313–319, March, 1996 [142]. Briefly, a 
neomycin resistance gene cassette replaced the exons containing the amino 
acids 505 to 584 of the Stat6 gene (region of the SH2 domain required to 
dimerization). Next, murine D3 embryonic stem cells were transduced by 
electroporation with the construct, and the G418-resistant clones that had 
undergone homologous recombination at the Stat6 locus were selected. 
Chimeras were generated injecting the construct into Balb/c blastocysts. 
Finally, heterozygous animals were intercrossed to generate mice 
homozygous for the Stat6 mutation (Figure 24). Homozygous mice are viable, 
fertile and with no behavioral abnormalities. Phenotypically, Stat6-deficient 
lymphocytes do not proliferate in response to IL-4, and exhibit a deficient IgE 
response upon in vivo immunization with anti-IgD. Stat6 knockout-derived 
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splenocytes have normal Th1 differentiation, and produce normal levels of 
IFNγ compared with WTs. However, Th2 cell differentiation is strongly 
reduced upon in vitro stimulation with IL-4 or IL-13. No other phenotypes are 
described in unchallenged Stat6-/- mice. 
 
         
Figure 24. Generation of Stat6-/-Mice. (Extracted and adapted with permission from Elsevier: Immunity, Vol. 4, 
313–319, March, 1996 [142]). A neomycin-resistant casset was inserted into the exon regions responsible for STAT6 
dimerization upon activation (SH2 domain). This strategy assured that any mutant protein produced would be 
unfunctional. Restriction enzymes sites B, BamHI; Bg, BglI; H2, HindII.  
  
The strain was donated to The JAX Laboratories (Bar Harbor, Maine, 
USA) in a C57BL/6 background, and is commercially available under the 
stock number 005977. 
 
3.4.4 AOM - DSS treatment protocols  
 
To study tumor development and progression driven by colitis mice 
were subjected to two intraperitoneal injections of AOM at concentration of 
10mg/kg of body weight, followed by three cycles of DSS in the drinking water, 
for five days. The animals were sacrificed and the organs harvested 84 days 
after the beginning of the experiment. Figure 25 depicts the protocol used in 
the study. The DSS concentration in the drinking water varied accordingly to 
the mouse strain ranging from 2.0% w/v to 2.5% w/v. Stat6-/- mice and mice 
that were subjected to adoptive transfer had to be sacrificed at an earlier time 
point due to severe anal hemorrhage and strong weight loss. 
To evaluate the early molecular events of carcinogenesis mice were 
subjected to a single intraperitoneal injection of AOM (10mg/kg of body 
weight) followed by one cycle of DSS in the drinking water, during five days. 
The DSS concentration in the drinking water varied accordingly mouse strains 
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ranging from 2.0% w/v to 2.5% w/v. After 15 days animals were sacrificed and 
the colon harvested.  
 
 
Figure 25. Azoxymethane (AOM) and dextran sodium sulphate (DSS) protocol diagrams.  
 
Alternatively, to closer observe the affects of AOM/DSS on IEC death, 
mice were subjected to a single intraperitoneal injection of AOM (10mg/kg of 
body weight) followed by one cycle of DSS in the drinking water, during 3 
days. At day eight, (3 days after the beginning of the DSS treatment) animals 
were sacrificed and the colon harvested. The DSS concentration in the 
drinking water was 2.0% w/v.  
Finally, to evaluate the acute effects of AOM on IEC, mice were 
intraperitoneally injected with AOM (10mg/kg of body weigh) and sacrificed 8 
hours after for tissue harvesting. 
 
 
3.5 Statistics 
 
 
Results were calculated using GraphPad Prisma 6 software. The p-
values were considered significant when ≤0.05, by Student’s T-test analysis. 
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4 RESULTS 
 
4.1 IL-4Rα -/- Mice 
 
4.1.1 Global deletion of Il-4rα does not cause any overt tumor-
promoting phenotype in unchallenged mice 
 
 First, to determine whether global Il-4rα deletion would influence 
homeostasis and promote tumorigenesis in the colonic epithelium of 
unchallenged mice, the colons of wild-type (WT) mice and mice with global 
deletion of Il-4rα (IL-4Rα-/- mice) were histologically analyzed at two different 
time points: at 1.5 and 18 months old (n≥4). Animals from both ages did not 
present any apparent spontaneous abnormalities in the colonic epithelium, 
showing no differences in intestinal development and with similar numbers of 
cells per colonic crypt (Figure 26 A, B). These results indicate that IL-4Rα is 
dispensable for colon homeostasis in steady state conditions. 
 
4.1.2 IL-4Rα signaling promotes tumor formation and tumor growth  
 
 The lack of detailed information about IL-4 signaling and its influence 
on the underlying mechanisms of colorectal malignant transformation raises 
the question of how IL-4Rα loss would affect colitis-associated colon 
carcinogenesis. In order to address this issue, WT and IL-4Rα-/- mice (both on 
Balb/c background) were exposed to two intraperitoneal injections of AOM 
and three cycles of 2% DSS in the drinking water (Figure 26 C). From the 
beginning of the treatment, it was observed that IL-4Rα-/- mice were less 
susceptible to weight loss than their WT counterparts, with significant 
differences at the end of the experiment (p≤0.05), (Figure 26 C). In response 
to AOM/DSS challenge, IL-4Rα-/- mice showed reduced tumor formation 
(p≤0.01) and reduced tumor growth than their WT controls (p=0.0674), (Figure 
D, E). Tumors from both genotypes displayed a classical tubular morphology 
and were exclusively located in the colon, both typical characteristics of 
AOM/DSS-induced tumors (Figure 26 D) [230]. To examine the reasons for 
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the observed differences in tumor load and size, the intratumoral proliferation 
rate was determined by staining FFPE tumor sections for BrdU incorporation 
and phospho-Histone H3 expression. Surprisingly, no changes in BrdU 
incorporation were observed. However, transformed epithelial cells from IL-
4Rα-/- mice showed a significant reduction in phosphorylated Histone H3 
expression, whereas WT mice exhibited an increase of approximately 40% 
compared    to     the    proliferation    rate    determined    for   IL-4Rα-/-    mice  
 
 
Figure 26. IL-4Rα -/- mice show reduced tumorigenesis in colitis-associated tumor model (A-H). Global deletion 
of IL-4Rα does not cause any overt tumor-promoting phenotype in the colon of unchallenged mice at 1,5 and after 18 
months, when compared with respective-age controls, (n≥4), (A, B); colitis-associated tumor model performed with 
WT (Balb/c) and IL-4Rα-/- mice (n≥07), (C-I); mice were subjected to two IP injections of AOM and exposed to 3 
cycles of 2% DSS in the drinking water, for 5 days. After 84 days animals were sacrificed, colons collected and fixed 
in 4%PFA and further stained with H&E for tumor counting and tumor measurement (D); IL-4Rα-/- mice showed 
reduced tumor formation (p≤0.01) and tumor growth (p=0.0611), (E); immunohistochemical analysis of tumors from 
IL-4Rα-/- mice do not show any differences in BrdU incorporation or cleaved-Caspase 3; however, express lower 
levels of phospho-Histone H3 (p≤0.01), (F, G), and phospho-Stat3 Y705 (p=0.0611), (H); immunoblot analysis of 
tumor lysates from IL-4Rα-/- mice at day 84 confirmed decreased Stat3 phosphorylation at tyrosine residue 705, 
followed by deregulated levels of SOCS3, decreased Bcl-xL, decreased Cyclins B1 and E, and increased Bad; no 
alterations in Erk phosphorylation was observed, although its total levels are decreased in IL-4Rαdel/de tumors (I). A, D 
– H&E; G, H – hematoxylin as co-staining. Scale bars: A, 1.5 months 1 mm, 18 months 0,2 mm; D,1 mm; G, H, 0,05 
mm. Data are mean ± SEM. 
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(Figure 26 F, G). In contrast, immunohistochemistry for cleaved-Caspase 3 to 
access apoptosis, performed with FFPE tumor sections did not reveal any 
alterations (Figure 26 F). 
 Additionally, the expression of signal transducer and activator of 
transcription 3 (STAT3), which has been proved to be a supportive molecule 
in colonic carcinogenesis [203] was checked in tumors from WT and IL-
4Rαdel/del mice. Immunohistochemical analysis revealed a specific nuclear 
localization of phosphorylated tyrosine 705 (active) of Stat3 (p-STAT3 Y705) 
in transformed enterocytes of WT mice, and this signal was decreased in 
transformed enterocytes from the colons of IL-4Rα-/- mice, (Figure 26 H). This 
finding was later confirmed by immunoblot analysis of tumor lysates from WT 
and IL-4Rα-/- mice (Figure 26 I, top panel).  
 Furthermore, STAT3 target molecules suppressor of cytokine signaling 
3 (SOCS3) and B-cell lymphoma-extra large (BCL-XL) were differentially 
regulated in IL-4Rα-/- tumors. SOCS3 expression, which is apparently 
increased in IL-4Rα-/- tumors, has the ability to act as a negative regulator of 
STAT3 activity; BCL-XL, an important anti-apoptotic molecule from the Bcl2 
family, is found strongly reduced (Figure 26 I). In accordance to the reduced 
tumorigenic phenotype observed in the IL-4Rα-/- mice, decreased expression 
of CYCLIN B1 and CYCLIN E, followed by strong upregulation of pro-
apoptotic molecule Bcl-2-antagonist of cell death (BAD), was also observed in 
IL-4Rα-/- tumors (Figure 26 I, middle panel). MAP kinase P44/42 (also known 
as ERK) phosphorylation did not show clear differences between genotypes. 
Interestingly, the total levels of ERK are decreased in IL-4Rα-/- tumors (Figure 
26 I, bottom panel).  
Collectively, these results indicate that Il-4rα ablation reduces colonic 
neoplastic transformation during colitis-associated tumor model with direct 
effects on cell proliferation and survival. Decreased STAT3 activity, altered 
expression of apoptosis-related molecules BCL-XL and BAD, followed by 
decreased CYCLIN B1 and CYCLIN E expression account for the phenotype 
observed in AOM/DSS-challenged IL-4Rα-/- mice. 
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4.2 IL-4RαΔIEC Mice 
  
4.2.1 Specific IL-4Rα signaling in IEC promotes tumor growth with 
effects on tumor cell proliferation and STAT3 phosphorylation 
 
 To investigate the role of IL-4Rα signaling specifically in intestinal 
epithelial cells (IEC) during colitis-associated tumorigenesis, IL-4Rα floxed 
(IL-4Rαflox) mice [239] were crossed to villin Cre transgenic mice [240], 
generating IL-4RαΔIEC mice. The crossing results in excision of exons seven to 
nine of the Il-4rα gene, thus abrogating the transcription of functional IL-4Rα 
mRNA (Figure 22). Based on the observations made using IL-4Rα-/- mice, was 
hypothesized that deletion of Il-4rα specifically in enterocytes would not 
induce any apparent tumor-promoting phenotype. Indeed, histological 
analysis of one and 18 months old unchallenged mice (n≥5) demonstrated 
that animals from both genotypes and ages did not develop any spontaneous 
colonic tumors (Figure 27 A). Notably, histological examination of the colons 
from IL-4RαΔIEC mice at 18 months revealed the presence of scattered areas 
showing signs of mild immune cells infiltration into the colonic mucosa and the 
area around the crypts, which were absent in WT mice. The adjacent 
epithelium did not show altered morphology or signs of transformation (Figure 
27 A, 200X and 400X magnifications). 
 Next, to better understand the effects of Il-4rα deletion on IEC during 
colitis-associated tumor, IL-4Rαflox (WT littermates) and IL-4RαΔIEC mice were 
exposed to two intraperitoneal injections of AOM and three cycles of 2% DSS 
in the drinking water, (Figure 27 B).  During the entire treatment with AOM 
and DSS, no significant differences in weight loss between genotypes were 
observed (Figure 27 B). In response to the challenge, IL-4RαΔIEC mice 
presented significantly reduced tumor growth (p≤0.05) but no effects on tumor 
incidence (Figure 27 C, D). Tumors of both genotypes had a classical tubular 
morphology and were exclusively located in the colon (Figure 27 C). To clarify 
the reasons for tumor size differences, the intratumoral proliferation rate was 
determined by staining FFPE tumor sections for BrdU incorporation and 
phosphorylated Histone H3 expression. A reduction in BrdU incorporation in 
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transformed epithelial cells of the IL-4RαΔIEC mice was observed (p≤0.05), 
whereas WT mice exhibited an increase of approximately 50% compared to 
the proliferation rate determined for IL-4RαΔIEC mice (Figure 27 E). In line with 
IL-4Rα-/- mice results, Histone H3 phosphorylation was also found significantly 
reduced (p≤0.001), (Figure 27 F). Interestingly, immunohistochemistry 
staining for cleaved-Caspase 3 using tumor sections did not reveal significant 
alterations in apoptosis between groups at this time point (84 days), (Figure 
27 G).  
To examine whether STAT3 expression was affected in IL-
4Rα−deficient transformed intestinal epithelia, immunohistochemical analysis 
with tumors from WT and IL-4RαΔIEC mice was performed. Notably, as 
formerly identified in IL-4Rα-/- mice tumors, a specific nuclear staining was 
observed in transformed enterocytes of WT mice, and this signal was 
approximately 4.5-fold decreased in transformed enterocytes from IL-4RαΔIEC 
mice (p≤0.05), (Figure 27 H).  
 Collectively, these results provide evidence that IL-4Rα signaling 
specifically in IEC has tumor-growth promoting effects during colitis-
associated tumorigenesis, and that IL-4Rα loss caused reduced cell 
proliferation and decreased STAT3 activity in the colonic epithelium. 
 
4.2.2 IEC-specific deletion of Il-4rα increases IEC apoptosis without 
affecting colonic epithelial regeneration at early events of AOM 
and DSS challenge 
 
 AOM/DSS administration initially leads to enterocyte DNA damage 
followed by DSS-induced apoptosis causing the disruption of the intestinal 
epithelial layer with translocation of microorganisms into the lamina propria. 
The presence of pathogens in the lamina propria triggers strong inflammatory 
response, which upon DSS-withdrawal starts to resolve and allow epithelial 
regeneration. This regeneration is widely promoted by immune cell-derived 
secreted cytokines, which induce IEC proliferation reconstructing tissue 
architecture. Homeostasis will be reached when the intestinal epithelial layer 
is re-established. At this time point usually, the expression of anti-
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inflammatory cytokines, such as IL-4 and IL-10 are found increased [175, 241, 
242]. As evidenced by the results here described, and by other elegant 
studies, IL-4/IL-4Rα signaling axis has crucial effects on cell survival and 
apoptosis  in  both  normal  and  transformed  epithelial  cells [162].  Therefore,  
 
 
Figure 27. IL-4RαΔIEC mice show reduced tumorigenesis in colitis-associated tumor model (A-H). Colonic 
histological analysis of unchallenged IL-4RαΔIEC mice does not show any tumor-promoting phenotype in mice at 1 and 
18 months of age, when compared with respective-age controls (n≥5), (A); 18 months of age IL-4RαΔIEC mice display 
increased mucosal infiltration of immune cells (A, 200X and 400X magnifications); colitis-associated tumor model 
performed with WT littermates (IL-4Rαflox) and IL-4RαΔIEC mice (n=10), (B-H); mice were subjected to two IP injections 
of AOM and exposed to 3 cycles of 2% DSS in the drinking water, for 5 days. After 84 days animals were sacrificed, 
colons collected and fixed in 4% PFA and further stained with H&E for tumor counting and tumor measurement (C-
D); IL-4RαΔIEC mice showed reduced tumor growth (p≤0.05), without significant changes in tumor formation (D); IHC 
showed that tumors from IL-4RαΔIEC mice exhibited lower BrdU incorporation (p≤0.01), compared with WT (n≥5), (E), 
and lower phospho-Histone H3 expression (n≥3) (F); immunohistochemical analysis for cleaved-Caspase 3 did not 
revel any significant difference between treated groups (G); IL-4RαΔIEC mice tumors expressed significant lower levels 
of phospho-STAT3 Y705 (n≥4), (p≤0.05), (H). A, C – H&E; E, H – hematoxylin as co-staining. Scale bars: A, 0,2 mm 
– 200X and 400X magnifications: 0,1 mm and 0,05 mm, respectively; C, 1 mm; E, 0,05 mm; H, 0,1 mm. Data are 
mean ± SEM. 
 
to evaluate the effects of IL-4Rα loss on DSS-induced apoptotic response, 
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WT and IL-4RαΔIEC mice were treated with one IP injection of AOM and 
exposed to 2% DSS in the drinking water for three days, being sacrificed and 
analyzed eight days after the beginning of the challenge (Figure 28 A). 
Efficient induction of apoptosis was confirmed by immunohistochemical 
staining performed on FFPE colon sections for cleaved-Caspase 3 (Figure 28 
B). Increased apoptosis in the epithelium of IL-4RαΔIEC mice (p≤0.01) was 
accompanied by a distinct reduction in BCL2 expression in lysates of isolated 
IEC at the 8th day of the regime (d8). No differences between unchallenged 
IEC lysates (d0) were observed (Figure 28 C, immunoblot analysis). 
Expression of the pro-apoptotic molecule BAD was not altered between 
treated groups (d8) but slightly increased in unchallenged IEC lysates (d0)  
(Figure 28 C). These findings are in agreement with the hypothesis that IL-
4/IL-4Rα signaling is involved in the regulation of apoptotic-related molecules 
in epithelial cells.  
 Next, to evaluate inflammatory response, epithelial damage and 
regeneration in the early events of tumorigenesis, WT and IL-4RαΔIEC mice 
were injected IP with AOM and exposed for five days to 2% DSS in the 
drinking water, followed by a five days recovery phase on normal water 
(Figure 28 D). It was hypothesized that IL-4RαΔIEC mice would experience 
stronger colitis based on the increased DSS-induced apoptotic response, and 
given the central role of IL-4Rα for IL-4 signaling, a strong immune-
suppressive pathway. Unexpectedly, histological analysis of inflammatory 
response, epithelial damage and regeneration did not reveal differences 
between treated groups, in spite of IL-4RαΔIEC mice exhibiting reduced BrdU 
incorporation at the 15th day of the analysis (Figure 28 E, F, K).  
 Corroborating the immune-histological findings, RT-PCR analysis of 
inflammatory and chemoattractant genes, performed with whole colonic 
mucosal samples from WT and IL-4RαΔIEC mice did not show any significant 
alterations in mRNA expression between treated (d15) and untreated mice 
(d0), (Figure 28 G-I). Finally, immunoblot analysis performed with lysates of 
isolated IEC at the 15th day of the regime showed reduced phosphorylation of 
STAT3 at Y705, followed by decreased expression of CYCLINS D2 and B1, 
both   relevant   cell   cycle   regulatory   proteins,  (Figure 28 J).   Interestingly,  
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Figure 28. IL-4Rα  deletion in intestinal epithelial cells sensitizes enterocytes to apoptosis, without affecting 
tissue regeneration after AOM and DSS administration (A-K). To determinate the apoptotic response to 
AOM/DSS, WT and IL-4RαΔIEC mice were treated with one IP injection of AOM and exposed to 2% DSS in the 
drinking water for 3 days, being sacrificed 8 days after the beginning of the challenge (n=5), (A); IHC for cleaved-
Caspase 3 performed with FFPE colonic sections from WT and IL-4RαΔIEC mice showed enhanced apoptosis in the 
epithelium of IL-4RαΔIEC mice compared with WT controls, (p≤0.01), (B); immunoblot performed with IEC lysates from 
WT and IL-4RαΔIEC mice revels decreased BCL2 expression at day 8 in IL-4Rα−deleted IEC when compared with WT 
IEC. BAD expression is unmodified (C); to determine inflammatory response, epithelial damage and regeneration 
after AOM/DSS treatment, animals were treated as previously, but 2% DSS was administrated for 5 days in the 
drinking water followed by a 5 days recovery phase on normal drinking water. Mice were sacrificed and analyzed on 
day 15 of the beginning of the challenge (n≥5) (D); histological analysis of inflammatory response, damage and 
ulceration did not revel differences between groups (E, F); RT-PCR analysis of whole colonic mucosa samples for 
inflammatory markers and chemoatractants at day 15 did not evidence significant changes in mRNA expression 
between treated and untreated groups (G-I); Immunoblot analysis showed decreased expression of p-STAT3 Y705, 
CYCLINS D2, CYCLIN B1 and p-STAT6 in IL-4Rα-deficient IEC lysates extracted at day 15, when compared with 
WT (J). IHC staining for BrdU incorporation at day 15 indicates decreased IEC proliferation in IL-4RαΔIEC mice 
compared with WT, (p≤0.05), (K). Scale bars: B, 0,05 mm; E, 0,2 mm; K, 0,05 mm; (B, K), hematoxylin as co-staining. 
(E) H&E; Data are mean ± SEM. 
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phosphorylation of STAT6, the most important transcription factor 
downstream IL-4/IL-4Rα was still observed in IL-4Rα-deficient IEC at day 15 
(Figure 28J).  
Taken together, these findings indicate that during the early events of 
carcinogenesis, IL-4Rα deletion in IEC affects the apoptotic response caused 
by AOM-DSS treatment. Additionally, loss of Il-4rα in IEC reduced epithelial 
cell hyperproliferation in the regenerative phase of the colitis, evidenced by 
lower BrdU incorporation caused by decreased CYCLIN D2 and CYCLIN B1 
expression. Strikingly, the enhanced apoptotic rate and reduced STAT3 
activity found in Il-4rα-deficient IEC must be compensated by other molecules 
not detected by our analysis, as we did not observe differences in tissue 
regeneration at the end of the treatment with AOM/DSS. Finally, the 
unexpected observation that STAT6 phosphorylation was still present in Il-
4rα-deficient IEC suggests IL-4-independent functions of STAT6. 
 
4.3 Stat6-/- Mice 
 
4.3.1 Stat6 global deletion does not cause any overt phenotype in 
unchallenged mice 
 
 To elucidate whether global Stat6 deletion would influence 
homeostasis or promote tumorigenesis in the colonic epithelium of 
unchallenged mice, the colons of WT mice and mice with global deletion of 
the Stat6 gene (Stat6-/- mice) were histologically analyzed at 1.5 and 18 
months of age. Animals from both genotypes and ages did not present any 
apparent abnormalities in the colonic epithelium, showing no differences in 
intestine development (Figure 29 A).  
 
4.3.2 Stat6 expression during colitis-associated tumor model protects 
against tumor formation and tumor growth 	
 To further clarify the role of IL-4 signaling during colitis-associated 
tumorigenesis WT and Stat6-/- mice were subjected to AOM/DSS treatment. It 
was hypothesized that being STAT6 one of the main components of the IL-4 
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pathway and a downstream target of the IL-4Rα, the effects of its loss during 
colitis-associated tumor model would be similar to the ones obtained with IL-
4Rα-/- and IL-4RαΔIEC mice. To address this issue, WT and Stat6-/- mice (both 
on a C57BL/6 background) were exposed to two intraperitoneal injections of 
AOM and three cycles of 2% DSS in the drinking water (n≥8), (Figure 29 B). 
From the second cycle of the treatment, it was observed that Stat6-/- mice 
were significantly more susceptible to weight loss than WT counterparts, with 
significant differences until the end of the experiment (respectively, p≤0.05 
and p≤0.01). Due to intense anal hemorrhage and weight loss, animals had to 
be sacrificed and tissues collected at an earlier time point, 57 days after the 
beginning of the treatment (Figure 29 B).  
 Surprisingly, and in disagreement with the initial hypothesis, Stat6-/- 
mice showed increased tumor formation and tumor growth compared to WT 
controls (p≤0.001), (Figure 29 C, D). Tumors from both genotypes had a 
classical tubular morphology and were exclusively located in the colon (Figure 
29 C). To elucidate the differences in tumor formation and growth, the 
intratumoral proliferation and apoptotic rates were determined by staining 
FFPE tumor sections from both genotypes for BrdU incorporation and 
cleaved-Caspase 3. Intriguingly, at this time point (57 days), no differences 
were detected in any of the genotypes in both parameters (Figure 29 E). Next, 
knowing that IL-4 signaling disruption during colitis-associated tumorigenesis 
was able to alter STAT3 activity in enterocytes, tumor sections from WT and 
Stat6-/- mice were immunohistochemically analyzed for STAT3 
phosphorylation. Interestingly, it was observed that Stat6-deficient tumors 
presented increased STAT3 phosphorylation at Y705 by 3-fold, when 
compared with WT tumors (n≥3), (Figure 29 F);  
 To further identify the molecular mechanisms that could be involved in 
the phenotype obtained, the lysates of unchallenged colons (d0) and tumors 
from WT and Stat6-/- mice were analyzed by immunoblot. Endorsing the IHC 
results, increased STAT3 phosphorylation at Y705 in Stat6-/- tumors, was re-
confirmed when compared to WT tumors (Figure 29 G, top); this was followed 
by deregulated SOCS3 expression in the tumor samples from Stat6-/- mice 
(Figure 29 G). Additionally, an increase in the expression of CYCLIN B1 in 
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Stat6-/- mice was detected, not only in tumors but also in unchallenged colons 
(Figure 29 G). This finding was followed by increased expression of anti-
apoptotic protein BCL-XL (Figure 29 G). 
 
 
Figure 29. Stat6 expression during colitis-associated tumor model protects against tumor formation and 
tumor growth (A-G). Histological analysis of the colon of unchallenged Stat6-/- mice do not revel any apparent 
tumor-promoting phenotype at 1,5 and 18 months of age, when compared with respective age-controls (n≥4), (A); 
colitis-associated tumor model performed with WT and Stat6-/- mice (n≥8), (B-G); mice were subjected to two IP 
injections of AOM and exposed to three cycles of 2% DSS in the drinking water, during five days; due to severe 
weight loss and anal hemorrhage, animals were sacrificed and tissues collected 57 days after the beginning of the 
treatment (B); colons were fixed in 4% PFA and stained with H&E for tumor counting and measurement (C); Stat6-/- 
mice presented increased tumor formation and tumor growth when compared with WT controls (p≤0.005) (D); BrdU 
incorporation and cleaved Caspase-3 expression evaluation by immunohistochemistry do not show any significant 
differences between groups at 57 days (E); immunohistochemical analysis of FFPE tumor sections from Stat6-/- and 
WT mice showed enhanced STAT3 phosphorylation at Y705 in Stat6-/- mice (p≤0.05) (n≥3), (F); immunoblot analysis 
performed with unchallenged colons and tumor-lysates from WT and Stat6-/- mice asserts increased STAT3 activity in 
Stat6-deficient tumors, followed by deregulated expression of STAT3-target molecule SOCS3, (G); upregulated 
expression of CYCLIN B1, BCL-XL and phosphorylated ERK in Stat6-/- tumors, when compared with tumors from WT; 
CYCLIN B1 and phosphorylated-ERK expressions were also found increased in unchallenged colon-lysates of Stat6-/- 
mice, when compared with unchallenged WT colon lysates (G). Scale bars: A, 0,2 mm; C, 1 mm; F, 0,1 mm; (A, C), 
H&E staining; (F) hematoxylin as co-staining. Data are mean ± SEM. 
 
 Finally, supporting the above findings, the ERK MAPK pathway, which 
is critical for cellular growth, was found to be dramatically upregulated in all 
Stat6-/- samples, notably, not only in tumors but also in unchallenged colons 
(Figure 29 G, bottom). Thus, these results clearly indicate that Stat6 
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expression during colitis-associated tumor model protects against tumor 
formation and tumor growth, with direct effects on STAT3 activity and STAT3-
regulated molecules. 
  
4.3.3 Stat6-deficient tumors present decreased P53 nuclear localization 
and reduced mRNA levels of Mgmt and P21 genes 
 
 The transcription factor P53 is regarded to be one of the most 
important tumor suppressors not only for colorectal carcinogenesis but also 
for nearly all malignancies. Under cellular stress, P53 activation occurs (due 
to post-translational modifications, such as phosphorylation) leading to its 
rapid nuclear translocation and accumulation. In the nucleus, P53 can initiate 
the expression of innumerous stress-response genes, which generally might 
result in three different outcomes: DNA repair, cell cycle arrest or apoptosis 
[243, 244]. Therefore, it was asked whether Stat6 ablation during colitis-
associated tumorigenesis would influence P53 cellular expression or 
localization. To answer this question, immunohistochemical analysis for P53 
activity was performed using FFPE tumor sections from WT and Stat6-/- mice. 
As a result, a 3-fold decrease in nuclear localization of P53 in transformed 
enterocytes from Stat6-/- mice tumors was observed when compared to WT 
tumors (p≤0.01), (Figure 30 A). In agreement with the immunohistochemical 
analysis, the mRNA level of O6-methylguanine DNA methyltransferase (Mgmt) 
gene, whose expression is regulated by P53 was found to be diminished in 
Stat6-/- tumors, as was the mRNA levels of the cell cycle regulator P21 gene, 
whose expression is also tightly controlled by P53 (RT-PCR; Figure 30 B). 
Expression levels of Mdm2 (a P53 negative regulator gene), or Noxa (a pro-
apoptotic P53-inducible gene), were not altered (RT-PCR; Figure 30 B). 
 Taken together, these data indicate that STAT6 activation during 
colitis-associated tumorigenesis provides tumor suppressive functions. 
Mechanistically, Stat6 ablation promotes Stat3 activation. Subsequently, Stat3 
activity might affect molecules involved in cell cycle regulation and cellular 
growth such as CYCLIN B1 and ERK, as well as tumor suppressor gene P53 
and its targets, Mgmt and P21. 
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Figure 30. STAT6 expression affects P53 nuclear localization during colitis-associated tumor model (A-B). 
Immunohistochemical analysis of P53 activity revels a 3-fold decrease in nuclear localization in Stat6-/- tumors 
(p≤0.01), (n≥3), (A); decreased mRNA levels of P53 target genes Mgmt and P21, by RT-PCR analysis in Stat6-/- 
tumors (p p≤0.05 and p≤0.01, respectively), (B); P21 mRNA expression is also found decreased in the colon of 
unchallenged Stat6-/- mice (p≤0.01), (B); mRNA expression of Mdm2 and Noxa genes, in the tumors of WT and  
Stat6-/- mice did not reveal any alterations. Scale bars: A, 0,05 mm; (A) hematoxylin as co-staining.  Data are mean ± 
SEM. 
 
4.3.4 Stat6-deficient enterocytes are the major contributors for 
increased colonic tumorigenesis in Stat6-/- mice during colitis-
associated tumor model  
 
 Considering that Stat6 deletion was global (whole-body), it was not 
possible to discriminate which cell population was responsible for the 
increased tumorigenic phenotype observed in these animals during colitis-
associated tumor model. Thus, to address the contribution of Stat6 loss in 
immune cells during tumorigenesis, adoptive transfer experiments were 
performed with either WT (C57BL/6 controls) or Stat6-deficient bone marrows 
(Figure 31 A). Eight weeks after the transplantation, WT mice, which received 
Stat6-deficient bone marrow   (Stat6-/- BM ! WT), and Stat6-/- mice that 
received WT bone marrow (WT BM ! Stat6-/-), were subjected to AOM/DSS 
challenge. However, during the second administration of 2% DSS, WT BM ! 
Stat6-/- mice started to lose weight dramatically followed by strong anal 
hemorrhage, being necessary to terminate the experiment 54 days after the 
first AOM injection (Figure 31 B). In response to the challenge, WT BM ! 
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Stat6-/- mice presented a 6-fold increase in tumor formation (p≤0.05) when 
compared to Stat6-/- BM ! WT mice (Figure 31 C, D). WT BM ! Stat6-/- mice 
tumors were also larger but failed to reach statistical significance. Tumors 
from both genotypes had a classical tubular morphology and were exclusively 
located in the colon (Figure 31 C). Interestingly, similarly to untransplanted 
Stat6-/- mice subjected to colitis-associated tumor model (Figure 29), IHC 
quantification for BrdU incorporation and cleaved-Caspase 3 expression did 
not reveal alterations in proliferation or apoptosis between groups, at 54 days 
(Figure 31 E).  
 To examine whether STAT3 expression was affected in transformed 
enterocytes, immunohistochemical analysis with tumors from WT BM ! 
Stat6-/- and Stat6-/- BM ! WT mice was performed. As formerly observed in 
untransplanted Stat6-/- mice tumors, a specific nuclear staining was detected 
in transformed enterocytes of WT BM ! Stat6-/- mice, and this signal was 2.5-
fold reduced in transformed enterocytes from Stat6-/- BM ! WT mice (p≤0.05), 
(Figure 31 F).  
 In addition to IEC and immune cells, vascular cells and fibroblasts are 
also components of the tumor milieu. Fibroblasts are one of the largest cell 
populations present in the tumor microenvironment, and many elegant studies 
have already shown that these cells can exert important features on intestinal 
transformed epithelial cells, promoting tumor development, growth and even 
metastasis [237, 245-247]. Thus, to evaluate the potential influence of colonic 
fibroblast in the phenotype obtained with WT BM ! Stat6-/- mice, WT 
fibroblasts and colonic organoids were extracted and stimulated in vitro with 
recombinant mouse IL-4 and analyzed after 30 and 60 minutes. Immunoblot 
analysis performed with lysates from WT colonic organoids and fibroblasts 
depicts clear STAT6 phosphorylation at Y641 in organoids at 30 and 60 
minutes after stimulation with recombinant IL-4 (Figure 31 G). However, 
STAT6 phosphorylation was completely absent at any time point in colonic 
fibroblasts, which also failed to express total levels of STAT6  (Figure 31 G). 
To assure the epithelial and mesenchymal origin of the samples, the 
immunoblot membrane was further incubated with anti-E-cadherin and anti-
Vimentin antibodies (Figure 31 G). 
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 Altogether, these results indicate that the non-hematopoietic system, 
primarily the Stat6-deficient enterocytes, are the major cells involved in 
increased tumor formation and tumor growth in Stat6-/- mice during the colitis-
associated tumor model. Moreover, deletion of Stat6 in enterocytes renders 
these cells more susceptible to STAT3 upregulation in response to 
inflammatory insults. STAT3 overexpression provides enterocytes with strong 
tumor-promoting features during colorectal tumorigenesis. 
 
 
 
Figure 31. Adoptive transfer experiments with Stat6-deficient and Stat6-proficient bone marrow (A-G). 9.5 Gy-
irradiated WT and Stat6-/- mice received either STAT6-deficient or WT bone marrow (A), and 8-weeks after the 
transplantation were subjected to two IP injections of AOM and two cycles of 2% DSS (n≥6). Due to severe weight 
loss and anal hemorrhage in the group of Stat6-/- mice which received WT bone marrow, animals had to be sacrificed 
and colons collected in 4% PFA 54 days after the beginning of the AOM/DSS treatment (B); Stat6-/- mice which 
received WT bone marrow showed 6-fold increase in tumor formation (p≤0.05), and larger tumors (C, D); 
immunohistochemical analysis of FFPE tumor sections from Stat6-/- and WT transplanted mice showed enhanced 
STAT3 phosphorylation at Y705 in Stat6-/- mice which received WT bone marrow (p≤0.01), (n≥3) (F); immunoblot 
analysis with lysates from WT colonic organoids and fibroblasts depicts STAT6 phosphorylation at Y641 in organoids 
after 30 and 60 minutes stimulation with recombinant mouse IL-4 (10ng/ml). However, this phosphorylation was 
complete absent at any time point in colonic fibroblasts, which failed to express total levels of STAT6 (G). To assure 
the epithelial and mesenchymal origin of the samples membranes were blotted with anti-E-CADHERIN and anti-
VIMENTIN antibodies (G); Stat6-deleted splenocytes, stimulated eight hours with recombinant mouse IFNg (5ng/ml) 
were used as negative control (neg. Stat6); WT abdominal macrophages, stimulated two hours with recombinant 
mouse IL-4 (10 ng/ml) were used as positive control (pos. Stat6). Scale bars: C, 1 mm; F, 0,05 mm; (C), H&E 
staining; (F), hematoxylin as co-staining; Data are mean ± SEM. 
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4.3.5 Lack of Stat6 increases IEC apoptosis in the early stages of 
tumorigenesis, leading to severe colitis in response to AOM/DSS 
challenge 
 
 Interleukin 4 and IL-13 binding to IL-4Rα trigger STAT6 
phosphorylation by JAK kinases and its nuclear translocation, which then may 
initiate the transcription of IL-4/IL-13 signaling-related genes. It is known that 
the activation of this pathway influences wound healing, cell survival and is 
able to exert anti-inflammatory effects [132, 136, 248]. Therefore, to 
determine by which mechanisms Stat6 loss affects colorectal tumorigenesis 
during AOM/DSS treatment, animals from both WT and Stat6-/- genotypes at 
the early stages of tumor development were examined, on day eight and 15 of 
the colitis-associated tumor model.  
 First, to determine the epithelial apoptotic response to DSS, WT and 
Stat6-/- mice were injected with AOM and sacrificed three days after the 
starting of DSS administration (Figure 32 A). As observed previously in IL-
4RαΔIEC mice, immunohistochemical analysis of cleaved-Caspase 3 revealed 
a 3-fold induction of apoptosis in Stat6-/- mice compared to WT (p≤0.01), 
(Figure 32 B). This result raised the question whether the increase in 
apoptosis detected at the 8th day of the colitis-associated tumor model would 
induce a stronger colitis in Stat6-/- mice. To address this issue, animals were 
treated as previously, but 2% DSS was administrated in the drinking water 
during five days followed by a five-day recovery phase on normal drinking 
water. This approach allowed the evaluation of inflammatory response, 
epithelial damage, and tissue regeneration. Throughout the treatment, the 
weight loss was similar between the genotypes (Figure 32 C). However, 
histological analysis of the colons at day 15 of the AOM/DSS challenge 
revealed that Stat6-/- mice suffered from more severe colitis than the WT 
counterparts (p≤0.001) (Figure 32 D). STAT6-deficient mice clearly showed a 
delay in induction of the healing phase with extensive damage to the colonic 
architecture, which was replaced by massive immune cell infiltration and 
ulcerations (Figure 32 D, E). 
RESULTS 
	 67	
 
Figure 32. Stat6-deficient colonocytes display increased susceptibility to DSS-induced apoptosis in early 
stages of tumorigenesis, resulting in severe colitis upon AOM/DSS treatment (A-L). WT and Stat6-/- mice were 
treated with 1 IP injection of AOM and exposed to 2% DSS in the drinking water for 3 days, being sacrificed 8 days 
after the beginning of the challenged (n=5), (A); immunohistochemistry for cleaved-Caspase 3 performed on FFPE 
colon sections from WT and Stat6-/- mice at day 8 showed enhanced apoptosis in colonocytes from Stat6-/- mice 
(p≤0.01), (B); WT and Stat6-/- mice were treated as previously (A), but 2% DSS was administrated for 5 days in the 
drinking water, followed by a 5 days recovery phase on normal drinking water. Animals were sacrificed at day 15 of 
the beginning of the challenge, (n≥5), (C); histological analysis of WT and Stat6-/- colons revealed increased 
inflammatory response and tissue damage in Stat6-/- mice, compared to WT, (p≤0.001), (D, E); RT-PCR analysis for 
inflammation-related and chemoattractant genes, performed with colonic mucosal samples at day 15, displayed 
mRNA upregulation for all tested genes in Stat6-/- mice at day 15 (F-H); Griess assay performed with supernatants of 
stimulated BMDM do not show any difference in NO production between groups (I); arginase assay performed with 
BMDM lysates stimulated with recombinant IL-4 and LPS showed reduced conversion of arginine to ornithine and 
urea in BMDM from Stat6-/- mice (I); immunohistochemical analysis of FFPE colon sections show increased STAT3 
phosphorylation at Y705 (p≤0.01) and BrdU incorporation (p≤0.001) in colons from Stat6-/- mice (J, L); immunoblot 
performed with unchallenged (d0) and AOM/DSS treated colon lysates from WT and  Stat6-/- mice revealed stronger 
STAT3 activity in Stat6-/- samples at day 15 (d15) (K); SOCS3 expression is deregulated between WT and Stat6-/- 
samples at day 15 (K). Scale bars: B, 0,05 mm; D, 0,2 mm; J, L, 0,05 mm. D, H&E staining. B, J, L, hematoxylin as 
co-staining. Data are mean ± SEM. 
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Supporting the histological findings, RT-PCR analysis of whole colonic 
mucosal samples for inflammatory and chemoattractants-related genes, 
revealed significantly increased mRNA expression of the genes encoding Il-1β, 
Cox-2, Kc, Mip-2, Ccl-2, Il-6 and Il-10 in Stat6-/- mice at day 15. No differences 
between unchallenged animals were found  (d0), (Figure 32 F-H). 
 Previously, John Elrod and colleagues speculated that Stat6 loss might 
render myeloid cells with enhanced nitric oxide (NO) cytotoxicity towards 
microbes, regulating colitis severity [249]. Therefore, to verify whether this 
reactive metabolite was increased in BMDM from Stat6-/- mice during 
inflammatory responses, BMDM were stimulated with different compounds. 
However, no differences were detected in NO release between genotypes, as 
depicted in Figure 32 I. Additionally, to check whether the ability to convert L-
arginine to urea and ornithine was altered in Stat6-/- mice - as IL-4 signaling 
controls arginase activity [250], which in turn modulates NO production - an 
arginase assay was performed. Upon IL-4 stimulation Stat6-/- BMDM failed to 
generate urea and ornithine, evidencing that arginase levels are dependent 
on STAT6 in vitro (Figure 32 I). 
 Because the previous results showed that disruption of the IL-4 
signaling during colitis-associated tumor model affected STAT3 activity, and 
considering that secretion of IL-6, IL-11 and IL-10 are known to influence its 
expression, STAT3 phosphorylation at Y705 was checked on day 15 in both 
genotypes. Immunohistochemistry detected a 6-fold stronger signal in Stat6-/- 
enterocytes, which was greatly decreased in WT enterocytes, (p≤0.001), 
(Figure 32 J). Moreover, immunoblot analysis performed with unchallenged 
(d0) and 15 days treated colon lysates confirmed STAT3 enhanced activation 
and SOCS3 overexpression in Stat6-deficient colon lysates (Figure 32 K). 
Finally, it was hypothesized that the intense inflammatory response followed 
by the robust STAT3 activation would alter the process of mucosal 
regeneration, which involves epithelial cell hyperproliferation. Indeed, 
immunohistochemical analysis for BrdU incorporation revealed a significant 
increase in proliferation in enterocytes from Stat6-/- mice at day 15 (p≤0.001), 
(Figure 32 L). 
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 Collectively, these data show that Stat6 deficiency affects IEC 
susceptibility to DSS-induced apoptosis, which leads to severe colitis. The 
extensive tissue damage found in Stat6-/- mice induces massive immune cell 
infiltration and cytokine release into the colonic mucosa, triggering strong 
STAT3 activation in Stat6-deficient enterocytes. During the regenerative 
phase, overexpression of STAT3 leads to aberrant epithelial proliferation, thus 
promoting colorectal tumorigenesis.  
 
4.3.6 Acute effects of AOM on Stat6-/- IEC leads to increased DNA 
double strand breaks and apoptosis 
 
 AOM has been widely used for more than 40 years to study the 
molecular mechanisms involved in colorectal carcinogenesis. Upon its 
administration, AOM is hepatic metabolized by cytochrome P450 generating 
MAM. MAM is further degraded into 2 other metabolites, formaldehyde and 
reactive alkylating species, both highly toxic agents that can cause DNA 
damage and initiate tumorigenesis [251-253]. Acutely, the DNA alkylation and 
formation of O6-methylguanine lead to DNA damage and to the activation of 
several intracellular signaling pathways related to DNA damage response. 
Phosphorylation of Histone H2AX (γ-H2AX) at DNA double strand breaks 
(DSB) is one of the initial signals upon DNA damage and it is generally 
followed by P53 phosphorylation at serine 15 (Ser15), which in mouse 
corresponds to serine 18. P53 activation can result in DNA repair, cell cycle 
arrest, senescence and/or apoptosis. The last generally triggered via 
transcriptional induction of genes that encode pro-apoptotic factors, such as 
Bax and Puma [228, 254, 255].  
 To observe the acute carcinogenic effects of AOM on IEC and better 
understand the underlying mechanisms for increased tumorigenesis in Stat6-/- 
mice, animals were subjected to one IP injection of AOM and sacrificed eight 
hours later (Figure 33 A). It was initially hypothesized that upon AOM 
administration STAT6-deficient IEC would be more susceptible to DNA 
damage with reduced P53 activation, which later would lead to increased 
acquisition of mutations, promoting colorectal tumor development. Indeed, 
immunohistochemical analysis for Histone H2AX phosphorylation using FFPE 
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colon sections from WT and Stat6-/- mice, revealed increased DNA damage in 
colonocytes from Stat6-/- mice, 8 hours after AOM administration (p≤0.01), 
(Figure 33 B). Additionally, and in line with our hypothesis, Stat6-/- mice 
displayed significant less phosphorylated P53, by IHC staining (Figure 33 C). 
Supporting the finding that P53 phosphorylation was reduced following DNA 
damaged induced by AOM, RT-PCR analysis for P53-target genes performed 
with unchallenged (d0) and 8 hours AOM-treated isolated IEC did not show 
any alteration on the mRNA levels of P21, Puma, Bax and Mgmt genes 
between treated groups (Figure 33 D). However, expression of the Mdm2 
gene was found to be increased after AOM administration (Figure 33 D, 
second lane). 
 
 
Figure 33. Acute effects of AOM on STAT6-deficient IEC (A-E). WT and Stat6-/- mice were IP injected with AOM 
(10mg/ Kg of body weight) and animals were sacrificed 8 hours later for analysis (A); immunohistochemical analysis 
for phosphorylated Histone H2AX, showed increased DNA damage in Stat6-/- mice enterocytes (p≤0.01), (B); Stat6-/- 
mice display decreased P53 phosphorylation by IHC staining (p≤0.05), (C); RT-PCR analysis for P53 target genes 
performed with IEC from untreated and 8 hours AOM-treated mice shows no alterations in P53-target genes, apart 
from increased mRNA expression for Mdm2, in treated mice, (p≤0.01) (D); enhanced cleaved-CASPASE 3 signal is 
observed in unchallenged and 8 hours AOM-treated IEC from Stat6-/- mice, compared with WT (p≤0.05 and p≤0.01, 
respectively) (E). Scale bars: B, 0,05 mm; C, 0,1 mm; E, 0,2 mm. B, C, E, hematoxylin as co-staining. Data are ± 
SEM. 
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 Finally, knowing that the alkylating hit produced by AOM administration 
also induces IEC apoptosis, and this effect is generally mediated by P53 
activity, the apoptotic response in enterocytes from WT and Stat6-/- mice was 
evaluated. It was predicted that apoptotic rates would be reduced in Stat6-/- 
IEC due to diminished P53 phosphorylation and unaltered expression of its 
target genes Puma and Bax, after DNA damage. Surprisingly, 8 hours after 
AOM treatment, Stat6-/- mice showed enhanced cleaved-CASPASE 3 
expression by IHC staining, when compared to WT mice (p≤0.01), (Figure 33 
E). Furthermore, unchallenged Stat6-/- mice also presented enhanced 
apoptosis rates than WT mice (p≤0.05), (Figure 33 E). 
 Thus, these results indicate that STAT6-deficient IEC are more 
susceptible to DNA damage produced by alkylating agents, such as AOM. 
Furthermore, they show that Stat6 loss influences P53 activation, evidenced 
by reduced P53 phosphorylation. Unexpectedly, we observed that Stat6 
signaling in enterocytes protects these cells from apoptosis, as both 
unchallenged and AOM-treated Stat6-/- mice show increased expression of 
cleaved-CASPASE 3. Intriguingly, this event seems to be independent of P53 
activity.  
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5 DISCUSSION 
 
 The aim of the current work was to determine the contribution of IL-4 
signaling molecules IL-4Rα and STAT6 to colorectal tumor development in a 
mouse model of colitis-associated tumorigenesis. The findings revealed that 
the role of IL-4 signaling differs dramatically depending on the signaling 
component analyzed. It was demonstrated that both IL-4Rα and STAT6 exert 
specific cell-intrinsic functions affecting IEC cell survival and proliferation 
during colitis-associated tumorigenesis. Above all, it was shown that despite 
IL-4Rα and STAT6 make part of the same signaling axis, their loss during the 
initial events of tumor development lead to remarkably opposite outcomes. 
This work provides further evidence for the underlying mechanisms of IL-4 
signaling in colorectal carcinogenesis and demonstrates the importance of 
dismembering cellular signaling pathways in order to comprehend their 
regulatory complexities better. 
 
5.1 Global deletion of Il-4rα suppresses colorectal tumorigenesis by 
reducing STAT3 activity and inducing intestinal epithelial cell cycle 
arrest 
 
 The lack of detailed information about IL-4Rα, a component of the IL-4 
signaling, in colorectal malignant transformation prompted the investigation of 
which would be the effects of Il-4rα loss during colitis-associated 
tumorigenesis. Making use of the AOM/DSS tumor model, it was shown that 
mice with global deletion of Il-4rα had fewer and smaller colonic tumors when 
compared to WT mice. These findings are partially in accordance with a 
preliminary report by Felicitas Koller and colleagues [157], where the authors 
suggested that Il-4rα loss during AOM/DSS treatment reduces tumorigenesis 
by inhibiting proliferation and enhancing apoptosis of transformed cells. 
However, in the present analysis, no differences in apoptosis in tumors were 
found. One possible explanation could be the differences in the adopted 
AOM/DSS protocol. Unlike in the study of Felicitas Koller and colleagues, that 
sacrificed animals approximately 40 days after the beginning of the treatment, 
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the currently experimental set up consisted in exposing the mice to two IP 
injections of AOM and three cycles of DSS, sacrificing animals 84 days after 
the beginning of the experiment. It is possible that at this later time point 
differences in cleaved-CASPASE 3 expression are not any longer detected.  
 Additionally, it was reported that global deletion of Il-4rα during colitis-
associated tumor model reduces STAT3 activity in transformed colonocytes. 
In normal and untransformed cells, the levels of activated STAT3 remain 
transient; however, STAT3 remains constitutively active in approximately 70% 
of solid human tumors [256]. Its constitutive activation regulates the 
expressions of many target genes, such as, Cyclin B1, Cyclin D1, c-Myc, Bcl-
xl, and Survivin, which are closely involved in tumorigenesis and tumor 
survival [257-262]. The importance of epithelial Stat3 expression to IEC 
survival and cell cycle progression has been already proven by many elegant 
studies [175, 203, 263-265]. The reduction in STAT3 activity after the Il-4rα 
loss could explain why pre-neoplastic lesions from IL-4Rαdel/del mice display 
similar rates of BrdU incorporation, an established S-phase marker, but show 
reduced proliferation by the M-phase marker phospho-Histone H3. Whereas 
transformed WT colonocytes progress to cell division, most IL-4Rα-deficient 
cells stay in cell-cycle arrest at G2. It was shown that the reduction in 
proliferation observed in the tumors of IL-4Rαdel/del mice was caused by 
decreased expression of CYCLIN E and CYCLIN B1 – the last, a crucial 
molecule for adequated cell cycle progression from G2 to the M-phase and 
known to be also regulated by STAT3 [266, 267]. Overexpression of CYCLIN 
B1 is observed in several malignancies including laryngeal and esophageal 
squamous cell carcinoma and colorectal carcinomas [268-271]. Therefore, 
CYCLIN B1 downregulation in Il-4rα-deficient mice could also be directly 
involved in the reduced neoplastic transformation and consequently in 
tumorigenesis. 
 Although immunohistochemical analysis of tumors from WT and IL-
4Rαdel/del mice at the 84th day of the AOM/DSS regime did not detect 
differences in cleaved-CASPASE 3 expression, it was demonstrated that IL-
4Rαdel/del mice tumors distinctly express reduced levels of the anti-apoptotic 
protein BCL-XL and increased expression of the pro-apoptotic protein BAD.  
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Whereas BCL-XL may be directly regulated by STAT3 activity [203, 264], 
BAD expression could be controlled through IL-4 signaling, as binding of IL-
4/IL-13 to IL-4Rα also induces the phosphorylation of insulin receptor 
substrate 1/2 (IRS 1/2) activating the PI3K/AKT pathway. When active, AKT is 
able to phosphorylate BAD, suppressing BAD expression and its antagonistic 
functions against anti-apoptotic proteins. In line, pharmacologic inhibitors and 
dominant inhibitory forms of PI3K and AKT abolish the anti-apoptotic effects 
of IL-4 [272]. Thus, Il-4rα deletion could cause a reduction in the PI3K/AKT 
pathway activity, explaining the increase in BAD expression.  
 
5.2 IEC-specific deletion of Il-4rα suppresses tumor development by 
inducing apoptosis of the initiated cells and by preventing 
epithelial hyperproliferation after DSS-induced colitis 	
 Since both tumor and stromal cells were deficient in IL-4Rα in the IL-
4Rαdel/del mice, the contribution of Il-4rα loss on IEC to the obtained 
phenotype during colitis-associated tumorigenesis could not be precisely 
evaluated. To address this issue, further experiments with IL-4RαΔIEC mice 
were performed.  
 As observed with IL-4Rαdel/del mice, it was shown that deletion of Il-4rα 
specifically in IEC during steady-state conditions did not induce any tumor-
promoter phenotype, whereas during colitis-associated tumor model IL-4Rα 
loss modulated tumorigenesis. Intriguingly, IL-4RαΔIEC mice showed 
significantly reduced tumor growth but no differences in tumor initiation.  This 
interesting finding made us speculate that Il-4rα loss in other cell types than 
enterocytes might also play a role during colorectal tumorigenesis. It is well 
known that in collaboration to intrinsic cellular mechanisms to counter 
tumorigenesis (e.g. activation of tumor suppressor genes), the immune 
system plays a critical role in the identification and elimination of transformed 
cells. This extraordinary action is executed based on the expression of 
molecules produced during cellular stress response and by the detection of 
specific tumor antigens in transformed cells [273-275]. Therefore, it was 
considered that Il-4rα expression in immune cells could affect tumor immune 
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surveillance. Moreover, it has been already shown that during the early stages 
of tumorigenesis some signaling pathways activated by transformed cells may 
disturb innate immune response against the establishment of tumors and 
consequently even accelerate their development and growth [276, 277]. This 
issue will be further addressed by future studies, but the preliminary data 
obtained by using mice with Il-4rα-specific deletion in myeloid cells indicate 
that Il-4rα expression in macrophages and neutrophils could influence 
colorectal tumor immune surveillance (unpublished, data not shown), 
explaining why IL-4RαΔIEC mice did not present differences in tumor initiation.  
 Focusing on the direct effects of Il-4rα loss in enterocytes it was further 
demonstrated that tumors from IL-4RαΔIEC mice also exhibited reduced 
proliferation by a clear reduction in phosphorylated Histone H3, once more 
denoting cell cycle arrest at the G2-phase. Additionally, although significant 
differences in apoptosis between IL-4Rα−deficient and proficient tumors could 
not be detected by cleaved-CASPASE 3, at the early stages of tumorigenesis 
Il-4rα−deficient enterocytes were highly susceptible to DSS-induced apoptosis 
caused by reduced BCL-2 and BCL-XL expression (Figure 28 C and data not 
shown, respectively). These findings support the idea that one of the reasons 
for reduced tumorigenesis in Il-4rα-deficient mice is the death of the initiated 
epithelium. This action prevents the accumulation of transformed epithelial 
cells, which can trigger intestinal tumor development due to a dysregulation in 
their genetic program controlling proliferation and apoptosis [203, 278]. BCL-2 
plays a crucial role in regulating cell survival through protein-protein 
interactions with other Bcl-2-related family members, including BCL-XL and 
the death agonists BAD and BAX [279]. The expression of these anti-
apoptotic proteins can be a direct consequence of IL-4 and STAT3-mediated 
transcriptional regulation, therefore explaining their reduced expression [203, 
248, 257, 280-282]. Interestingly, it was observed that although IL-4Rα-
deficient IEC presented enhanced apoptosis, there were no differences in the 
resolution of inflammation at day 15 of the AOM/DSS regime. This finding 
could be theoretically caused by the inability of IL-4RαΔIEC mice to recruit 
inflammatory cells into the lamina propria after DSS exposure. Supporting this 
hypothesis, RT-PCR analysis for chemoattractants and inflammatory 
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cytokines expression did not reveal any differences between the two 
genotypes at this time point (d15). 
 Furthermore, it could be speculated that Il-4rα loss in IEC may be 
compensated by other factors involved in mucosal wound healing which were 
not evaluated in this study and remain to be determined such as, pancreatitis 
associated protein (PAP), heat shock proteins (HSPs) and Toll-like receptors 
(TLR) [283-285]. It has been suggested that PAP represents an anti-
inflammatory mechanism in colitis due to its ability to inhibit NF-κB activation, 
decrease cytokine production and adhesion molecule expression in inflamed 
tissue [286-288]. Thus, PAP could counteract the inflammatory response by 
inhibiting leukocyte recruitment into the intestine.  
 During colitis, intestinal epithelial cells secrete many pro-inflammatory 
cytokines and chemokines. The regulation of this secretion is necessary to 
prevent chronic inflammation and extra mucosal damage. HSPs play a major 
role protecting against inflammation by inhibiting pro-inflammatory cytokine 
production. Moreover, It has been shown that HSP70 has important anti-
apoptotic effects on IEC and can protect them from DSS-induced colitis [289, 
290]. Additionally, TLR expression has been already correlated with intestinal 
epithelial cell protection during bacterial LPS-induced inflammation. Moreover, 
TLR can mediate IEC responses during the development of colitis [291-293]. 
Hence, TLR can modulate colonic homeostasis protecting IECs from injury. 
 Lastly, it has been shown by elegant studies on colitis-associated 
cancer that aberrant epithelial proliferation during inflammatory insults can 
predispose to neoplastic transformation [197, 201, 203, 294-296]. Therefore, 
the finding that IL-4RαΔIEC mice presented reduced IEC proliferation at the 
regenerative phase after acute DSS-induced colitis could represent another 
mechanism by which these animals exhibited reduced tumorigenesis. 
 
5.3 Stat6 deletion promotes colorectal tumorigenesis by inducing 
aberrant overexpression of STAT3 during colitis-associated tumor 
 
 In vitro and in vivo studies support the concept that STAT6 is crucial to 
transcriptional activation in response to IL-4 and IL-13 stimulation, highlighting 
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the importance of STAT6 to IL-4 signaling inducible genes [124, 142, 297, 
298]. Therefore, it was hypothesized that Stat6 ablation during colitis-
associated tumor model would generate similar results as the ones obtained 
with Il-4rα knockout mice. The results obtained demonstrated that Stat6 loss 
did not perturbed intestinal homeostasis in steady-state conditions; however, 
it strongly modulated colorectal tumorigenesis. Conversely to what was 
observed in IL-4Rαdel/del and IL-4RαΔIEC mice, Stat6-/- mice showed increased 
tumor formation and enhanced tumor growth when compared to WT mice. 
Interestingly, although tumors from both genotypes did not show differences 
regarding tumor cell proliferation or apoptosis, Stat6-deficient tumors 
exhibited significantly enhanced STAT3 activity.  
 It is well known that many cytokine receptors are phosphorylated on 
their cytoplasmic tyrosine residues in response to stimuli, and that these 
phosphorylated residues can function as docking sites for Stats and other 
signaling molecules [299]. Most important, previous experiments using Stat-
deficient cells showed that when the dominant STAT does not occupy its 
cytokine receptor, another STAT member might take over the unoccupied 
receptor and be activated in response to stimuli signaling through this 
receptor [300, 301]. This effect can be observed in Stat1-deficient mouse 
embryonic fibroblasts (MEFs). STAT1 is the main transcription factors of 
IFNγ, and noticeably under normal physiological conditions, STAT3 activation 
can also be faintly observed upon IFNγ stimulation. However,  in Stat1-
deficient MEFs Src Kinases trigger robust STAT3 tyrosine phosphorylation 
upon IFNγ stimulation [300]. Furthermore, Costa-Pereira and colleagues 
demonstrated a similar switch in MEFs lacking STAT3. In this scenario, 
stimulation with IL-6 mediates an IFNγ-like response, including STAT1 
activation and expression of IFNγ related genes [302]. It is relevant to mention 
that STAT3 and STAT6 have similar structures and are both phosphorylated 
on tyrosine residues by Janus kinases upon cytokine stimulation. Both Stats 
form dimers through their reciprocal SH2 domain and translocate to the 
nucleus to activate the transcription of their target genes [144, 301]. Thereby, 
the loss of Stat6 in IEC could induce a STAT3 compensatory activation. In line, 
the unexpected STAT3 overexpression in Stat6-deficient tumors cells could 
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also be explained by IL-4 signaling being able to activate the downstream 
signaling pathways JAK, PI3K/AKT and MAPK/ERK, which can further 
promote STAT3 expression [136, 137, 303]. Therefore, it is theoretically 
conceivable that in the absence of STAT6, these signaling pathways become 
sensitized to stimuli transmitted through IL-4Rα and IL-13Rs due to the 
unmasking of tyrosine residues on the cytoplasmic domain of those receptors 
(which were previously blocked by the physical presence of STAT6). Indeed, 
western blot analysis of tumor lysates shows strong ERK phosphorylation in 
Stat6-deficient tumors. Moreover, it cannot be excluded that STAT6 ablation 
might affect IL-4Rα physical interaction with IL-13Rα1, causing 
conformational changes in the receptor complex favoring the recruitment and 
activation of STAT3 [304]. These hypotheses need to be further evaluated in 
the context of colitis-associated tumorigenesis, but our results support the 
idea that Stat6-deficiency during colitis-associated tumorigenesis leads to 
STAT3 compensatory activation.  
 Additionally, it was shown that P53 activity, which is crucial for cell-
autonomous mechanisms such as cell cycle regulation, senescence and 
apoptosis and which tumor-suppressor function is well established in 
colorectal cancer [205, 305], is highly decreased in Stat6-/- tumors. P53 can 
be regulated by many different factors, and recent reports showed a direct 
and indirect cross-talk with STAT3 [306-310]. STAT3 activation is able to 
disrupt P53 function through various mechanisms. First, it is suggested that 
STAT3 might directly bind and interact with the P53 promoter and exert 
inhibitory effects on its activity [306, 309]. Second, STAT3 may induce the 
expression of molecules that can repress the transcriptional activity of P53 
such as Fat10 [307]. Last, Stat3 might transcriptionally induce molecules that 
increase MDM2 expression and consequently increase P53 protein 
degradation. Thus, the high STAT3 activity found in Stat6-deficient tumors 
provides a functional explanation for the observations on P53 decreased 
expression [310]. 
 In addition to the above hypothesis, it is suggested that the total 
cellular levels of P53 are not strictly regulated by the ratio of its production, 
but by the ratio of its degradation [311]. Therefore, it could be speculated that 
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Stat6 deficiency could directly increase P53 degradation, which usually is 
mediated by ubiquitination and proteasomal degradation [312, 313]. However, 
the activity of MDM2 – P53 major negative regulator – and other ubiquitin 
ligases involved in this process were not assessed and remain to be 
evaluated. 
   
5.4 DSS-induced colitis is exacerbated in Stat6-/- mice 
 
 The current literature on STAT6 contribution to intestinal inflammation 
is sparse and notably contradictory depending on the model studied [249, 314, 
315]. In the current work, it was demonstrated that loss of Stat6 in IEC at the 
early stages of carcinogenesis leads to a strong inflammatory response and to 
a tumor-promoter phenotype. These findings are in agreement with the 
previous work of Elrod and colleagues [249], as this study also shows that 
DSS-induced colitis is exacerbated in Stat6-/- mice. Furthermore, adoptive 
transfer experiments support the idea that the severe colitis phenotype 
observed in Stat6-/- mice is probably due to intrinsic IEC changes caused by 
Stat6 loss. DSS-induced colitis does not require T or B cells, as demonstrated 
by experiments with C.B17 severe immune deficient mice. In fact, the immune 
response in these mice is largely based on macrophages and myeloid-derived 
cytokines, such as IL-6 and IL-11 [316]. For this reason BMDM from Stat6-/- 
mice were analyzed, and in contrast to what was proposed in previous studies 
[249, 315], Stat6-deficient macrophages did not present enhanced nitric oxide 
cytotoxicity (Figure 32 I) or showed reduced expression of canonical Wnt 
ligands (data not shown), which could regulate colitis severity. Nevertheless, 
additional experiments are needed to clarify the impact of Stat6 deficiency in 
other immune cells than macrophages during AOM/DSS-induced colitis.  
 Additionally, it was demonstrated that due to the extensive tissue 
damage during colitis, Stat6-/- mice have significantly increased expression of 
inflammatory cytokines and chemokines. Strong IL-6, IL-10, and IL-11 
expression during colitis are known to induce STAT3 activation in IEC, which 
in Stat6-deficient enterocytes could disturb the regeneration phase and induce 
aberrant hyperproliferation. Moreover, the mutual positive feedback loop 
between STAT3, IL-6, IL-10 and IL-11 could lead to tumor formation and 
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tumor maintenance in long-term experiments with AOM/DSS [317]. The 
higher proliferative rates observed in Stat6-deficient IEC on day 15 of the 
AOM/DSS regime (regenerative phase) support this hypothesis. Lastly, the 
evaluation of the STAT6 contribution in colitis-independent tumor models 
remains to be evaluated. 
 
5.5 Stat6 expression protects IEC from AOM-induced DNA damage and 
apoptosis 
 
 Based on the existing literature, this is the first study to show that 
Stat6-deficient IEC are highly susceptible to DNA damage caused by AOM 
followed by reduced P53 effector response. It is unknown how STAT6 
expression could participate in DNA damage response, but it could be 
speculated that its loss may disturb the activity of molecules involved in this 
process, such as ataxia-telangiectasia mutated (ATM), ataxia-telangiectasia 
mutated and Rad3-related (ATR) and DNA-dependent protein kinase catalytic 
subunit (DNA-PK), among others. The proper function of these kinases is 
crucial for detection of DNA breaks, DNA repair and further activation of 
downstream effectors proteins, in particular, X-ray repair cross-
complementary protein 4 (XRCC4), implicated in non-homologous end joining 
(NHEJ) DNA repair, cell division cycle 25 (CDC25), associated with cell cycle 
arrest, and P53, which can be involved in the two previous outcomes, plus 
apoptosis [318-320]. 
 Alkylating agents are considered to induce P53-dependent apoptosis in 
IEC within the first hours after its administration, generally through the 
activation of pro-apoptotic proteins such as PUMA, BAX, and NOXA. [321-
325]. Therefore, it was reasoned that reduced P53 activation in IEC upon 
AOM administration would suppress the initial apoptotic response preventing 
loss of the initiated epithelia that would subsequently increase tumorigenesis 
in Stat6-/- mice. Instead, Stat6-deficient enterocytes presented increased 
apoptotic rates upon the initial AOM challenge.  
 Whereas P53 reduced activity can be related to increased DNA 
damage in Stat6-/- mice, its reduced activation cannot be linked to the 
enhanced apoptotic phenotype. These findings are supported by the strong 
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evidence that IEC-specific deletion of P53 does not cause spontaneous or 
AOM-induced apoptosis in vivo [205], suggesting that the AOM-induced 
apoptosis detected in Stat6-deficient IEC is a P53-independent event.  
Moreover, the involvement of P63 and P73 in P53-independent apoptosis 
could probably be neglected in Stat6-deficient IEC as these transcription 
factors ordinarily induce Puma and Bax expression to trigger mitochondrial 
membrane permeabilization [326, 327]. Both Puma and Bax mRNA levels 
were not found altered between WT and Stat6-deficient IEC at this time point. 
Thus, the underlying mechanisms that led to Caspase 3 cleavage and the 
possible involvement of other molecules such as Caspase 8 and 9, BID and 
DIABLO in this process still need to be evaluated. 
 
   REFERENCES 
	 82	
REFERENCES 
 1.	 Standring	S,	G.H.,	Gray’s	anatomy:	the	anatomical	basis	of	clinical	practice.	40th	ed.	2008,	Edinburg:	Churchill	Livingstone.	2.	 Weaver,	 L.T.,	 S.	 Austin,	 and	 T.J.	 Cole,	 Small	 intestinal	 length:	 a	 factor	
essential	for	gut	adaptation.	Gut,	1991.	32(11):	p.	1321-3.	3.	 Aron-Wisnewsky,	 J.,	 J.	 Dore,	 and	 K.	 Clement,	 The	 importance	 of	 the	 gut	
microbiota	after	bariatric	 surgery.	 Nat	 Rev	 Gastroenterol	 Hepatol,	 2012.	
9(10):	p.	590-8.	4.	 Nguyen,	 T.L.A.,	 et	 al.,	 How	 informative	 is	 the	 mouse	 for	 human	 gut	
microbiota	research?	Disease	Models	&	Mechanisms,	2015.	8(1):	p.	1-16.	5.	 Droy-Dupre,	L.,	et	al.,	A	multiparametric	approach	to	monitor	the	effects	of	
gamma-secretase	 inhibition	 along	 the	 whole	 intestinal	 tract.	 Dis	 Model	Mech,	2012.	5(1):	p.	107-14.	6.	 Barker,	 N.,	 M.	 van	 de	Wetering,	 and	 H.	 Clevers,	 The	 intestinal	 stem	 cell.	Genes	Dev,	2008.	22(14):	p.	1856-64.	7.	 Abdul	 Khalek,	 F.J.,	 G.I.	 Gallicano,	 and	 L.	 Mishra,	 Colon	 cancer	 stem	 cells.	Gastrointest	Cancer	Res,	2010(Suppl	1):	p.	S16-23.	8.	 Troughton,	W.D.	 and	 J.S.	 Trier,	 Paneth	 and	 goblet	 cell	 renewal	 in	mouse	
duodenal	crypts.	J	Cell	Biol,	1969.	41(1):	p.	251-68.	9.	 Crosnier,	 C.,	 D.	 Stamataki,	 and	 J.	 Lewis,	 Organizing	 cell	 renewal	 in	 the	
intestine:	 stem	 cells,	 signals	 and	 combinatorial	 control.	 Nat	 Rev	 Genet,	2006.	7(5):	p.	349-59.	10.	 van	 der	 Flier,	 L.G.	 and	 H.	 Clevers,	 Stem	 cells,	 self-renewal,	 and	
differentiation	in	the	intestinal	epithelium.	Annu	Rev	Physiol,	2009.	71:	p.	241-60.	11.	 Peterson,	L.W.	and	D.	Artis,	Intestinal	epithelial	cells:	regulators	of	barrier	
function	and	immune	homeostasis.	Nat	Rev	Immunol,	2014.	14(3):	p.	141-53.	12.	 Humphries,	 A.	 and	 N.A.	 Wright,	 Colonic	 crypt	 organization	 and	
tumorigenesis.	Nat	Rev	Cancer,	2008.	8(6):	p.	415-24.	13.	 Barker,	N.,	et	al.,	Identification	of	stem	cells	in	small	intestine	and	colon	by	
marker	gene	Lgr5.	Nature,	2007.	449(7165):	p.	1003-7.	14.	 Sangiorgi,	E.	and	M.R.	Capecchi,	Bmi1	is	expressed	in	vivo	in	intestinal	stem	
cells.	Nat	Genet,	2008.	40(7):	p.	915-20.	15.	 Barker,	 N.,	 Adult	 intestinal	 stem	 cells:	 critical	 drivers	 of	 epithelial	
homeostasis	and	regeneration.	Nat	Rev	Mol	Cell	Biol,	2014.	15(1):	p.	19-33.	16.	 Rothenberg,	 M.E.,	 et	 al.,	 Identification	 of	 a	 cKit(+)	 colonic	 crypt	 base	
secretory	 cell	 that	 supports	 Lgr5(+)	 stem	 cells	 in	mice.	 Gastroenterology,	2012.	142(5):	p.	1195-1205	e6.	17.	 Ross,	M.P.,	W.,	Histology:	a	 text	and	atlas.	 5th	 ed.	 2006,	 USA:	 Lippincott	Williams	&	Wilkins.	906.	18.	 Sandle,	 G.I.,	 Salt	 and	 water	 absorption	 in	 the	 human	 colon:	 a	 modern	
appraisal.	Gut,	1998.	43(2):	p.	294-9.	
REFERENCES 
	 83	
19.	 Cardell,	 R.R.,	 Jr.,	 S.	 Badenhausen,	 and	 K.R.	 Porter,	 Intestinal	 triglyceride	
absorption	 in	 the	 rat.	 An	 electron	 microscopical	 study.	 J	 Cell	 Biol,	 1967.	
34(1):	p.	123-55.	20.	 Kim,	 Y.S.	 and	 S.B.	 Ho,	 Intestinal	 goblet	 cells	 and	 mucins	 in	 health	 and	
disease:	recent	insights	and	progress.	Curr	Gastroenterol	Rep,	2010.	12(5):	p.	319-30.	21.	 William	 K.	 Ovalle,	 P.C.N.,	Netter's	 Essential	 Histology.	 2008:	 SAUNDERS-	ELSEVIER.	22.	 Bergstrom,	K.S.,	et	al.,	Goblet	Cell	Derived	RELM-beta	Recruits	CD4+	T	Cells	
during	 Infectious	 Colitis	 to	 Promote	 Protective	 Intestinal	 Epithelial	 Cell	
Proliferation.	PLoS	Pathog,	2015.	11(8):	p.	e1005108.	23.	 Velcich,	A.,	et	al.,	Colorectal	cancer	in	mice	genetically	deficient	in	the	mucin	
Muc2.	Science,	2002.	295(5560):	p.	1726-9.	24.	 Rudolph,	U.,	et	al.,	Ulcerative	colitis	and	adenocarcinoma	of	the	colon	in	G	
alpha	i2-deficient	mice.	Nat	Genet,	1995.	10(2):	p.	143-50.	25.	 Hermiston,	 M.L.	 and	 J.I.	 Gordon,	 Inflammatory	 bowel	 disease	 and	
adenomas	 in	 mice	 expressing	 a	 dominant	 negative	 N-cadherin.	 Science,	1995.	270(5239):	p.	1203-7.	26.	 Engle,	 S.J.,	 et	 al.,	 Transforming	 growth	 factor	 beta1	 suppresses	
nonmetastatic	colon	cancer	at	an	early	stage	of	tumorigenesis.	Cancer	Res,	1999.	59(14):	p.	3379-86.	27.	 Gunawardene,	A.R.,	B.M.	Corfe,	and	C.A.	Staton,	Classification	and	functions	
of	enteroendocrine	cells	of	the	lower	gastrointestinal	tract.	Int	J	Exp	Pathol,	2011.	92(4):	p.	219-31.	28.	 Melmed,	 P.M.C.S.,	 Endocrinology:	 Basic	 and	 Clinical	 Principles.	 The	Endocrine	 System	of	 the	Gastrointestinal	 Tract,	 ed.	 R.F.	 Gary	A.	Wittert,	John	E.	Morley.	1997:	Humana	Press.	29.	 Sjolund,	 K.,	 et	 al.,	 Endocrine	 cells	 in	 human	 intestine:	 an	
immunocytochemical	study.	Gastroenterology,	1983.	85(5):	p.	1120-30.	30.	 Schonhoff,	S.E.,	M.	Giel-Moloney,	and	A.B.	Leiter,	Minireview:	Development	
and	differentiation	of	gut	endocrine	cells.	Endocrinology,	2004.	145(6):	p.	2639-44.	31.	 Bertrand,	 P.P.	 and	 R.L.	 Bertrand,	 Serotonin	 release	 and	 uptake	 in	 the	
gastrointestinal	tract.	Auton	Neurosci,	2010.	153(1-2):	p.	47-57.	32.	 Skibicka,	 K.P.,	 The	 central	 GLP-1:	 implications	 for	 food	 and	 drug	 reward.	Front	Neurosci,	2013.	7:	p.	181.	33.	 Furness,	 J.B.,	 et	 al.,	 The	 gut	 as	 a	 sensory	 organ.	 Nat	 Rev	 Gastroenterol	Hepatol,	2013.	10(12):	p.	729-40.	34.	 Rindi,	G.,	 et	 al.,	The	"normal"	endocrine	cell	of	the	gut:	changing	concepts	
and	new	evidences.	Ann	N	Y	Acad	Sci,	2004.	1014:	p.	1-12.	35.	 Rhodin,	 J.	 and	 T.	 Dalhamn,	 Electron	 microscopy	 of	 the	 tracheal	 ciliated	
mucosa	in	rat.	Z	Zellforsch	Mikrosk	Anat,	1956.	44(4):	p.	345-412.	36.	 Jarvi,	 O.	 and	 O.	 Keyrilainen,	 On	 the	 cellular	 structures	 of	 the	 epithelial	
invasions	 in	 the	 glandular	 stomach	 of	 mice	 caused	 by	 intramural	
application	 of	 20-methylcholantren.	 Acta	 Pathol	 Microbiol	 Scand	 Suppl,	1956.	39(Suppl	111):	p.	72-3.	37.	 Jarvi,	O.,	et	al.,	The	cytologic	diagnosis	of	pulmonary	carcinoma.	Acta	Pathol	Microbiol	Scand	Suppl,	1962.	Suppl	154:	p.	177-8.	
REFERENCES 
	 84	
38.	 Luciano,	L.,	E.	Reale,	and	H.	Ruska,	[On	a	"chemoreceptive"	sensory	cell	in	
the	tachea	of	the	rat].	Z	Zellforsch	Mikrosk	Anat,	1968.	85(3):	p.	350-75.	39.	 Luciano,	L.,	E.	Reale,	and	H.	Ruska,	[Brush	cells	in	the	alveolar	epithelium	of	
the	rat	lung].	Z	Zellforsch	Mikrosk	Anat,	1969.	95(2):	p.	198-201.	40.	 Hofer,	D.	and	D.	Drenckhahn,	Identification	of	brush	cells	in	the	alimentary	
and	respiratory	system	by	antibodies	to	villin	and	fimbrin.	Histochemistry,	1992.	98(4):	p.	237-42.	41.	 Chang,	 L.Y.,	 R.R.	Mercer,	 and	 J.D.	 Crapo,	Differential	distribution	of	brush	
cells	in	the	rat	lung.	Anat	Rec,	1986.	216(1):	p.	49-54.	42.	 Hammond,	J.B.	and	L.	LaDeur,	Fibrillovesicular	cedlls	in	the	fundic	glands	of	
the	canine	stomach:	evidence	for	a	new	cell	type.	Anat	Rec,	1968.	161(4):	p.	393-411.	43.	 Luciano,	L.,	E.	Reale,	and	H.	Ruska,	[On	a	glycogen	containing	brusc	cell	in	
the	rectum	of	the	rat].	Z	Zellforsch	Mikrosk	Anat,	1968.	91(1):	p.	153-8.	44.	 Isomaki,	 A.M.,	A	new	cell	 type	 (tuft	cell)	 in	 the	gastrointestinal	mucosa	of	
the	 rat.	 A	 transmission	 and	 scanning	 electron	 microscopic	 study.	 Acta	Pathol	Microbiol	Scand	A,	1973:	p.	Suppl	240:1-35.	45.	 Wattel,	W.	and	J.J.	Geuze,	The	cells	of	the	rat	gastric	groove	and	cardia.	An	
ultrastructural	 and	 carbohydrate	 histochemical	 study,	 with	 special	
reference	 to	 the	 fibrillovesicular	 cells.	 Cell	 Tissue	 Res,	 1978.	 186(3):	 p.	375-91.	46.	 Tsubouchi,	S.	and	C.P.	Leblond,	Migration	and	turnover	of	entero-endocrine	
and	caveolated	cells	in	the	epithelium	of	the	descending	colon,	as	shown	by	
radioautography	after	continuous	infusion	of	3H-thymidine	into	mice.	Am	J	Anat,	1979.	156(4):	p.	431-51.	47.	 Luciano,	L.,	M.	Castellucci,	and	E.	Reale,	The	brush	cells	of	the	common	bile	
duct	 of	 the	 rat.	 This	 section,	 freeze-fracture	 and	 scanning	 electron	
microscopy.	Cell	Tissue	Res,	1981.	218(2):	p.	403-20.	48.	 Luciano,	L.	and	E.	Reale,	Brush	cells	of	the	mouse	gallbladder.	A	correlative	
light-	and	electron-microscopical	 study.	 Cell	 Tissue	Res,	 1990.	262(2):	 p.	339-49.	49.	 Hofer,	 D.	 and	 D.	 Drenckhahn,	 Identification	 of	 the	 taste	 cell	 G-protein,	
alpha-gustducin,	in	brush	cells	of	the	rat	pancreatic	duct	system.	Histochem	Cell	Biol,	1998.	110(3):	p.	303-9.	50.	 Reid,	 L.,	 et	 al.,	The	mysterious	pulmonary	brush	 cell:	 a	 cell	 in	 search	of	 a	
function.	Am	J	Respir	Crit	Care	Med,	2005.	172(1):	p.	136-9.	51.	 Gerbe,	F.,	et	al.,	Distinct	ATOH1	and	Neurog3	requirements	define	tuft	cells	
as	a	new	secretory	cell	 type	 in	 the	 intestinal	epithelium.	 J	 Cell	 Biol,	 2011.	
192(5):	p.	767-80.	52.	 Noah,	 T.K.,	 B.	 Donahue,	 and	 N.F.	 Shroyer,	 Intestinal	 development	 and	
differentiation.	Exp	Cell	Res,	2011.	317(19):	p.	2702-10.	53.	 von	 Moltke,	 J.,	 et	 al.,	 Tuft-cell-derived	 IL-25	 regulates	 an	 intestinal	 ILC2-
epithelial	response	circuit.	Nature,	2016.	529(7585):	p.	221-5.	54.	 Howitt,	M.R.,	et	al.,	Tuft	cells,	taste-chemosensory	cells,	orchestrate	parasite	
type	2	immunity	in	the	gut.	Science,	2016.	351(6279):	p.	1329-33.	55.	 van	Es,	J.H.,	et	al.,	Dll1+	secretory	progenitor	cells	revert	to	stem	cells	upon	
crypt	damage.	Nat	Cell	Biol,	2012.	14(10):	p.	1099-104.	56.	 Hofer,	D.,	E.	Asan,	and	D.	Drenckhahn,	Chemosensory	Perception	in	the	Gut.	News	Physiol	Sci,	1999.	14:	p.	18-23.	
REFERENCES 
	 85	
57.	 Gill,	S.R.,	et	al.,	Metagenomic	analysis	of	the	human	distal	gut	microbiome.	Science,	2006.	312(5778):	p.	1355-9.	58.	 Sartor,	 R.B.,	 Microbial	 influences	 in	 inflammatory	 bowel	 diseases.	Gastroenterology,	2008.	134(2):	p.	577-94.	59.	 Eckburg,	 P.B.,	 et	 al.,	 Diversity	 of	 the	 human	 intestinal	 microbial	 flora.	Science,	2005.	308(5728):	p.	1635-8.	60.	 Palmer,	 C.,	 et	 al.,	Development	 of	 the	 human	 infant	 intestinal	microbiota.	PLoS	Biol,	2007.	5(7):	p.	e177.	61.	 Johansson,	M.E.,	et	al.,	The	inner	of	the	two	Muc2	mucin-dependent	mucus	
layers	 in	 colon	 is	 devoid	 of	 bacteria.	 Proc	 Natl	 Acad	 Sci	 U	 S	 A,	 2008.	
105(39):	p.	15064-9.	62.	 Gallo,	R.L.	and	L.V.	Hooper,	Epithelial	antimicrobial	defence	of	the	skin	and	
intestine.	Nat	Rev	Immunol,	2012.	12(7):	p.	503-16.	63.	 Chassard,	C.	and	C.	Lacroix,	Carbohydrates	and	the	human	gut	microbiota.	Curr	Opin	Clin	Nutr	Metab	Care,	2013.	16(4):	p.	453-60.	64.	 Fukuda,	 S.,	 et	 al.,	 Bifidobacteria	 can	 protect	 from	 enteropathogenic	
infection	through	production	of	acetate.	Nature,	2011.	469(7331):	p.	543-7.	65.	 Lawley,	T.D.,	et	al.,	Antibiotic	treatment	of	clostridium	difficile	carrier	mice	
triggers	 a	 supershedder	 state,	 spore-mediated	 transmission,	 and	 severe	
disease	in	immunocompromised	hosts.	Infect	Immun,	2009.	77(9):	p.	3661-9.	66.	 Osawa,	 N.	 and	 S.	 Mitsuhashi,	 Infection	 of	 Germeree	 Mice	 with	 Shigella	
Flexneri	3a.	Jpn	J	Exp	Med,	1964.	34:	p.	77-80.	67.	 Bohnhoff,	 M.,	 B.L.	 Drake,	 and	 C.P.	 Miller,	 Effect	 of	 streptomycin	 on	
susceptibility	of	 intestinal	 tract	to	experimental	Salmonella	 infection.	 Proc	Soc	Exp	Biol	Med,	1954.	86(1):	p.	132-7.	68.	 Hentges,	 D.J.	 and	 R.	 Freter,	 In	 vivo	 and	 in	 vitro	 antagonism	 of	 intestinal	
bacteria	 against	 Shigella	 flexneri.	 I.	 Correlation	 between	 various	 tests.	 J	Infect	Dis,	1962.	110:	p.	30-7.	69.	 Hooper,	 L.V.	 and	 A.J.	 Macpherson,	 Immune	 adaptations	 that	 maintain	
homeostasis	with	the	intestinal	microbiota.	Nat	Rev	Immunol,	2010.	10(3):	p.	159-69.	70.	 Stecher,	B.	and	W.D.	Hardt,	Mechanisms	controlling	pathogen	colonization	
of	the	gut.	Curr	Opin	Microbiol,	2011.	14(1):	p.	82-91.	71.	 Tremaroli,	 V.	 and	 F.	 Backhed,	 Functional	 interactions	 between	 the	 gut	
microbiota	and	host	metabolism.	Nature,	2012.	489(7415):	p.	242-9.	72.	 Sjogren,	K.,	 et	al.,	The	gut	microbiota	regulates	bone	mass	in	mice.	 J	Bone	Miner	Res,	2012.	27(6):	p.	1357-67.	73.	 Glaister,	 J.R.,	 Factors	 affecting	 the	 lymphoid	 cells	 in	 the	 small	 intestinal	
epithelium	of	 the	mouse.	 Int	Arch	Allergy	Appl	 Immunol,	 1973.	45(5):	 p.	719-30.	74.	 Lee,	Y.K.	 and	S.K.	Mazmanian,	Has	the	microbiota	played	a	critical	role	in	
the	evolution	of	the	adaptive	immune	system?	Science,	2010.	330(6012):	p.	1768-73.	75.	 Jostins,	 L.,	 et	 al.,	 Host-microbe	 interactions	 have	 shaped	 the	 genetic	
architecture	of	 inflammatory	bowel	disease.	 Nature,	 2012.	491(7422):	 p.	119-24.	
REFERENCES 
	 86	
76.	 Sun,	 L.,	 G.M.	 Nava,	 and	 T.S.	 Stappenbeck,	 Host	 genetic	 susceptibility,	
dysbiosis,	 and	 viral	 triggers	 in	 inflammatory	 bowel	 disease.	 Curr	 Opin	Gastroenterol,	2011.	27(4):	p.	321-7.	77.	 Seksik,	 P.,	 et	 al.,	 Alterations	 of	 the	 dominant	 faecal	 bacterial	 groups	 in	
patients	with	Crohn's	disease	of	the	colon.	Gut,	2003.	52(2):	p.	237-42.	78.	 Rajilic-Stojanovic,	M.,	et	al.,	Phylogenetic	analysis	of	dysbiosis	in	ulcerative	
colitis	during	remission.	Inflamm	Bowel	Dis,	2013.	19(3):	p.	481-8.	79.	 Machiels,	K.,	et	al.,	A	decrease	of	the	butyrate-producing	species	Roseburia	
hominis	and	Faecalibacterium	prausnitzii	defines	dysbiosis	in	patients	with	
ulcerative	colitis.	Gut,	2014.	63(8):	p.	1275-83.	80.	 He,	Q.,	et	al.,	Dysbiosis	of	the	fecal	microbiota	in	the	TNBS-induced	Crohn's	
disease	mouse	model.	Appl	Microbiol	Biotechnol,	2016.	100(10):	p.	4485-94.	81.	 Kang,	 S.,	 et	 al.,	Dysbiosis	of	 fecal	microbiota	 in	Crohn's	disease	patients	as	
revealed	by	a	custom	phylogenetic	microarray.	 Inflamm	Bowel	Dis,	 2010.	
16(12):	p.	2034-42.	82.	 Duboc,	 H.,	 et	 al.,	 Connecting	 dysbiosis,	 bile-acid	 dysmetabolism	 and	 gut	
inflammation	in	inflammatory	bowel	diseases.	Gut,	2013.	62(4):	p.	531-9.	83.	 Frank,	 D.N.,	 et	 al.,	 Molecular-phylogenetic	 characterization	 of	 microbial	
community	 imbalances	 in	 human	 inflammatory	 bowel	 diseases.	 Proc	 Natl	Acad	Sci	U	S	A,	2007.	104(34):	p.	13780-5.	84.	 Dalal,	 S.R.	 and	 E.B.	 Chang,	 The	 microbial	 basis	 of	 inflammatory	 bowel	
diseases.	J	Clin	Invest,	2014.	124(10):	p.	4190-6.	85.	 Kim,	E.R.	and	D.K.	Chang,	Colorectal	cancer	in	inflammatory	bowel	disease:	
the	 risk,	 pathogenesis,	 prevention	 and	 diagnosis.	 World	 J	 Gastroenterol,	2014.	20(29):	p.	9872-81.	86.	 Schwabe,	 R.F.	 and	 C.	 Jobin,	The	microbiome	and	cancer.	 Nat	 Rev	 Cancer,	2013.	13(11):	p.	800-12.	87.	 Biedermann,	L.	 and	G.	Rogler,	The	intestinal	microbiota:	its	role	in	health	
and	disease.	Eur	J	Pediatr,	2015.	174(2):	p.	151-67.	88.	 Arthur,	 J.C.,	 et	al.,	 Intestinal	inflammation	targets	cancer-inducing	activity	
of	the	microbiota.	Science,	2012.	338(6103):	p.	120-3.	89.	 Irrazabal,	 T.,	 et	 al.,	 The	 multifaceted	 role	 of	 the	 intestinal	 microbiota	 in	
colon	cancer.	Mol	Cell,	2014.	54(2):	p.	309-20.	90.	 Mowat,	A.M.	and	W.W.	Agace,	Regional	specialization	within	the	intestinal	
immune	system.	Nat	Rev	Immunol,	2014.	14(10):	p.	667-85.	91.	 Eberl,	G.	and	M.	Lochner,	The	development	of	intestinal	lymphoid	tissues	at	
the	interface	of	self	and	microbiota.	Mucosal	Immunol,	2009.	2(6):	p.	478-85.	92.	 Tomasello,	 E.	 and	 S.	 Bedoui,	 Intestinal	 innate	 immune	 cells	 in	 gut	
homeostasis	 and	 immunosurveillance.	 Immunol	 Cell	 Biol,	 2013.	91(3):	 p.	201-3.	93.	 Neutra,	M.R.,	N.J.	Mantis,	and	J.P.	Kraehenbuhl,	Collaboration	of	epithelial	
cells	with	organized	mucosal	lymphoid	tissues.	Nat	 Immunol,	2001.	2(11):	p.	1004-9.	94.	 O'Brien,	L.M.,	et	al.,	Eosinophil-nerve	interactions	and	neuronal	plasticity	in	
rat	gut	associated	lymphoid	tissue	(GALT)	in	response	to	enteric	parasitism.	J	Neuroimmunol,	2008.	197(1):	p.	1-9.	
REFERENCES 
	 87	
95.	 Sipos,	 F.,	 et	 al.,	 The	 possible	 role	 of	 isolated	 lymphoid	 follicles	 in	 colonic	
mucosal	repair.	Pathol	Oncol	Res,	2010.	16(1):	p.	11-8.	96.	 Neutra,	M.R.,	A.	Frey,	and	J.P.	Kraehenbuhl,	Epithelial	M	cells:	gateways	for	
mucosal	infection	and	immunization.	Cell,	1996.	86(3):	p.	345-8.	97.	 Siebers,	 A.	 and	 B.B.	 Finlay,	M	 cells	 and	 the	 pathogenesis	 of	mucosal	 and	
systemic	infections.	Trends	Microbiol,	1996.	4(1):	p.	22-9.	98.	 Mantis,	 N.J.,	 et	 al.,	 Selective	 adherence	 of	 IgA	 to	murine	 Peyer's	 patch	M	
cells:	evidence	for	a	novel	IgA	receptor.	J	Immunol,	2002.	169(4):	p.	1844-51.	99.	 Neutra,	 M.R.,	 et	 al.,	 Transport	 of	membrane-bound	macromolecules	 by	M	
cells	in	follicle-associated	epithelium	of	rabbit	Peyer's	patch.	Cell	Tissue	Res,	1987.	247(3):	p.	537-46.	100.	 Jung,	C.,	J.P.	Hugot,	and	F.	Barreau,	Peyer's	Patches:	The	Immune	Sensors	of	
the	Intestine.	Int	J	Inflam,	2010.	2010:	p.	823710.	101.	 Mitragotri,	 S.,	 Immunization	 without	 needles.	 Nat	 Rev	 Immunol,	 2005.	
5(12):	p.	905-16.	102.	 Coombes,	J.L.	and	F.	Powrie,	Dendritic	cells	in	intestinal	immune	regulation.	Nat	Rev	Immunol,	2008.	8(6):	p.	435-46.	103.	 Scott,	 C.L.,	A.M.	Aumeunier,	 and	A.M.	Mowat,	 Intestinal	CD103+	dendritic	
cells:	 master	 regulators	 of	 tolerance?	 Trends	 Immunol,	 2011.	 32(9):	 p.	412-9.	104.	 Bogunovic,	M.,	 et	 al.,	Origin	 of	 the	 lamina	propria	dendritic	 cell	 network.	Immunity,	2009.	31(3):	p.	513-25.	105.	 Schulz,	O.,	et	al.,	Intestinal	CD103+,	but	not	CX3CR1+,	antigen	sampling	cells	
migrate	 in	 lymph	 and	 serve	 classical	 dendritic	 cell	 functions.	 J	 Exp	 Med,	2009.	206(13):	p.	3101-14.	106.	 Cerovic,	V.,	 et	 al.,	 Intestinal	CD103(-)	dendritic	cells	migrate	in	lymph	and	
prime	effector	T	cells.	Mucosal	Immunol,	2013.	6(1):	p.	104-13.	107.	 Lee,	 S.H.,	 P.M.	 Starkey,	 and	 S.	 Gordon,	 Quantitative-Analysis	 of	 Total	
Macrophage	 Content	 in	 Adult-Mouse	 Tissues	 -	 Immunochemical	 Studies	
with	Monoclonal-Antibody	F4/80.	Journal	of	Experimental	Medicine,	1985.	
161(3):	p.	475-489.	108.	 Bain,	 C.C.	 and	 A.M.	 Mowat,	 Macrophages	 in	 intestinal	 homeostasis	 and	
inflammation.	Immunol	Rev,	2014.	260(1):	p.	102-17.	109.	 Farache,	 J.,	 et	 al.,	 Contributions	 of	 dendritic	 cells	 and	 macrophages	 to	
intestinal	 homeostasis	 and	 immune	 defense.	 Immunol	 Cell	 Biol,	 2013.	
91(3):	p.	232-9.	110.	 Delamarre,	L.,	et	al.,	Differential	lysosomal	proteolysis	in	antigen-presenting	
cells	determines	antigen	fate.	Science,	2005.	307(5715):	p.	1630-4.	111.	 Charles	A	Janeway,	J.,	Paul	Travers,	Mark	Walport,	and	Mark	J	Shlomchik,	
Immunobiology:	 Principles	 of	 innate	 and	 adaptive	 immunity.	 2001,	 New	York:	Garland	Science.	112.	 Salmi,	 M.	 and	 S.	 Jalkanen,	 Lymphocyte	 homing	 to	 the	 gut:	 attraction,	
adhesion,	and	commitment.	Immunol	Rev,	2005.	206:	p.	100-13.	113.	 Nutt,	S.L.,	et	al.,	The	generation	of	antibody-secreting	plasma	cells.	Nat	Rev	Immunol,	2015.	15(3):	p.	160-71.	114.	 Andersen,	M.H.,	et	al.,	Cytotoxic	T	cells.	J	Invest	Dermatol,	2006.	126(1):	p.	32-41.	
REFERENCES 
	 88	
115.	 Hirahara,	 K.	 and	 T.	 Nakayama,	 CD4+	 T-cell	 subsets	 in	 inflammatory	
diseases:	beyond	the	Th1/Th2	paradigm.	Int	Immunol,	2016.	28(4):	p.	163-71.	116.	 Kiraz,	 Y.,	 Y.	 Baran,	 and	 A.	 Nalbant,	 T	 cells	 in	 tumor	 microenvironment.	Tumour	Biol,	2016.	37(1):	p.	39-45.	117.	 Barnes,	 M.J.	 and	 F.	 Powrie,	 Regulatory	 T	 cells	 reinforce	 intestinal	
homeostasis.	Immunity,	2009.	31(3):	p.	401-11.	118.	 Rubtsov,	 Y.P.,	 et	 al.,	 Regulatory	 T	 cell-derived	 interleukin-10	 limits	
inflammation	at	environmental	interfaces.	Immunity,	2008.	28(4):	p.	546-58.	119.	 Howard,	 M.,	 et	 al.,	 Identification	 of	 a	 T	 cell-derived	 b	 cell	 growth	 factor	
distinct	from	interleukin	2.	J	Exp	Med,	1982.	155(3):	p.	914-23.	120.	 Paul,	W.E.,	History	of	interleukin-4.	Cytokine,	2015.	75(1):	p.	3-7.	121.	 Ahdieh,	M.,	T.	Vandenbos,	and	A.	Youakim,	Lung	epithelial	barrier	function	
and	wound	healing	are	decreased	by	IL-4	and	IL-13	and	enhanced	by	IFN-
gamma.	Am	J	Physiol	Cell	Physiol,	2001.	281(6):	p.	C2029-38.	122.	 Yan,	D.,	et	al.,	STAT3	and	STAT6	Signaling	Pathways	Synergize	to	Promote	
Cathepsin	Secretion	from	Macrophages	via	IRE1alpha	Activation.	Cell	Rep,	2016.	16(11):	p.	2914-27.	123.	 Zurawski,	G.	and	J.E.	de	Vries,	Interleukin	13	elicits	a	subset	of	the	activities	
of	its	close	relative	interleukin	4.	Stem	Cells,	1994.	12(2):	p.	169-74.	124.	 Shimoda,	 K.,	 et	 al.,	 Lack	 of	 IL-4-induced	 Th2	 response	 and	 IgE	 class	
switching	in	mice	with	disrupted	Stat6	gene.	Nature,	1996.	380(6575):	p.	630-3.	125.	 de	 Waal	 Malefyt,	 R.,	 et	 al.,	 Differential	 regulation	 of	 IL-13	 and	 IL-4	
production	by	human	CD8+	and	CD4+	Th0,	Th1	and	Th2	T	cell	clones	and	
EBV-transformed	B	cells.	Int	Immunol,	1995.	7(9):	p.	1405-16.	126.	 Terabe,	 M.,	 et	 al.,	 NKT	 cell-mediated	 repression	 of	 tumor	
immunosurveillance	by	IL-13	and	the	IL-4R-STAT6	pathway.	Nat	Immunol,	2000.	1(6):	p.	515-20.	127.	 Nelms,	 K.,	 et	 al.,	 The	 IL-4	 receptor:	 signaling	 mechanisms	 and	 biologic	
functions.	Annu	Rev	Immunol,	1999.	17:	p.	701-38.	128.	 Gallina,	G.,	 et	 al.,	Tumors	induce	a	subset	of	 inflammatory	monocytes	with	
immunosuppressive	activity	on	CD8+	T	cells.	J	Clin	Invest,	2006.	116(10):	p.	2777-90.	129.	 Miossec,	P.,	et	al.,	Inhibition	of	the	production	of	proinflammatory	cytokines	
and	 immunoglobulins	 by	 interleukin-4	 in	 an	 ex	 vivo	model	 of	 rheumatoid	
synovitis.	Arthritis	Rheum,	1992.	35(8):	p.	874-83.	130.	 de	 Waal	 Malefyt,	 R.,	 et	 al.,	 Effects	 of	 IL-13	 on	 phenotype,	 cytokine	
production,	 and	 cytotoxic	 function	 of	 human	monocytes.	 Comparison	with	
IL-4	and	modulation	by	IFN-gamma	or	IL-10.	J	Immunol,	1993.	151(11):	p.	6370-81.	131.	 Urban,	 J.F.,	 Jr.,	 et	 al.,	 IL-13,	 IL-4Ralpha,	 and	 Stat6	 are	 required	 for	 the	
expulsion	 of	 the	 gastrointestinal	 nematode	 parasite	 Nippostrongylus	
brasiliensis.	Immunity,	1998.	8(2):	p.	255-64.	132.	 Huaux,	 F.,	 et	 al.,	Dual	 roles	of	 IL-4	 in	 lung	 injury	and	 fibrosis.	 J	 Immunol,	2003.	170(4):	p.	2083-92.	
REFERENCES 
	 89	
133.	 Leopold	 Wager,	 C.M.	 and	 F.L.	 Wormley,	 Jr.,	 Classical	 versus	 alternative	
macrophage	 activation:	 the	 Ying	 and	 the	 Yang	 in	 host	 defense	 against	
pulmonary	fungal	infections.	Mucosal	Immunol,	2014.	7(5):	p.	1023-35.	134.	 Martinez,	 F.O.	 and	 S.	 Gordon,	 The	M1	 and	M2	 paradigm	 of	macrophage	
activation:	time	for	reassessment.	F1000Prime	Rep,	2014.	6:	p.	13.	135.	 Mantovani,	A.,	et	al.,	The	chemokine	system	in	diverse	forms	of	macrophage	
activation	and	polarization.	Trends	Immunol,	2004.	25(12):	p.	677-86.	136.	 LaPorte,	 S.L.,	 et	 al.,	 Molecular	 and	 structural	 basis	 of	 cytokine	 receptor	
pleiotropy	in	the	interleukin-4/13	system.	Cell,	2008.	132(2):	p.	259-72.	137.	 Heller,	N.M.,	et	al.,	Type	I	IL-4Rs	selectively	activate	IRS-2	to	induce	target	
gene	expression	in	macrophages.	Sci	Signal,	2008.	1(51):	p.	ra17.	138.	 Chiaramonte,	 M.G.,	 et	 al.,	 Regulation	 and	 function	 of	 the	 interleukin	 13	
receptor	alpha	2	during	a	T	helper	cell	type	2-dominant	immune	response.	J	Exp	Med,	2003.	197(6):	p.	687-701.	139.	 Fichtner-Feigl,	S.,	et	al.,	IL-13	signaling	through	the	IL-13alpha2	receptor	is	
involved	in	induction	of	TGF-beta1	production	and	fibrosis.	Nat	Med,	2006.	
12(1):	p.	99-106.	140.	 Gandhi,	N.A.,	 et	al.,	Targeting	key	proximal	drivers	of	type	2	inflammation	
in	disease.	Nat	Rev	Drug	Discov,	2016.	15(1):	p.	35-50.	141.	 Luzina,	 I.G.,	et	al.,	Regulation	of	inflammation	by	interleukin-4:	a	review	of	
"alternatives".	J	Leukoc	Biol,	2012.	92(4):	p.	753-64.	142.	 Kaplan,	M.H.,	et	al.,	Stat6	is	required	for	mediating	responses	to	IL-4	and	for	
development	of	Th2	cells.	Immunity,	1996.	4(3):	p.	313-9.	143.	 Takeda,	 K.,	 et	 al.,	Essential	 role	 of	 Stat6	 in	 IL-4	 signalling.	 Nature,	 1996.	
380(6575):	p.	627-30.	144.	 Wurster,	A.L.,	T.	Tanaka,	 and	M.J.	Grusby,	The	biology	of	Stat4	and	Stat6.	Oncogene,	2000.	19(21):	p.	2577-84.	145.	 Schroder,	A.J.,	et	al.,	Cutting	edge:	STAT6	serves	as	a	positive	and	negative	
regulator	of	gene	expression	in	IL-4-stimulated	B	lymphocytes.	 J	 Immunol,	2002.	168(3):	p.	996-1000.	146.	 Kotanides,	H.	and	N.C.	Reich,	 Interleukin-4-induced	STAT6	recognizes	and	
activates	a	target	site	in	the	promoter	of	the	interleukin-4	receptor	gene.	 J	Biol	Chem,	1996.	271(41):	p.	25555-61.	147.	 Schindler,	U.,	et	al.,	Components	of	a	Stat	recognition	code:	evidence	for	two	
layers	of	molecular	selectivity.	Immunity,	1995.	2(6):	p.	689-97.	148.	 Mikita,	 T.,	 et	 al.,	 Requirements	 for	 interleukin-4-induced	 gene	 expression	
and	 functional	 characterization	 of	 Stat6.	 Mol	 Cell	 Biol,	 1996.	 16(10):	 p.	5811-20.	149.	 Fujisawa,	T.,	B.H.	 Joshi,	and	R.K.	Puri,	IL-13	regulates	cancer	invasion	and	
metastasis	through	IL-13Ralpha2	via	ERK/AP-1	pathway	in	mouse	model	of	
human	ovarian	cancer.	Int	J	Cancer,	2012.	131(2):	p.	344-56.	150.	 Todaro,	M.,	 et	 al.,	Apoptosis	resistance	 in	epithelial	 tumors	 is	mediated	by	
tumor-cell-derived	interleukin-4.	Cell	Death	Differ,	2008.	15(4):	p.	762-72.	151.	 Barderas,	 R.,	 et	 al.,	High	expression	of	 IL-13	receptor	alpha2	 in	colorectal	
cancer	 is	 associated	 with	 invasion,	 liver	 metastasis,	 and	 poor	 prognosis.	Cancer	Res,	2012.	72(11):	p.	2780-90.	152.	 Fujisawa,	 T.,	 et	 al.,	 A	 novel	 role	 of	 interleukin-13	 receptor	 alpha2	 in	
pancreatic	 cancer	 invasion	 and	metastasis.	 Cancer	 Res,	 2009.	 69(22):	 p.	8678-85.	
REFERENCES 
	 90	
153.	 Nguyen,	 V.,	 et	 al.,	 IL-13Ralpha2-Targeted	Therapy	Escapees:	Biologic	and	
Therapeutic	Implications.	Transl	Oncol,	2011.	4(6):	p.	390-400.	154.	 Todaro,	M.,	et	al.,	Autocrine	production	of	interleukin-4	and	interleukin-10	
is	required	for	survival	and	growth	of	thyroid	cancer	cells.	Cancer	Res,	2006.	
66(3):	p.	1491-9.	155.	 Prokopchuk,	 O.,	 et	 al.,	 Interleukin-4	 enhances	 proliferation	 of	 human	
pancreatic	cancer	cells:	evidence	 for	autocrine	and	paracrine	actions.	 Br	 J	Cancer,	2005.	92(5):	p.	921-8.	156.	 Joshi,	 B.H.,	 et	 al.,	 Interleukin-4	 receptor	 alpha	 overexpression	 in	 human	
bladder	 cancer	 correlates	 with	 the	 pathological	 grade	 and	 stage	 of	 the	
disease.	Cancer	Med,	2014.	3(6):	p.	1615-28.	157.	 Koller,	 F.L.,	 et	 al.,	 Epithelial	 interleukin-4	 receptor	 expression	 promotes	
colon	tumor	growth.	Carcinogenesis,	2010.	31(6):	p.	1010-7.	158.	 Joshi,	 B.H.,	 et	 al.,	 In	 situ	 expression	 of	 interleukin-4	 (IL-4)	 receptors	 in	
human	 brain	 tumors	 and	 cytotoxicity	 of	 a	 recombinant	 IL-4	 cytotoxin	 in	
primary	glioblastoma	cell	cultures.	Cancer	Res,	2001.	61(22):	p.	8058-61.	159.	 Wang,	 H.W.	 and	 J.A.	 Joyce,	 Alternative	 activation	 of	 tumor-associated	
macrophages	by	 IL-4:	priming	 for	protumoral	 functions.	 Cell	 Cycle,	 2010.	
9(24):	p.	4824-35.	160.	 Ostrand-Rosenberg,	S.,	 Immune	surveillance:	a	balance	between	protumor	
and	antitumor	immunity.	Curr	Opin	Genet	Dev,	2008.	18(1):	p.	11-8.	161.	 Li,	B.H.,	et	al.,	Stat6	activity-related	Th2	cytokine	profile	and	tumor	growth	
advantage	of	human	colorectal	cancer	cells	in	vitro	and	in	vivo.	Cell	Signal,	2012.	24(3):	p.	718-25.	162.	 Bankaitis,	 K.V.	 and	 B.	 Fingleton,	Targeting	 IL4/IL4R	 for	 the	 treatment	of	
epithelial	cancer	metastasis.	Clin	Exp	Metastasis,	2015.	32(8):	p.	847-56.	163.	 Todaro,	M.,	 et	 al.,	Colon	cancer	stem	cells	dictate	tumor	growth	and	resist	
cell	death	by	production	of	interleukin-4.	Cell	Stem	Cell,	2007.	1(4):	p.	389-402.	164.	 Ferlay,	 J.,	 et	 al.,	 Cancer	 incidence	 and	 mortality	 worldwide:	 sources,	
methods	 and	 major	 patterns	 in	 GLOBOCAN	 2012.	 Int	 J	 Cancer,	 2015.	
136(5):	p.	E359-86.	165.	 Filho,	G.B.,	Bogliolo.	8th	ed.	2011:	Guanabara	Koogan.	1524.	166.	 Hannan,	L.M.,	E.J.	Jacobs,	and	M.J.	Thun,	The	association	between	cigarette	
smoking	and	risk	of	colorectal	cancer	in	a	large	prospective	cohort	from	the	
United	States.	Cancer	Epidemiol	Biomarkers	Prev,	2009.	18(12):	p.	3362-7.	167.	 Beyaz,	 S.,	 et	 al.,	 High-fat	 diet	 enhances	 stemness	 and	 tumorigenicity	 of	
intestinal	progenitors.	Nature,	2016.	531(7592):	p.	53-8.	168.	 Schmid,	 D.	 and	 M.F.	 Leitzmann,	 Television	 viewing	 and	 time	 spent	
sedentary	 in	 relation	 to	 cancer	 risk:	 a	 meta-analysis.	 J	 Natl	 Cancer	 Inst,	2014.	106(7).	169.	 Jasperson,	 K.W.,	 et	 al.,	 Hereditary	 and	 familial	 colon	 cancer.	Gastroenterology,	2010.	138(6):	p.	2044-58.	170.	 Lasry,	A.,	A.	Zinger,	and	Y.	Ben-Neriah,	Inflammatory	networks	underlying	
colorectal	cancer.	Nat	Immunol,	2016.	17(3):	p.	230-40.	171.	 Eaden,	J.A.,	K.R.	Abrams,	and	J.F.	Mayberry,	The	risk	of	colorectal	cancer	in	
ulcerative	colitis:	a	meta-analysis.	Gut,	2001.	48(4):	p.	526-35.	172.	 Abraham,	C.	and	J.H.	Cho,	Inflammatory	bowel	disease.	N	Engl	J	Med,	2009.	
361(21):	p.	2066-78.	
REFERENCES 
	 91	
173.	 Melton,	G.B.,	et	al.,	Do	preoperative	factors	predict	subsequent	diagnosis	of	
Crohn's	 disease	 after	 ileal	 pouch-anal	 anastomosis	 for	 ulcerative	 or	
indeterminate	colitis?	Colorectal	Dis,	2010.	12(10):	p.	1026-32.	174.	 Baumgart,	 D.C.	 and	 S.R.	 Carding,	 Inflammatory	 bowel	 disease:	 cause	 and	
immunobiology.	Lancet,	2007.	369(9573):	p.	1627-40.	175.	 Bollrath,	 J.,	 Diverse	 functions	 of	 Stat3	 in	 intestinal	 epithelial	 cells	 during	
inflammation-associated	 and	 sporadic	 carcinogenesis,	 in	 Biology.	 2010,	Technischen	Universität	München:	Munich,	Germany.	176.	 Fearon,	 E.R.,	 Molecular	 genetics	 of	 colorectal	 cancer.	 Annu	 Rev	 Pathol,	2011.	6:	p.	479-507.	177.	 Aoki,	 K.	 and	 M.M.	 Taketo,	 Adenomatous	 polyposis	 coli	 (APC):	 a	 multi-
functional	tumor	suppressor	gene.	J	Cell	Sci,	2007.	120(Pt	19):	p.	3327-35.	178.	 Sansom,	O.J.,	et	al.,	Loss	of	Apc	in	vivo	immediately	perturbs	Wnt	signaling,	
differentiation,	and	migration.	Genes	Dev,	2004.	18(12):	p.	1385-90.	179.	 Zumbrunn,	 J.,	 et	 al.,	Binding	of	 the	adenomatous	polyposis	 coli	 protein	 to	
microtubules	increases	microtubule	stability	and	is	regulated	by	GSK3	beta	
phosphorylation.	Curr	Biol,	2001.	11(1):	p.	44-9.	180.	 Kobayashi,	 M.,	 et	 al.,	 Nuclear	 translocation	 of	 beta-catenin	 in	 colorectal	
cancer.	Br	J	Cancer,	2000.	82(10):	p.	1689-93.	181.	 Vogelstein,	 B.,	 et	 al.,	 Genetic	 alterations	 during	 colorectal-tumor	
development.	N	Engl	J	Med,	1988.	319(9):	p.	525-32.	182.	 Fujii,	S.,	T.	Fujimori,	and	H.	Kashida,	Ulcerative	colitis-associated	neoplasia.	Pathol	Int,	2002.	52(3):	p.	195-203.	183.	 Kheirelseid,	 E.A.,	 et	 al.,	Mismatch	 repair	 protein	 expression	 in	 colorectal	
cancer.	J	Gastrointest	Oncol,	2013.	4(4):	p.	397-408.	184.	 Fishel,	 R.,	Mismatch	 repair,	 molecular	 switches,	 and	 signal	 transduction.	Genes	Dev,	1998.	12(14):	p.	2096-101.	185.	 Boland,	 C.R.	 and	 A.	 Goel,	 Microsatellite	 instability	 in	 colorectal	 cancer.	Gastroenterology,	2010.	138(6):	p.	2073-2087	e3.	186.	 Wheeler,	 J.M.,	 W.F.	 Bodmer,	 and	 N.J.	 Mortensen,	 DNA	 mismatch	 repair	
genes	and	colorectal	cancer.	Gut,	2000.	47(1):	p.	148-53.	187.	 Duval,	 A.	 and	 R.	 Hamelin,	 Mutations	 at	 coding	 repeat	 sequences	 in	
mismatch	repair-deficient	human	cancers:	Toward	a	new	concept	of	target	
genes	for	instability.	Cancer	Research,	2002.	62(9):	p.	2447-2454.	188.	 Jabbari,	K.	and	G.	Bernardi,	Cytosine	methylation	and	CpG,	TpG	(CpA)	and	
TpA	frequencies.	Gene,	2004.	333:	p.	143-9.	189.	 Lao,	 V.V.	 and	 W.M.	 Grady,	 Epigenetics	 and	 colorectal	 cancer.	 Nat	 Rev	Gastroenterol	Hepatol,	2011.	8(12):	p.	686-700.	190.	 Samowitz,	 W.S.,	 et	 al.,	 Evaluation	 of	 a	 large,	 population-based	 sample	
supports	 a	 CpG	 island	 methylator	 phenotype	 in	 colon	 cancer.	Gastroenterology,	2005.	129(3):	p.	837-45.	191.	 Toyota,	 M.,	 et	 al.,	 CpG	 island	 methylator	 phenotype	 in	 colorectal	 cancer.	Proc	Natl	Acad	Sci	U	S	A,	1999.	96(15):	p.	8681-6.	192.	 Jones,	 P.A.,	Functions	of	DNA	methylation:	 islands,	 start	 sites,	 gene	bodies	
and	beyond.	Nat	Rev	Genet,	2012.	13(7):	p.	484-92.	193.	 Jjingo,	 D.,	 et	 al.,	 On	 the	 presence	 and	 role	 of	 human	 gene-body	 DNA	
methylation.	Oncotarget,	2012.	3(4):	p.	462-74.	
REFERENCES 
	 92	
194.	 Nazemalhosseini	Mojarad,	E.,	 et	 al.,	The	CpG	island	methylator	phenotype	
(CIMP)	in	colorectal	cancer.	Gastroenterol	Hepatol	Bed	Bench,	2013.	6(3):	p.	120-8.	195.	 Sturlan,	 S.,	 et	 al.,	 Interleukin-10-deficient	 mice	 and	 inflammatory	 bowel	
disease	 associated	 cancer	 development.	 Carcinogenesis,	 2001.	 22(4):	 p.	665-71.	196.	 Lee,	 G.,	 et	 al.,	 Phosphoinositide	 3-kinase	 signaling	 mediates	 beta-catenin	
activation	 in	 intestinal	 epithelial	 stem	 and	 progenitor	 cells	 in	 colitis.	Gastroenterology,	2010.	139(3):	p.	869-81,	881	e1-9.	197.	 Grivennikov,	 S.I.,	 Inflammation	 and	 colorectal	 cancer:	 colitis-associated	
neoplasia.	Semin	Immunopathol,	2013.	35(2):	p.	229-44.	198.	 Kaler,	P.,	et	al.,	The	NF-kappaB/AKT-dependent	Induction	of	Wnt	Signaling	
in	Colon	Cancer	Cells	by	Macrophages	and	IL-1beta.	Cancer	Microenviron,	2009.	2(1):	p.	69-80.	199.	 Brown,	J.B.,	et	al.,	Mesalamine	inhibits	epithelial	beta-catenin	activation	in	
chronic	ulcerative	colitis.	Gastroenterology,	2010.	138(2):	p.	595-605,	605	e1-3.	200.	 Oguma,	K.,	 et	 al.,	Activated	macrophages	promote	Wnt	signalling	through	
tumour	 necrosis	 factor-alpha	 in	 gastric	 tumour	 cells.	 EMBO	 J,	 2008.	
27(12):	p.	1671-81.	201.	 Greten,	 F.R.,	 et	 al.,	 IKKbeta	 links	 inflammation	 and	 tumorigenesis	 in	 a	
mouse	model	of	colitis-associated	cancer.	Cell,	2004.	118(3):	p.	285-96.	202.	 Bollrath,	 J.	 and	F.R.	Greten,	 IKK/NF-kappaB	and	STAT3	pathways:	central	
signalling	 hubs	 in	 inflammation-mediated	 tumour	 promotion	 and	
metastasis.	EMBO	Rep,	2009.	10(12):	p.	1314-9.	203.	 Bollrath,	J.,	et	al.,	gp130-mediated	Stat3	activation	in	enterocytes	regulates	
cell	 survival	 and	 cell-cycle	 progression	 during	 colitis-associated	
tumorigenesis.	Cancer	Cell,	2009.	15(2):	p.	91-102.	204.	 Fang,	 H.Y.	 and	 F.R.	 Greten,	 Cell	 Autonomous	 and	 Non-Autonomous	
Functions	 of	 IKKbeta	 and	 NF-kappaB	 during	 the	 Pathogenesis	 of	
Gastrointestinal	Tumors.	Cancers	(Basel),	2011.	3(2):	p.	2214-22.	205.	 Schwitalla,	S.,	et	al.,	Loss	of	p53	in	Enterocytes	Generates	an	Inflammatory	
Microenvironment	 Enabling	 Invasion	 and	 Lymph	 Node	 Metastasis	 of	
Carcinogen-Induced	Colorectal	Tumors.	Cancer	Cell,	2013.	23(1):	p.	93-106.	206.	 Park,	J.,	et	al.,	MLLT11/AF1q	boosts	oncogenic	STAT3	activity	through	Src-
PDGFR	tyrosine	kinase	signaling.	Oncotarget,	2016.	207.	 Song,	L.,	et	al.,	Activation	of	Stat3	by	receptor	tyrosine	kinases	and	cytokines	
regulates	survival	in	human	non-small	cell	carcinoma	cells.	Oncogene,	2003.	
22(27):	p.	4150-65.	208.	 Yu,	 H.,	 M.	 Kortylewski,	 and	 D.	 Pardoll,	 Crosstalk	 between	 cancer	 and	
immune	 cells:	 role	 of	 STAT3	 in	 the	 tumour	 microenvironment.	 Nat	 Rev	Immunol,	2007.	7(1):	p.	41-51.	209.	 Hirano,	 T.,	 K.	 Ishihara,	 and	M.	 Hibi,	Roles	 of	 STAT3	 in	mediating	 the	 cell	
growth,	differentiation	and	survival	signals	relayed	through	the	IL-6	family	
of	cytokine	receptors.	Oncogene,	2000.	19(21):	p.	2548-56.	210.	 Grivennikov,	S.I.	and	M.	Karin,	Dangerous	liaisons:	STAT3	and	NF-kappaB	
collaboration	and	crosstalk	in	cancer.	Cytokine	Growth	Factor	Rev,	2010.	
21(1):	p.	11-9.	
REFERENCES 
	 93	
211.	 Siveen,	K.S.,	et	al.,	Targeting	the	STAT3	signaling	pathway	in	cancer:	role	of	
synthetic	and	natural	inhibitors.	Biochim	Biophys	Acta,	2014.	1845(2):	p.	136-54.	212.	 Schwitalla,	S.,	The	role	of	IKKβ--dependent	NF‐κB	signaling	on	different	
stages	 of	 intestinal	 carcinogenesis,	 in	 Lehrstuhl	 für	 Biotechnologie	 der	
Nutztiere.	2012,	TECHNISCHE	UNIVERSITÄT	MÜNCHEN:	Munich.	p.	147.	213.	 Karin,	 M.,	 et	 al.,	NF-kappaB	 in	 cancer:	 from	 innocent	 bystander	 to	major	
culprit.	Nat	Rev	Cancer,	2002.	2(4):	p.	301-10.	214.	 Haura,	E.B.,	J.	Turkson,	and	R.	Jove,	Mechanisms	of	disease:	Insights	into	the	
emerging	 role	 of	 signal	 transducers	 and	 activators	 of	 transcription	 in	
cancer.	Nat	Clin	Pract	Oncol,	2005.	2(6):	p.	315-24.	215.	 Schwitalla,	 S.,	 et	 al.,	 Intestinal	 tumorigenesis	 initiated	by	dedifferentiation	
and	acquisition	of	stem-cell-like	properties.	Cell,	2013.	152(1-2):	p.	25-38.	216.	 Hayden,	M.S.	and	S.	Ghosh,	Shared	principles	in	NF-kappaB	signaling.	Cell,	2008.	132(3):	p.	344-62.	217.	 Hayden,	 M.S.	 and	 S.	 Ghosh,	 NF-kappaB,	 the	 first	 quarter-century:	
remarkable	progress	and	outstanding	questions.	Genes	Dev,	2012.	26(3):	p.	203-34.	218.	 Karin,	 M.,	Nuclear	 factor-kappaB	 in	 cancer	 development	 and	progression.	Nature,	2006.	441(7092):	p.	431-6.	219.	 Rezapour,	 S.,	 et	 al.,	 STC1	 and	 NF-kappaB	 p65	 (Rel	 A)	 is	 Constitutively	
Activated	in	Colorectal	Cancer.	Clin	Lab,	2016.	62(3):	p.	463-9.	220.	 Giri,	 D.K.	 and	 B.B.	 Aggarwal,	Constitutive	activation	of	NF-kappaB	causes	
resistance	to	apoptosis	in	human	cutaneous	T	cell	 lymphoma	HuT-78	cells.	
Autocrine	role	of	tumor	necrosis	factor	and	reactive	oxygen	intermediates.	J	Biol	Chem,	1998.	273(22):	p.	14008-14.	221.	 Braunstein,	 S.,	 S.C.	 Formenti,	 and	 R.J.	 Schneider,	 Acquisition	 of	 stable	
inducible	up-regulation	of	nuclear	 factor-kappaB	by	 tumor	necrosis	 factor	
exposure	 confers	 increased	 radiation	 resistance	 without	 increased	
transformation	in	breast	cancer	cells.	Mol	Cancer	Res,	2008.	6(1):	p.	78-88.	222.	 Jackson-Bernitsas,	 D.G.,	 et	 al.,	 Evidence	 that	 TNF-TNFR1-TRADD-TRAF2-
RIP-TAK1-IKK	 pathway	 mediates	 constitutive	 NF-kappaB	 activation	 and	
proliferation	in	human	head	and	neck	squamous	cell	carcinoma.	Oncogene,	2007.	26(10):	p.	1385-97.	223.	 De,	 S.,	 J.K.	 Dermawan,	 and	 G.R.	 Stark,	 EGF	 receptor	 uses	 SOS1	 to	 drive	
constitutive	activation	of	NFkappaB	in	cancer	cells.	Proc	Natl	Acad	Sci	U	S	A,	2014.	111(32):	p.	11721-6.	224.	 Fearon,	E.R.	and	B.	Vogelstein,	A	genetic	model	for	colorectal	tumorigenesis.	Cell,	1990.	61(5):	p.	759-67.	225.	 Tong,	 Y.,	 W.	 Yang,	 and	 H.P.	 Koeffler,	Mouse	models	 of	 colorectal	 cancer.	Chin	J	Cancer,	2011.	30(7):	p.	450-62.	226.	 De	Robertis,	M.,	 et	 al.,	The	AOM/DSS	murine	model	 for	 the	study	of	colon	
carcinogenesis:	From	pathways	to	diagnosis	and	therapy	studies.	J	Carcinog,	2011.	10:	p.	9.	227.	 Karim,	B.O.	and	D.L.	Huso,	Mouse	models	for	colorectal	cancer.	Am	J	Cancer	Res,	2013.	3(3):	p.	240-50.	228.	 Wali,	 R.K.,	 et	 al.,	 Inhibition	of	O(6)-methylguanine-DNA	methyltransferase	
increases	 azoxymethane-induced	 colonic	 tumors	 in	 rats.	 Carcinogenesis,	1999.	20(12):	p.	2355-60.	
REFERENCES 
	 94	
229.	 Pegg,	 A.E.,	Methylation	 of	 the	 O6	 position	 of	 guanine	 in	 DNA	 is	 the	most	
likely	 initiating	 event	 in	 carcinogenesis	 by	 methylating	 agents.	 Cancer	Invest,	1984.	2(3):	p.	223-31.	230.	 Clapper,	M.L.,	H.S.	Cooper,	and	W.C.	Chang,	Dextran	sulfate	sodium-induced	
colitis-associated	 neoplasia:	 a	 promising	 model	 for	 the	 development	 of	
chemopreventive	interventions.	Acta	Pharmacol	Sin,	2007.	28(9):	p.	1450-9.	231.	 Egger,	B.,	et	al.,	Characterisation	of	acute	murine	dextran	sodium	sulphate	
colitis:	 cytokine	 profile	 and	 dose	 dependency.	 Digestion,	 2000.	 62(4):	 p.	240-8.	232.	 Aust,	 D.E.,	 et	 al.,	 Altered	 distribution	 of	 beta-catenin,	 and	 its	 binding	
proteins	E-cadherin	and	APC,	in	ulcerative	colitis-related	colorectal	cancers.	Mod	Pathol,	2001.	14(1):	p.	29-39.	233.	 Bolt,	 A.B.,	 et	 al.,	 Azoxymethane	 induces	 KI-ras	 activation	 in	 the	 tumor	
resistant	AKR/J	mouse	colon.	Mol	Carcinog,	2000.	27(3):	p.	210-8.	234.	 De	Filippo,	C.,	 et	 al.,	Mutations	of	the	Apc	gene	 in	experimental	colorectal	
carcinogenesis	 induced	by	azoxymethane	 in	F344	 rats.	 Br	 J	 Cancer,	 1998.	
77(12):	p.	2148-51.	235.	 Kobaek-Larsen,	M.,	et	al.,	Review	of	colorectal	cancer	and	its	metastases	in	
rodent	 models:	 comparative	 aspects	 with	 those	 in	 humans.	 Comp	 Med,	2000.	50(1):	p.	16-26.	236.	 Erdman,	 S.H.,	 et	 al.,	 Assessment	 of	 mutations	 in	 Ki-ras	 and	 p53	 in	 colon	
cancers	 from	 azoxymethane-	 and	 dimethylhydrazine-treated	 rats.	 Mol	Carcinog,	1997.	19(2):	p.	137-44.	237.	 Pallangyo,	 C.K.,	 P.K.	 Ziegler,	 and	 F.R.	 Greten,	 IKKbeta	 acts	 as	 a	 tumor	
suppressor	in	cancer-associated	fibroblasts	during	intestinal	tumorigenesis.	J	Exp	Med,	2015.	212(13):	p.	2253-66.	238.	 Noben-Trauth,	 N.,	 et	 al.,	An	 interleukin	4	 (IL-4)-independent	pathway	 for	
CD4+	T	cell	IL-4	production	is	revealed	in	IL-4	receptor-deficient	mice.	Proc	Natl	Acad	Sci	U	S	A,	1997.	94(20):	p.	10838-43.	239.	 Herbert,	 D.R.,	 et	 al.,	 Alternative	 macrophage	 activation	 is	 essential	 for	
survival	 during	 schistosomiasis	 and	 downmodulates	 T	 helper	 1	 responses	
and	immunopathology.	Immunity,	2004.	20(5):	p.	623-35.	240.	 Madison,	 B.B.,	 et	 al.,	 Cis	 elements	 of	 the	 villin	 gene	 control	 expression	 in	
restricted	 domains	 of	 the	 vertical	 (crypt)	 and	 horizontal	 (duodenum,	
cecum)	axes	of	the	intestine.	J	Biol	Chem,	2002.	277(36):	p.	33275-83.	241.	 West,	G.A.,	et	al.,	Interleukin	4	in	inflammatory	bowel	disease	and	mucosal	
immune	reactivity.	Gastroenterology,	1996.	110(6):	p.	1683-95.	242.	 Nielsen,	O.H.,	 et	 al.,	 Involvement	of	 interleukin-4	and	 -10	 in	 inflammatory	
bowel	disease.	Dig	Dis	Sci,	1996.	41(9):	p.	1786-93.	243.	 Marchenko,	 N.D.,	 et	 al.,	 Stress-mediated	 nuclear	 stabilization	 of	 p53	 is	
regulated	by	ubiquitination	and	importin-alpha3	binding.	Cell	Death	Differ,	2010.	17(2):	p.	255-67.	244.	 Marine,	J.C.,	p53	stabilization:	the	importance	of	nuclear	import.	Cell	Death	Differ,	2010.	17(2):	p.	191-2.	245.	 Calon,	 A.,	 et	 al.,	 Dependency	 of	 colorectal	 cancer	 on	 a	 TGF-beta-driven	
program	in	stromal	cells	for	metastasis	initiation.	Cancer	Cell,	2012.	22(5):	p.	571-84.	
REFERENCES 
	 95	
246.	 Calon,	A.,	et	al.,	Stromal	gene	expression	defines	poor-prognosis	subtypes	in	
colorectal	cancer.	Nat	Genet,	2015.	47(4):	p.	320-9.	247.	 Isella,	C.,	et	al.,	Stromal	contribution	to	the	colorectal	cancer	transcriptome.	Nat	Genet,	2015.	47(4):	p.	312-9.	248.	 Aronica,	M.A.,	S.	Goenka,	and	M.	Boothby,	IL-4-dependent	induction	of	BCL-
2	 and	 BCL-X(L)IN	 activated	 T	 lymphocytes	 through	 a	 STAT6-	 and	 pi	 3-
kinase-independent	pathway.	Cytokine,	2000.	12(6):	p.	578-87.	249.	 Elrod,	 J.W.,	 et	 al.,	 DSS-induced	 colitis	 is	 exacerbated	 in	 STAT-6	 knockout	
mice.	Inflamm	Bowel	Dis,	2005.	11(10):	p.	883-9.	250.	 Rutschman,	 R.,	 et	 al.,	 Cutting	 edge:	 Stat6-dependent	 substrate	 depletion	
regulates	nitric	oxide	production.	J	Immunol,	2001.	166(4):	p.	2173-7.	251.	 Chen,	 J.	 and	 X.F.	 Huang,	 The	 signal	 pathways	 in	 azoxymethane-induced	
colon	cancer	and	preventive	implications.	Cancer	Biol	Ther,	2009.	8(14):	p.	1313-7.	252.	 Ward,	 J.M.,	 R.S.	 Yamamoto,	 and	 C.A.	 Brown,	 Pathology	 of	 intestinal	
neoplasms	and	other	lesions	in	rats	exposed	to	azoxymethane.	J	Natl	Cancer	Inst,	1973.	51(3):	p.	1029-39.	253.	 Raju,	 J.,	 Azoxymethane-induced	 rat	 aberrant	 crypt	 foci:	 relevance	 in	
studying	 chemoprevention	 of	 colon	 cancer.	 World	 J	 Gastroenterol,	 2008.	
14(43):	p.	6632-5.	254.	 Loughery,	 J.,	 et	 al.,	 Critical	 role	 for	 p53-serine	 15	 phosphorylation	 in	
stimulating	transactivation	at	p53-responsive	promoters.	Nucleic	Acids	Res,	2014.	42(12):	p.	7666-80.	255.	 Chao,	C.,	 et	al.,	Phosphorylation	of	murine	p53	at	ser-18	regulates	the	p53	
responses	 to	 DNA	 damage.	 Proc	 Natl	 Acad	 Sci	 U	 S	 A,	 2000.	 97(22):	 p.	11936-41.	256.	 Furtek,	S.L.,	et	al.,	Strategies	and	Approaches	of	Targeting	STAT3	for	Cancer	
Treatment.	ACS	Chem	Biol,	2016.	11(2):	p.	308-18.	257.	 Bromberg,	J.F.,	et	al.,	Stat3	as	an	oncogene.	Cell,	1999.	98(3):	p.	295-303.	258.	 Epling-Burnette,	P.K.,	et	al.,	Inhibition	of	STAT3	signaling	leads	to	apoptosis	
of	 leukemic	 large	granular	 lymphocytes	and	decreased	Mcl-1	expression.	 J	Clin	Invest,	2001.	107(3):	p.	351-62.	259.	 Catlett-Falcone,	R.,	 et	al.,	Constitutive	activation	of	Stat3	signaling	confers	
resistance	 to	 apoptosis	 in	 human	 U266	 myeloma	 cells.	 Immunity,	 1999.	
10(1):	p.	105-15.	260.	 Kanda,	N.,	et	al.,	STAT3	is	constitutively	activated	and	supports	cell	survival	
in	 association	 with	 survivin	 expression	 in	 gastric	 cancer	 cells.	 Oncogene,	2004.	23(28):	p.	4921-9.	261.	 Iwamaru,	 A.,	 et	 al.,	 A	 novel	 inhibitor	 of	 the	 STAT3	 pathway	 induces	
apoptosis	 in	 malignant	 glioma	 cells	 both	 in	 vitro	 and	 in	 vivo.	 Oncogene,	2007.	26(17):	p.	2435-44.	262.	 Zhang,	 J.,	 et	 al.,	The	cell	death	regulator	GRIM-19	 is	an	 inhibitor	of	 signal	
transducer	and	activator	of	transcription	3.	Proc	Natl	Acad	Sci	U	S	A,	2003.	
100(16):	p.	9342-7.	263.	 Blaskovich,	 M.A.,	 et	 al.,	 Discovery	 of	 JSI-124	 (cucurbitacin	 I),	 a	 selective	
Janus	 kinase/signal	 transducer	 and	 activator	 of	 transcription	 3	 signaling	
pathway	 inhibitor	 with	 potent	 antitumor	 activity	 against	 human	 and	
murine	cancer	cells	in	mice.	Cancer	Res,	2003.	63(6):	p.	1270-9.	
REFERENCES 
	 96	
264.	 Grivennikov,	S.,	et	al.,	 IL-6	and	Stat3	are	required	for	survival	of	intestinal	
epithelial	 cells	 and	 development	 of	 colitis-associated	 cancer.	 Cancer	 Cell,	2009.	15(2):	p.	103-13.	265.	 Putoczki,	 T.L.,	 et	 al.,	 Interleukin-11	 is	 the	 dominant	 IL-6	 family	 cytokine	
during	gastrointestinal	tumorigenesis	and	can	be	targeted	therapeutically.	Cancer	Cell,	2013.	24(2):	p.	257-71.	266.	 Liu,	T.,	et	al.,	Inhibitory	effects	of	cucurbitacin	B	on	laryngeal	squamous	cell	
carcinoma.	Eur	Arch	Otorhinolaryngol,	2008.	265(10):	p.	1225-32.	267.	 Su,	 Y.,	 et	 al.,	 JSI-124	 inhibits	 glioblastoma	 multiforme	 cell	 proliferation	
through	G(2)/M	cell	cycle	arrest	and	apoptosis	augment.	Cancer	Biol	Ther,	2008.	7(8):	p.	1243-9.	268.	 Dong,	 Y.,	 et	 al.,	Clinical	 relevance	of	 cyclin	B1	overexpression	 in	 laryngeal	
squamous	cell	carcinoma.	Cancer	Lett,	2002.	177(1):	p.	13-9.	269.	 Hassan,	K.A.,	et	al.,	Cyclin	B1	overexpression	and	resistance	to	radiotherapy	
in	head	and	neck	 squamous	cell	 carcinoma.	 Cancer	 Res,	 2002.	62(22):	 p.	6414-7.	270.	 Li,	 J.Q.,	 et	 al.,	 Cyclin	 B1,	 unlike	 cyclin	 G1,	 increases	 significantly	 during	
colorectal	carcinogenesis	and	during	later	metastasis	to	lymph	nodes.	 Int	 J	Oncol,	2003.	22(5):	p.	1101-10.	271.	 Fang,	 Y.,	 et	 al.,	 Chk1-induced	 CCNB1	 overexpression	 promotes	 cell	
proliferation	 and	 tumor	 growth	 in	 human	 colorectal	 cancer.	 Cancer	 Biol	Ther,	2014.	15(9):	p.	1268-79.	272.	 Carey,	 G.B.,	 et	 al.,	 IL-4	 protects	 the	 B-cell	 lymphoma	 cell	 line	 CH31	 from	
anti-IgM-induced	 growth	 arrest	 and	 apoptosis:	 contribution	 of	 the	 PI-3	
kinase/AKT	pathway.	Cell	Res,	2007.	17(11):	p.	942-55.	273.	 Swann,	 J.B.	 and	M.J.	 Smyth,	 Immune	surveillance	of	 tumors.	 J	 Clin	 Invest,	2007.	117(5):	p.	1137-46.	274.	 Burnet,	F.M.,	The	concept	of	immunological	surveillance.	Prog	Exp	Tumor	Res,	1970.	13:	p.	1-27.	275.	 Ehrlich,	P.,	Uber	den	jetzigen	Stand	der	Karzinomforschung.	Ned.	Tijdschr.	Genees.,	1909.	5:	p.	273–290.	276.	 Raulet,	D.H.	and	N.	Guerra,	Oncogenic	stress	sensed	by	the	immune	system:	
role	of	natural	killer	cell	receptors.	Nat	Rev	 Immunol,	2009.	9(8):	p.	568-80.	277.	 Zanoni,	I.	and	F.	Granucci,	Regulation	and	dysregulation	of	innate	immunity	
by	 NFAT	 signaling	 downstream	 of	 pattern	 recognition	 receptors	 (PRRs).	Eur	J	Immunol,	2012.	42(8):	p.	1924-31.	278.	 Gunther,	 C.,	 et	 al.,	 Regulation	 and	 pathophysiological	 role	 of	 epithelial	
turnover	in	the	gut.	Semin	Cell	Dev	Biol,	2014.	35:	p.	40-50.	279.	 Huang,	 Z.,	 The	 chemical	 biology	 of	 apoptosis.	 Exploring	 protein-protein	
interactions	and	the	life	and	death	of	cells	with	small	molecules.	Chem	Biol,	2002.	9(10):	p.	1059-72.	280.	 Bhattacharya,	S.,	R.M.	Ray,	and	L.R.	Johnson,	STAT3-mediated	transcription	
of	 Bcl-2,	Mcl-1	 and	 c-IAP2	 prevents	 apoptosis	 in	 polyamine-depleted	 cells.	Biochem	J,	2005.	392(Pt	2):	p.	335-44.	281.	 Rahaman,	 S.O.,	 et	 al.,	 Inhibition	 of	 constitutively	 active	 Stat3	 suppresses	
proliferation	 and	 induces	 apoptosis	 in	 glioblastoma	 multiforme	 cells.	Oncogene,	2002.	21(55):	p.	8404-13.	
REFERENCES 
	 97	
282.	 Stephanou,	A.,	 et	 al.,	Opposing	actions	of	STAT-1	and	STAT-3	on	the	Bcl-2	
and	Bcl-x	promoters.	Cell	Death	Differ,	2000.	7(3):	p.	329-30.	283.	 Greten,	F.R.	and	M.	Karin,	The	IKK/NF-kappaB	activation	pathway-a	target	
for	prevention	and	treatment	of	cancer.	Cancer	Lett,	2004.	206(2):	p.	193-9.	284.	 Iizuka,	M.	and	S.	Konno,	Wound	healing	of	intestinal	epithelial	cells.	World	J	Gastroenterol,	2011.	17(17):	p.	2161-71.	285.	 Cario,	E.,	Toll-like	receptors	in	inflammatory	bowel	diseases:	a	decade	later.	Inflamm	Bowel	Dis,	2010.	16(9):	p.	1583-97.	286.	 Ogawa,	H.,	et	al.,	Increased	expression	of	HIP/PAP	and	regenerating	gene	III	
in	 human	 inflammatory	 bowel	 disease	 and	 a	 murine	 bacterial	
reconstitution	model.	Inflamm	Bowel	Dis,	2003.	9(3):	p.	162-70.	287.	 A.	Shytenberg,	E.K.,	Y.	Lin,	A.	Schwartzman,	H.	Zhang,	M.E.	Zenilman,	Up-
regulation	of	pancreatitis-associated	protein	in	a	rat	model	of	inflammatory	
bowel	disease.	J	Surg	Res,	2003.	114(2):	p.	292-293.	288.	 Gironella,	 M.,	 et	 al.,	 Anti-inflammatory	 effects	 of	 pancreatitis	 associated	
protein	in	inflammatory	bowel	disease.	Gut,	2005.	54(9):	p.	1244-53.	289.	 Sikora,	A.	 and	E.	Grzesiuk,	Heat	shock	response	in	gastrointestinal	tract.	 J	Physiol	Pharmacol,	2007.	58	Suppl	3:	p.	43-62.	290.	 Tanaka,	K.,	et	al.,	Genetic	evidence	for	a	protective	role	for	heat	shock	factor	
1	and	heat	shock	protein	70	against	colitis.	 J	Biol	Chem,	2007.	282(32):	p.	23240-52.	291.	 Abreu,	M.T.,	 et	 al.,	Decreased	 expression	of	Toll-like	 receptor-4	and	MD-2	
correlates	 with	 intestinal	 epithelial	 cell	 protection	 against	 dysregulated	
proinflammatory	 gene	 expression	 in	 response	 to	 bacterial	
lipopolysaccharide.	J	Immunol,	2001.	167(3):	p.	1609-16.	292.	 Hausmann,	M.,	 et	 al.,	Toll-like	 receptors	 2	 and	4	 are	 up-regulated	during	
intestinal	inflammation.	Gastroenterology,	2002.	122(7):	p.	1987-2000.	293.	 Singh,	J.C.,	et	al.,	Toll-like	receptor-mediated	responses	of	primary	intestinal	
epithelial	cells	during	the	development	of	colitis.	Am	J	Physiol	Gastrointest	Liver	Physiol,	2005.	288(3):	p.	G514-24.	294.	 Rigby,	R.J.,	et	al.,	Suppressor	of	cytokine	signaling	3	(SOCS3)	limits	damage-
induced	 crypt	 hyper-proliferation	 and	 inflammation-associated	
tumorigenesis	in	the	colon.	Oncogene,	2007.	26(33):	p.	4833-41.	295.	 Terzic,	 J.,	 et	 al.,	 Inflammation	 and	 colon	 cancer.	 Gastroenterology,	 2010.	
138(6):	p.	2101-2114	e5.	296.	 Jess,	 T.,	 C.	 Rungoe,	 and	 L.	 Peyrin-Biroulet,	 Risk	 of	 colorectal	 cancer	 in	
patients	with	ulcerative	colitis:	a	meta-analysis	of	population-based	cohort	
studies.	Clin	Gastroenterol	Hepatol,	2012.	10(6):	p.	639-45.	297.	 Linehan,	 L.A.,	 et	 al.,	 STAT6	 is	 required	 for	 IL-4-induced	 germline	 Ig	 gene	
transcription	and	switch	recombination.	J	Immunol,	1998.	161(1):	p.	302-10.	298.	 O'Reilly,	 S.,	 et	 al.,	 IL-13	 mediates	 collagen	 deposition	 via	 STAT6	 and	
microRNA-135b:	a	role	for	epigenetics.	Sci	Rep,	2016.	6:	p.	25066.	299.	 Stahl,	N.,	 et	al.,	Choice	of	STATs	and	other	substrates	specified	by	modular	
tyrosine-based	motifs	 in	 cytokine	 receptors.	 Science,	 1995.	267(5202):	 p.	1349-53.	300.	 Qing,	 Y.	 and	 G.R.	 Stark,	 Alternative	 activation	 of	 STAT1	 and	 STAT3	 in	
response	to	interferon-gamma.	J	Biol	Chem,	2004.	279(40):	p.	41679-85.	
REFERENCES 
	 98	
301.	 Murray,	P.J.,	The	JAK-STAT	signaling	pathway:	input	and	output	integration.	J	Immunol,	2007.	178(5):	p.	2623-9.	302.	 Costa-Pereira,	 A.P.,	 et	 al.,	 Mutational	 switch	 of	 an	 IL-6	 response	 to	 an	
interferon-gamma-like	response.	Proc	Natl	Acad	Sci	U	S	A,	2002.	99(12):	p.	8043-7.	303.	 Lee,	 P.J.,	 et	 al.,	 ERK1/2	 mitogen-activated	 protein	 kinase	 selectively	
mediates	 IL-13-induced	 lung	 inflammation	 and	 remodeling	 in	 vivo.	 J	 Clin	Invest,	2006.	116(1):	p.	163-73.	304.	 Constantinescu,	 S.N.,	 Gathering	 support	 for	 critical	 mass:	 interleukin	 4	
receptor	 signaling	 requires	 clustering	 in	 endosomes.	 Biophys	 J,	 2014.	
107(11):	p.	2479-80.	305.	 Iacopetta,	B.,	TP53	mutation	in	colorectal	cancer.	Hum	Mutat,	2003.	21(3):	p.	271-6.	306.	 Niu,	G.,	 et	al.,	Role	of	Stat3	in	regulating	p53	expression	and	function.	Mol	Cell	Biol,	2005.	25(17):	p.	7432-40.	307.	 Choi,	 Y.,	 J.K.	 Kim,	 and	 J.Y.	 Yoo,	 NFkappaB	 and	 STAT3	 synergistically	
activate	 the	 expression	 of	 FAT10,	 a	 gene	 counteracting	 the	 tumor	
suppressor	p53.	Mol	Oncol,	2014.	8(3):	p.	642-55.	308.	 Hallenborg,	 P.,	 et	 al.,	MDM2	 facilitates	 adipocyte	 differentiation	 through	
CRTC-mediated	activation	of	STAT3.	Cell	Death	Dis,	2016.	7(6):	p.	e2289.	309.	 Wormann,	S.M.,	et	al.,	Loss	of	P53	Function	Activates	JAK2-STAT3	Signaling	
to	 Promote	 Pancreatic	 Tumor	 Growth,	 Stroma	 Modification,	 and	
Gemcitabine	 Resistance	 in	 Mice	 and	 Is	 Associated	 With	 Patient	 Survival.	Gastroenterology,	2016.	151(1):	p.	180-193	e12.	310.	 Yu,	 H.,	 et	 al.,	 LIF	 negatively	 regulates	 tumour-suppressor	 p53	 through	
Stat3/ID1/MDM2	in	colorectal	cancers.	Nat	Commun,	2014.	5:	p.	5218.	311.	 Vogelstein,	 B.,	 D.	 Lane,	 and	 A.J.	 Levine,	 Surfing	 the	p53	network.	 Nature,	2000.	408(6810):	p.	307-10.	312.	 Scheffner,	 M.,	 et	 al.,	 The	 HPV-16	 E6	 and	 E6-AP	 complex	 functions	 as	 a	
ubiquitin-protein	 ligase	 in	 the	ubiquitination	of	p53.	 Cell,	 1993.	75(3):	 p.	495-505.	313.	 Yang,	 Y.,	 C.C.	 Li,	 and	 A.M.	Weissman,	Regulating	 the	p53	 system	 through	
ubiquitination.	Oncogene,	2004.	23(11):	p.	2096-106.	314.	 Rosen,	M.J.,	et	al.,	STAT6	deficiency	ameliorates	severity	of	oxazolone	colitis	
by	 decreasing	 expression	 of	 claudin-2	 and	 Th2-inducing	 cytokines.	 J	Immunol,	2013.	190(4):	p.	1849-58.	315.	 Cosin-Roger,	 J.,	 et	 al.,	 The	 activation	 of	 Wnt	 signaling	 by	 a	 STAT6-
dependent	macrophage	phenotype	promotes	mucosal	repair	in	murine	IBD.	Mucosal	Immunol,	2016.	9(4):	p.	986-98.	316.	 Dieleman,	 L.A.,	 et	 al.,	 Dextran	 sulfate	 sodium-induced	 colitis	 occurs	 in	
severe	combined	immunodeficient	mice.	Gastroenterology,	1994.	107(6):	p.	1643-52.	317.	 Rokavec,	 M.,	 et	 al.,	 IL-6R/STAT3/miR-34a	 feedback	 loop	 promotes	 EMT-
mediated	colorectal	cancer	invasion	and	metastasis.	The	Journal	of	Clinical	Investigation,	2014.	124(4):	p.	1853-67.	318.	 Sulli,	 G.,	 R.	 Di	 Micco,	 and	 F.	 d'Adda	 di	 Fagagna,	 Crosstalk	 between	
chromatin	 state	 and	 DNA	 damage	 response	 in	 cellular	 senescence	 and	
cancer.	Nat	Rev	Cancer,	2012.	12(10):	p.	709-20.	
 	 99	
319.	 Menon,	 V.	 and	 L.	 Povirk,	 Involvement	of	p53	 in	 the	 repair	of	DNA	double	
strand	 breaks:	 multifaceted	 Roles	 of	 p53	 in	 homologous	 recombination	
repair	 (HRR)	 and	 non-homologous	 end	 joining	 (NHEJ).	 Subcell	 Biochem,	2014.	85:	p.	321-36.	320.	 Jackson,	 S.P.,	 Sensing	 and	 repairing	 DNA	 double-strand	 breaks.	Carcinogenesis,	2002.	23(5):	p.	687-96.	321.	 Toft,	 N.J.,	 et	 al.,	 Msh2	 status	 modulates	 both	 apoptosis	 and	 mutation	
frequency	 in	 the	murine	 small	 intestine.	 Proc	 Natl	 Acad	 Sci	 U	 S	 A,	 1999.	
96(7):	p.	3911-5.	322.	 Oda,	E.,	et	al.,	Noxa,	a	BH3-only	member	of	the	Bcl-2	family	and	candidate	
mediator	of	p53-induced	apoptosis.	Science,	2000.	288(5468):	p.	1053-8.	323.	 Qiu,	 W.,	 et	 al.,	 PUMA	 suppresses	 intestinal	 tumorigenesis	 in	mice.	 Cancer	Res,	2009.	69(12):	p.	4999-5006.	324.	 Hu,	Y.,	R.K.	Le	Leu,	and	G.P.	Young,	Absence	of	acute	apoptotic	response	to	
genotoxic	 carcinogens	 in	 p53-deficient	 mice	 is	 associated	 with	 increased	
susceptibility	to	azoxymethane-induced	colon	tumours.	 Int	 J	Cancer,	2005.	
115(4):	p.	561-7.	325.	 Pietsch,	E.C.,	et	al.,	The	p53	family	and	programmed	cell	death.	Oncogene,	2008.	27(50):	p.	6507-21.	326.	 Bender,	 T.	 and	 J.C.	Martinou,	Where	killers	meet--permeabilization	of	 the	
outer	 mitochondrial	 membrane	 during	 apoptosis.	 Cold	 Spring	 Harb	Perspect	Biol,	2013.	5(1):	p.	a011106.	327.	 Flores,	E.R.,	et	al.,	p63	and	p73	are	required	for	p53-dependent	apoptosis	in	
response	to	DNA	damage.	Nature,	2002.	416(6880):	p.	560-4.	
  	  
ABBREVIATIONS 
	100	
ABBREVIATIONS 
 
AOM Azoxymethane 
APC Adenomatous polyposis coli 
BCL2  Pro apoptotic B cell lymphoma 2  
Bcl-xl  B-cell lymphoma-extra large  
Bmi1 Bmi1 polycombo ring finger 
BrdU Bromodesoxyuridine 
CAC Colitis-associated colon cancer 
CCL  Chemokine C-C motif ligand  
CD Cluster of differentiation 
CD Crohn’s disease 
CKIT Mas cell growth factor receptor 
COX2  Cyclooxygenase 2  
CRC Colorectal cancer 
CXCL  Chemokine ligand C-X-C motif  
DC  Dendritic cell  
DEPC  Diethylpyrocarbonate  
DMEM  Dulbecco's modified eagle medium  
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
dNTP Deoxynucleotide triphosphate 
DSS  Dextran sodium sulphate  
DTT  Dithiothreitol  
ECM1  Extracellular matrix protein 1  
EEC Enteroendocrine cell 
EDTA  Ethylenediaminetetraacetic acid  
ELISA  Enzyme-linked immunosorbent assay  
FAE Follicle associated epithelium 
FAP Familial adenomatous polyposis 
Fcgbp Fc gamma binding protein 
FCS Fetal calf serum 
H&E Hamatoxylin and eosin 
HRP  Horseradish peroxidase  
IBD Inflammatory bowel disease 
IEC  Intestinal epithelial cells  
IEL Intraepithelial lymphocyte 
IFNγ  Interferon γ  
IHC Immunohistochemistry 
IL  Interleukin  
iNOS  Inducible nitric oxide  
IP Intraperitoneal 
IV Intravenous 
JNK  C-Jun-N-terminal kinase  
Lgr5 Leucine-rich repeat-containing G-
protein coupled receptor 5 
LIF Leukemia inhibitor factor  
LOH Loss of heterozygosity 
LP Lamina propria 
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MAPK  Mitogen-activated protein kinase  
MHC Major histocompatibility complex 
MIP  Macrophage inflammatory 
protein  
MMP  Matrix metalloproteinase  
mRNA  Messenger RNA  
MUC2  Mucin 2  
NaCl  Sodium chloride  
NF-κB  Nuclear factor kappa-light-chain-
enhancer of activated B cells  
NHEJ Non-homologous end joining 
NK Natural killer 
NLRs  NOD-like receptors  
PAMPS  Pathogen-associated molecular 
patterns  
PBS  Phosphate buffered saline  
FFPE Paraformaldehyde fixed paraffin 
embedded  
PFA  Paraformaldehyde  
PMSF  Phenylmethylsulfonyl fluoride  
Poly I:C Polyinosinic : polycytidylic acid 
PP Peyer’s Patch 
PRRs  Pattern recognition receptors  
RNA Ribonucleic acid 
RELMß Resistin-like molecule beta 
ROS  Reactive oxygen species  
RT-PCR  Real time-polymerase chain 
reaction  
SEM  Standard error of the mean  
SNPs  Single nucleotide polymorphisms  
STAT Signal transducer and activator 
of transcription 
TA Transitory amplifying 
TEMED  Tetramethylethylenediamine  
TFF3 Intestinal trefoil factor 3 
Th T helper 
TLR  Toll-like receptor  
TNFα  Tumor necrosis factor α  
TRPM5 Transient receptor potential 
cation channel subfamily M 
member 5 
TUNEL  TdT-mediated dUTP-biotin nick 
end labeling  
VEGF  Vascular endothelial growth 
factor  
WNT  Mouse homolog of wingless  
 
Other common abbreviations may not be listed here 
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